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A b stra c t
During the haematogenous spread of tumours, the metastasizing ceils 
must arrest within the blood vessels of the organs they colonize. There 
is still much debate upon the mechanism of such arrest, whether it is due 
to mechanical trapping or, more specifically, to adhesion of the tumour
cells to the blood vessel wall. This work demonstrates that tumour cells 
are capable of adhering to blood vessel wall components.
According to the hypothesis of specific adhesion. It is thought that 
metastasizing tumour cells would only come into contact with the vessel 
wall for a very short time and therefore their adhesion to the vessel wall 
must be extremely rapid. It has been shown in the past that tumour cells 
can adJiere rapidly to components of the blood vessel wall such as exposed 
sub-endothelial matrix. Adhesion to endothelial cells was believed to occur 
at a much slower rate and therefore the involvement of the endothelium
during the arrest phase of the metastatic process was thought to be 
marginal.
The experiments carried out during this study show that, in v itro , 
tumour cells do adhere to the endothelium at a rate comparable to that for 
isolated components of the sub-endothelial matrix. Furthermore, this work 
provides some evidence that the molecular basis for such rapid adhesion
to the endothelium may be different from the ones involved in the 
adhesion to known components of the sub-endothelial matrix.
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Aims of the protect |
One of the crucial phases of the m etastatic process is that of arrest of 
the metastasizing cells within the microvasculature of the target organ.
Tumour cells, detached from the primary mass, are carried by the blood
stream and are known to exit the circulation and establish foci of growth
in distant organs. While In the blood stream, tumour cells of non­
lymphoid or myeloid origin are thought to be most vulnerable because of 
the turbulence of flow in the arterial side and because of the difficulty to 
negotiate the narrow passages of the reticuio-endothelial system. It is 
postulated that tumour cells that enter the circulation either successfully 
arrest within the first few artero-venous passages or they die (Weiss,
1985). If this hypothesis proves to be true, the prevention of haematic 
spread of tumours could be achieved by interfering with the mechanisms
these cells use in the arrest phase.
The project described in this thesis had two aims:
1. To demonstrate an active role of the (endothelium during the
arrest phase of circulating metastasizing tumour cells.
2. To extract and characterize the endothelial molecule or molecules 
responsible for promoting the adhesion of tumour cells.
For this purpose it was necessary to devise an in v itro  assay to study 
the rapid adhesion of a suspension of tumour cells to either an endothelial 
monolayer or a molecular substratum. This assay allowed the study and 
comparison of the adliesion-pr omo tin g activity of various substrata.
A second assay, called spreading assay,. was also devised and used to 
investigate the effects of various molecular substrata on the morphology 
of the adherent tumomr cells. While the first (adhesion) assay was used 
to measure very rapid (1-5 minutes) events, the events measured by the 
second (spreading) assay were of much slower onset (30-60 minutes).
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A rrest and e x tr a v a sa tio n  o f  m e ta s ta t ic  c e l ls
A metastasis is a focus of tumour growth not contiguous with and not 
necessarily similar to the one of origin. The ability to metastasize is a 
characteristic of malignant neoplasms and is often what makes the therapy
of these tumours unsuccessful.
Although it is thought that tumour cells may reach the distant
m etastatic site in a variety of ways (spread by direct contact, intra- 
coelomic spread, spread through the cerebrospinal fluid), the most
predominant routes of dissemination is via the two established systems of 
transport in the body; the lymphatic and the haematic systems.
When tumour cells metastasize via the blood, as is generally the case
for sarcomas, they may gain access to the blood stream in different ways. 
In some cases the tumour destroys the wall of a blood vessel and invades 
into the lumen where cells can be shed into the circulation as single cells 
or as clumps. The Invasion of blood vessels is usually restricted to the
venous side of the circulation, arterial vessels rarely being involved.
Within the venous tree, vessels of all calibers may be affected, even the 
larger ones as is the case of the jugular vein in tumours of the pharynx 
and larynx (Willis, 1973). Another way in which tumour cells can enter 
the blood stream is via the lymphatic-venous shunts a t all levels of the 
lymphatic tree. Cells could invade the lymphatics or could be washed into 
them by interstitial fluid currents through the clefts of the walls of the 
lymphatic capillaries and then either pass through the lymphatic tissue or 
be retained by it to be released at later stages (Willis, 1973; Scanlon, 
1985). A more specific way to gain access to the blood circulation is by
12
migration through the walls of small calibre veins in the same way that
lymphocytes are thought to migrate through the walls of the high 
endothelium venules (Harlan, 1985).
blood v esse l
tumour
lymphatic 
v esse l
lymphatic-venous 
shunt
Figure 1: Blood-borne metastasis: mechanisms of access to the circulation.
a: destruction of the vessel wall and invasion into the lumen followed by
shedding of single cells or tumour emboli, 
b: migration of single cells through the vessel wall.
c: tumour cells may gain entry into the lymphatics either by direct
invasion (bottom) or by means of interstitial fluid currents (top), and 
later arrive into the blood stream via a lymphatic-venous shunt.
Once tumour cells are in the blood circulation, they have to arrest at a 
distant site in order to form a metastatic growth. Again this event may 
happen in a variety of ways. Tumour cells can be physically trapped in 
the vascular compartment at the metastatic site. This trapping may 
happen both to clumps of tumour cells, usually seen caught at bifurcations 
on the arterial side of the circulation, or to single cells, that can be 
trapped while progressing through the capillary bed (Willis, 1973). 
Platelets have been implicated in this phenomenon and are said to form
13
aggregates with tumour cells that facilitate the lodging of the metastatic 
cells entrapped in such thrombi (Weiss, 1985).
Another way circulating tumour cells can extravasate is by adhering to 
the endothelium. A link has been established between the in vivo 
colonization pattern of some experimental tumours with their in vitro  
preference for adhesion to endothelium derived from the parenchyma of 
the organs colonized (Nicolson, 1982).
a
tumour
embolus
flow
single cell
single cell
Figure 2: Blood-home metastasis: arrest at metastatic site.
Cells can be mechanically trapped in the arterial side of the circulation (a)
or they can arrest specifically in postcapillary venules (b).
Once tumour cells are arrested, they may migrate through the 
endothelium, or they can begin to grow within the lumen of the vessel and 
may eventually erode the wall and infiltrate the tissue (Nicolson, 1982). 
Metastatic tumour cells that extravasate in this former way can begin to 
grow between the endothelium and the basement membrane or directly
invade the tissue and then establish a focus of growth (Nicolson, 1982). 
Because neoplastic growth is characterized by marked heterogeneity 
(Heppner, 1984), both within a neoplasm and between neoplasms, any of 
the different ways of gaining access to the blood stream could be used by
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any type of tumour. This is also true for the different ways these cells 
can extravasate and thus tumours can theoretically use any of these 
mechanisms, or even a combination of them, to establish a metastasis.
In the case of extravasation by adhesion to the endothelium, tumour 
cells would need to possess a molecular mechanism to allow them to 
establish an adhesion to components of the endothelium. It has been 
argued that tumour cells do not adhere to the endothelium but to exposed 
sub-endothelial matrix (Kramer et a l ., 1980). This matrix is rich in
adhesive molecules such as laminin, fibronectin, collagen type IV, 
vitronectin and thrombospondin (see pages 25-66) and would be an ideal 
target for the adhesion of circulating tumour cells.
Although neoplastic cells have been shown in v itro to be able to
adhere quite effectively to the sub-endothelial matrix or to one or more of 
its known components (reviewed in Roos, 1984), there are some doubts as
to whether the arrest of tumour cells at the metastatic site is due to their 
adhesion to sub-endothelial matrix exposed through wounded endothelium. 
Such a supposition would in fact tend to underestimate the efficiency of 
two physiological phenomena: the ability of the endothelium to re-establish 
its continuity and the thrombogenic activity of platelets. The process of
healing of a wound in an endothelial monolayer is very rapid and efficient, 
since the endothelium has the ability to stretch and fill the gaps left by 
dead endothelial cells (see pages 18-19). Circulating platelets are activated 
by exposed sub-endothelial matrix to which they rapidly adhere and 
spread to form the basis for further platelet-platelet aggregation and the 
development of a thrombus, if the severity of the lesion requires it (Weiss 
et al. ,  1986).
The ability of the endothelium to repair itself, combined, in the case of 
non-haematological tumours, with the overwhelming number of platelets in 
the blood when compared with that of circulating tumour cells, make it
15
unlikely, although not impossible, for the tumour cells ever to come into 
contact with exposed sub-endothelial matrix.
Tumour
Sub-endotheiial Endothelium 
matrix
Figure 3: Blood-bome metastasis: different mechanisms that can lead to
metastatic growth.
After the arrest phase (a), a tumour can grow within the lumen of the
vessel (b) and later break through the vessel wall (c) or pass through
the endothelium but not the subendothelial matrix (d) where it can grow 
(e) before invading the tissue (f). Alternatively tumour cells can 
extravasate and migrate into the tissue (g) before establishing a focus of 
growth (h).
Although there are no data available to rule out the hypothesis that 
tumour cells do occasionally arrest by adhering to exposed sub-endothelial 
matrix, in view of the above arguments it seems likely that a more common 
mechanism is dependent on molecular interactions between the endothelium
and the tumour cell surface.
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The endothelium
Until recently it was believed that the main functions of the
endothelium were to provide a smooth and suitable surface to facilitate 
blood flow and to control transcapillary solute movements. The first
observation of an active role played by the pulmonary endothelium was 
made two decades ago (Ryan et a l . ,  1968) but it is only very recently
that a new concept of the endothelium has emerged. It is now justifiable 
to look at the endothelium as an extensive and contiguous organ with very 
complex and important functions which are shared throughout the vascular 
tree, certain features being of more significance in particular organs or in 
vessels of particular dimensions.
These functions can be generally divided into 5 categories:
1. Maintenance of homeostasis.
The endothelium is capable of metabolizing a wide variety of molecules 
such as hormones, drugs, neurotransmitters, derivatives of arachidonic
acid, biogenic amines and nucleotides. For instance, the endothelium 
clears noradrenalin and serotonin from the circulation, both effectively
and selectively (adrenalin or histamine are not metabolized), prostaglandins 
of the series E and F are synthesized and degraded by the endothelial
cell membrane, there is an endothelial cell surface carbonic anhydrase
which enhances. COg removal from plasma bicarbonates and controls pH, 
and there are enzymes such as carboxypeptidase N for the metabolism of 
anaphylotoxin (Ryan and Ryan, 1977; Pamavelas et a l , ,  1985; Ryan, 1986
a; Vanhoutte et a l . ,  1986).
17
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2. Repair and angiogenesis.
Endothelial cells are capable of rapidly and effectively restoring the 
continuity of a damaged endothelial monolayer through proliferation and 
directional migration (Ryan et a l . ,  1982 b). They are also able to
respond to appropriate stimuli by initiating endothelial sprouting and to
continue the angiogenic process through the formation of anastomoses and
the process of canalization to allow blood flow in the newly formed blood 
vessels (Folkman, 1986). The process of angiogenesis, which in the human 
embryo contributes to the rapid formation of the first functional system 
(the cardiovascular system) is not only an obvious necessity for the 
developing embryo but is also of prime importance for all repair 
processes. The ability of the endothelium to respond to angiogenic stimuli 
and the effectiveness of the angiogenic process is unfortimately well
exploited by the growing neoplasm and can be considered an integral part 
of neoplastic growth (Folkman, 1986).
A number of diffusible angiogenic factors have been identified. They 
fall broadly into two categories: structurally related factors that bind
heparin and which are found in tissues, and structurally unrelated factors 
that do not bind heparin and are mainly found in biological fluids. In
adition there are a number of low Mr (200-15,000) factors, only partially 
characterized, that are mitogenic and/or chemotactic for endothelial cells. 
Among the heparin-binding factors there are the basic and the acidic 
fibroblast growth factors (basic-FGF and acidic-FGF), tumour angiogenic 
factor (TAF) and endothelial cell growth factor (ECGF). Among the non 
heparin-binding factors there are angiogenin, alpha and beta transforming 
growth factors (TGF-alpha and TGF-beta) and the endothelial cell 
stimulating angiogenic factor (ESAF) (Folkman and Klagsbrun, 1987).
All these factors can stimulate angiogenesis in vivo but have quite 
different effects on endothelial cells in vitro. Many are not specific for
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these cells, some stimulate their proliferation or locomotion, some even 
cause inhibition rather than stimulation of these functions, and finally 
some factors do not seem to have the endothelial cells as targets. It
seems therefore that angiogenesis can be evoked in a number of different 
ways which are likely to include both direct and indirect pathways 
(Folkman and Klagsbrun, 1987; Findlay, 1986).
3. Immuno-modulation.
The vast surface area of the smaller calibre vessels provides an
interface between the tissues and circulating immunocompetent cells. This 
interface is very sensitive to local changes within the parenchyma that
lies immediately behind it. Leukocytes continually scan the endothelium, 
principally in the small branches of the venous circulation, by adhering to 
and migrating across the luminal surface of the endothelium for many 
endothelial cell diameters before de-adhering to continue their circulation 
(Harlan, 1985). Subtle stimuli provided by tissue macrophages or mast
cells, as well as more potent and decisive stimuli such as bacterial toxins, 
can cause changes in the endothelium which can be detected by the 
scanning leukocytes and lead to their migration through the endothelium
and into the tissue (Faustmann and Dermietzel, 1985). Neutrophils are 
normally heavily involved in this activity but in certain immunological
events lymphocytes are known to specifically adhere to and migrate 
through the endothelium (Harlan, 1985). Such a mechanism can be
postulated to be used also by metastasizing tumour cells. Selective 
extravasation is a very precise and efficient process whose molecular 
mechanisms and, in particular, the contribution of the endothelial surface,
are far from being understood. The luminal surface of the endothelial cell 
is capable of expressing receptors for the Fc tail of immunoglobulins G, 
receptors for two activated components of the complement cascade, C3b
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and C l q ,  and can also be Induced to express DR antigens and function as 
an antigen-presenting cell (McCarron et a l . ,  1985; Ryan, 1986 a; Ryan, 
1986 b). The contribution of these molecules to the selective extravasation 
of white blood cells has not been assessed but it is likely to be of 
importance.
4. Haemostasis.
The endothelium provides an active and very effective anti- 
thrombogenic surface, principally by means of the production of Pgig, 
plasminogen activator and anti thrombin III, as well as through the uptake 
and clearance of thrombin (Van Mourik et a l . ,  1984; De Caterina et a l . ,  
1985; Ryan, 1986 a).
The anti-thrombogenic state can be very readily reversed and the 
endothelium can be transformed into a surface capable of supporting 
procoagulant activity. To achieve this, production of Pgig and
anti thrombin III are inhibited, thromboplastin activity appears, factor V is 
synthesized which, together with factor X@ activates prothrombin. 
Shifting from anti-thrombogenic to procoagulant activity is triggered by 
stimuli such as endotoxin, interleukins or decreased blood flow (Bevilacqua 
et a l . ,  1985; Frangos et a l . ,  1985; Hall et a l . ,  1986). Such stimuli, 
although injurious, are far from being damaging and they certainly do not 
suggest the occurrence of a gross trauma to the endothelium as it would 
be in the case of the exposure of sub-endothelial matrix.
5. Phagocytosis.
It has been observed in vitro that the endothelial cell, traditionally 
considered non-phagocytic, is capable of ingesting large quantities of 
fixed red blood cells, heat killed Staphylococci, or inert particles (Ryan, 
1986 a). In in vitro experiments many endothelial cells may ingest 10 or
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more beads of 5-10 um in diameter. It has also been reported that, 
during wound repair experiments, phagocytosis activates endothelial cell 
division and migration as well as the expression of Fc receptors and DR 
antigens (Ryan, 1986 a). When confronted with larger particles the
endothelial cells rapidly spread their cytoplasm around the foreign body 
(Ryan et a l . ,  1982 a).
The phagocytic property of the endothelium has been successfully 
exploited as a way of obtaining arterial or venous endothelial cells 
explants from many organs of laboratory animals. The main advantage 
over previously used methods of isolation is the possibility to determine 
the size of the blood vessels from which the endothelial cells will be taken 
(Ryan e t a l . ,  1982 a): the organ of choice is canuiated and perfused with 
a suspension of microcarrier beads and, by reversing the flow of the 
perfusing system, beads covered in endothelial cells are recovered.
The phagocytic ability of the endothelial cells is such that only a small 
proportion of beads of 5-10 um in diameter are returned from such 
experiments. This behaviour encourages speculation that the endothelium 
may serve as a very efficient filter to clear lodging emboli or thrombi: 
when these are small enough they are phagocytosed and the lumen of the 
vessel is rapidly recanalized to allow blood flow. In the case of a large 
particle the endothelial cells surround it and begin to permeate it with 
sprouts while encouraging migration of scavengers from the surrounding 
tissue, in a process similar to that occurring during the organization of 
thrombi.
Surface morphology.
Conventional thin section electron microscopy shows the endothelial cell 
as being extremely thin, with a rather smooth luminal surface, a prominent 
nucleus and scanty cytoplasm, with very few organelles and only a hint of
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structural specialization. However, this picture of endothelial cells is far 
from accurate and some special electron microscopical techniques such as 
grazing sections or surface replication of freeze fractured cells have 
demonstrated the existence of a number of structures that once recognized
can be readily identified in thin section profiles (Smith and Ryan, 1973; 
Ryan, 1986 b).
The endothelial cells have compressed within their flat dimensions all 
the major intracellular organelles: abundant elongated mitochondria and a
large number of polyribosomes attached to the cisternae of a pronounced 
endoplasmic reticulum in close association with the numerous nuclear pores 
can all be seen (Haudenschild e t a l . ,  1975). Pictures showing the compact 
disposition of all these organelles and the way in which they are all 
placed so close to the luminal surface and to the nucleus, help to explain 
the speed and the efficiency with wliich these cells execute their metabolic 
tasks.
There are three structures present on the luminal surface of the 
endothelium that have significant functional importance: the endothelial cell
is covered by projections of varying size, shape, distribution and density, 
it possesses large numbers of vesicles (caveolae) and it is covered by a 
supramembranous layer of amorphous material called the glycocalyx (Ryan, 
1986 a).
Endothelial projections have the immediate effect of increasing the 
surface area of the cells and can be seen at times just above the surface 
of the glycocalyx. Their presence could be interpreted as being 
nqcessary to hold the glycocalyx in place and they may have a functional 
role when the glycocalyx is disorganized. It is nevertheless only through 
these projections that the plasma membrane is normally directly in contact
with the cell free layer of plasma.
The glycocalyx appears in electron micrographs of surface replicas as a
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deep pile carpet several hundred A thick covering the luminal surface. It 
may serve as a mass, shape or charge barrier that can facilitate or 
restrict access of solute molecules from the plasma of the boundary layer 
to the cell membrane. The composition of the glycocalyx can certainly be 
modified by the cell in response to certain stimuli (for instance, 
interleukins and interferon produced by activated leukocytes) or indeed it 
can be completely disarrayed, unmasking tlie underlying membrane (Ryan, 
1986 a).
Fi^mre 4: Morphology of the endothelial surface.
The lipid bilayer (b) is entirely covered by the glycocalyx (g); finger-like 
projections (p) emerge from the tliick carpet formed by the glycocalyx; 
small indentations of the plasma membrane or caveolae (c) are also shown.
This morphology can be rapidly changed if perturbing agents (such as
antibodies against surface proteins) are used: the glycocalyx will be
disarrayed and will show clumps and pits.
The caveolae are present at high density, usually remote from 
intercellular junctions- These vesicles are mostly round, with a diameter 
rarely bigger than 0.1 um, and they frequently possess a delicate
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diaphragm at their entrance. At the caveolae the plasma membrane seems 
enriched in enzymes such as carboxypeptidase N, klnlnase II and 5’ 
nucleotidase (Ryan, 1986 b). The presence of the caveolae and projections 
greatly increases the surface area of the endothelium (Smith and Ryan, 
1973). The luminal surface of the endothelium is summarized in figure 4.
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Sub-endothelial matrix
Within a tissue, cells are in contact with a dense latticework of collagen 
and elastin fibers which are embedded in a viscous medium composed of 
proteoglycans and glycoproteins. This structure is called the extraceilluiar 
matrix. Its components are secreted and assembled by the parenchymal 
cells and although extracellular matrices throughout the body have the 
same overall structure, they differ in the relative quantity of their 
molecular components. This confers specificity to individual matrices and, 
as well as mediating cell adhesion, the extracellular matrix is thought to 
modulate differentiation, mitosis and migration and therefore determine the 
architecture of the tissue (Kleinman et al. ,  1984; von der Mark at al. ,  
1984; Grinnell, 1982; McClay and Ettersohn, 1987; Ekblom et a l . ,  1986).
Every organ is composed of interstitial stroma and a collection of 
various tissue compartments, all bordered by basement membrane. 
Basement membranes are very thin sheets of extracellular matrix rich in 
type IV collagen, which provides their structural backbone. 
Ultrastructural studies reveal that the basement membrane is composed of 
an electron lucid region, called the lamina lucida, immediately adjacent to 
the cell layer and a distal, electron dense region called the lamina densa 
(von der Mark and Kuhl, 1985; Kleinman et al. ,  1984).
As for any extracellular matrix, the composition and the supramolecular 
characteristics of the basement membrane vary in relation to its location 
and to the type of cells responsible for its assembly. The mode of 
deposition of basement membranes is not clear and currently there are 
three postulated models of assembly. According to the layered model.
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layers of collagen and structural glycoproteins are alternatively and 
separately deposited in the matrix and the interactions between molecules 
of different layers contribute to produce a three dimensional structure. 
The matrisome model suggests that the matrix is deposited as assembled 
units; these units contain the major components of the basement membrane 
in stable complexes of well defined stochiometry and, only after deposition, 
tlie collagen IV molecules rearrange into a fibrillar network. The third 
model, or polymorphic polymerization model, postulates that the properties 
and structure of individual matrices are determined by variations in the
synthesis and secretions of the individual components. The layered model 
(Schwartz and Veis, 1980) is based on observations that the main
components of the matrix can form homopolymers and indeed in some
basement membranes there is evidence of the presence of layers with 
distinct antigenic characteristics. The matrisome model (Martin e t a l ., 
1984) draws evidence from the fact that it is possible to extract from 
matrices soluble complexes containing major structural components. As for 
the polymorphic polymerization model (Furthrnayr e t a l . , 1985), there is
some evidence to suggest that cells may be able to alter the composition 
of the matrix at discrete sites (Martin and Timpl, 1987). Matrix deposition, 
although a very fundamental phenomenon, has proven quite elusive to 
study and, to date, evidence to suggest that matrix is assembled following 
any of such hypothetical models is all indirect and there is much
uncertainty on the likelihood of their validity.
The specialized basement membrane present on the basal aspect of the 
vascular endothelium, separating its cells from other structures, is called 
the sub-endothelial matrix. The constituents of the sub-endothelial matrix 
can be classified into four categories: elastin, the collagens, the
glycosaminoglycans and the structural glycoproteins.
Elastin is a highly insoluble protein, rich in hydrophobic amino acids
and possessing very few polar groups. It is derived from a soluble
precursor, a Mr 72,000 protein called tropoelastin. Elastin molecules are
extensively crosslinked to each other to form a network of filaments
which, together with the collagen fibres, constitute the structural
framework of any basement membrane. While the collagen fibres confer
resistance, elastin, due to its random coiled structure, gives the matrix a
great degree of elasticity (Eyre et al.,  1984).
Collagens
The collagens are large molecules composed of three polypeptide chains
that have a helical tertiary structure. They can either be hetero or
homotrimers and, while at present there are at least 11 recognized types 
of collagen, it is likely that other types will be identified in the future.
Two criteria must be fulfilled in order to classify any molecule as collagen:
firstly a sizable part of this molecule must be arranged in the typical
triple helix and secondly it must form extracellular aggregates whose main 
function is support. The collagens can be separated into three different 
groups according to their size and tertiary structure. One group is
composed of molecules having chains with Mp> 95,000 and possessing long 
("300 nm) uninterrupted helical domains. Collagen type I, II, III, V and
K (XI) belong to this group and they are the main collagens found in
fibers and fibrils. The second group molecules, like those of the first
group, have chains of M^ ) 95,000 but have a number of helical domains 
separated by non helical (usually globular) regions. These molecules are 
collagen type IV, VI, VII and VIII. A third group is composed of molecules 
with chains of Mp< 95,000 and type IX and type X belong to this group.
All collagens are synthesized and secreted as larger precursor molecules 
(procollagens) which possess additional domains of non-coil agenous 
structure. These domains, which resemble those of the structural
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glycoproteins (see page 32) with asparagine-linked carbohydrate side 
chains and an overall globular structure, are removed In the case of the 
type Î, II and III collagens. The collagens found in the sub-endothelial 
matrix are predominantly of type IV and type VI (Sage et a l., 1981).
Collagen type IV seems to be present exclusively in basement 
membrane, usually as aggregates which are not readily dissociated. 
Pepsin readily disperse these aggregates but also causes fragmentation of 
the molecule. It is composed of three chains: two alpha 1 (IV), each of
185,000, and one alpha2(IV), of Mp 170,000. Differently from the collagens 
of the first group, the precursors of these chains, pro-alpha 1 (IV) and 
pro-alpha2(IV), undergo little or no post transcriptional processing.
The monomeric form of type IV collagen is a molecule approximately 400 
nm long with a collagenous domain at the NHj end called 7S and a non 
collagenous globular domain at the COOH terminus called NCI which are 
joint by a long non collagenous domain called NC2 (see figure 5). It is 
thought that dimer formation is achieved by interaction of the NCI 
domains, while tetramers are formed by interactions of four monomers at 
the 7S domain. This type of polymerization gives rise to an open mesh 
network which seems suitable to serve as scaffolding for the basement 
membrane. (Rauterberg et a l . , 1986; Miller and Gay, 1987).
Type VI collagen has been previously reported as microfibrillar protein 
1 (MFP 1), gpl40 and collagen-like glycoprotein (CLGP; see Miller and Gay, 
1987 and references within). It has the smallest collagenous domain among 
collagens (" 30 % of the whole molecule) and in fact it can be said to be 
more a glycoprotein than a collagen. Many cell types, including 
fibroblasts, synthesize this molecule and type VI collagen is by no means 
confined to basement membranes.
There are three subunits, alpha 1 (VI), alpha2(VI) and alpha3(VI), each of 
Mp " 140,000 and the collagen type VI molecule can be an alpha l(VI)a or
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an assembly of the three different subunits. The assembled molecule has 
a Mr of 340,000-400,000 and consists of two large globular domains at both 
ends of the linear triple helix rod, which is ~ 105 nm in length (see
figure 5).
7 S NC2 NCI
400 nm
Figure 5: Structure of collagen type IV (top) and type VI (bottom).
Staggered association of two monomers which intertwine with each other 
forms a dimer; side to side assembly of four monomers into a tetramer 
gives the basic unit of the fibrils of collagen VI, which are end to end 
associations of tetramers via their globular domains. The fibrils are ~ 3 
nm in diameter and have an axial periodicity of ~ 120 nm (Rauterberg et 
al., 1986; Miller and Gay, 1987).
Glvcosaminoglvcans
Glycosaminoglycans (GAGs) consist of a carbohydrate backbone made of 
repeating disaccharide units. Such carbohydrate chains are negatively 
charged and may possess sulphated groups, which contribute to rendering 
the molecule polyanionic in nature. Proteoglycans are GAGs which possess
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a core protein and one or more carbohydrate chains. With the exception of
hyaluronic acid, proteoglycans are the predominant form of GAGs in the
tissues. GAGs, which are classified according to their repeating
disaccharide units, are heterogeneous for number and location of
sulphated groups, length of the carbohydrate chains and relative ratio of 
the saccharide components, and they also exhibit differences in the core 
proteins (Hook et a l . ,  1984). For these reasons extreme diversity in
properties and functions can be expected.
8 nm
70 nm
carbohydrate chains
Figure 6: Model of high density (right) and low density (left) heparan
sulfate proteoglycans of the extracellular matrix of EHS tumour 
(from Paulsson et a 1 . , 1986, modified).
The high density form has a small core protein (M^  5,000-12,000) to which 
an average of 4 carbohydrate chains (Mr ~ 29,000) are attached. The low
density form has a very large core protein (Mr ~ 400,000) with globular 
domains and connecting rods and its carbohydrate chains are ~ 3 times
longer than in the low density form (Fujiwara et a 1 . , 1984; Martin and 
Timpl, 1987); Ruoslahti, 1988.
Hyaluronic acid is a very large molecule, usually exceeding a Mr of 10® 
and there is evidence that suggests that it is assembled extracellularly at 
the plasma membrane (Hook e t al . , 1984).
Heparan sulphate is present in plasma membranes and basement
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membranes and its is extremely variable (75,000-450,000) as is the size 
of the core protein (Mr 5,000-300,000) (Fujiwara at al. ,  1984; Paulsson at 
al. ,  1986), It is associated with the plasma membrane either as an integral 
or a peripheral membrane component (Hook at a l . ,  1984).
Peripheral membrane GAGs are non-covalently attached to membrane 
components, mostly phosphatidylinositol (Yanagishita, 1989). Additionally 
there are membrane molecules that serve as receptors for the peripheral 
membrane GAGs. The binding to such receptors is reversible, saturable, 
can be specifically inhibited and does not cause any internalization or 
degradation of the ligand. It is not known whether the association of 
GAGs with their membrane receptor conveys a signal intracellularly. The 
Mr of the core proteins seems smaller than in the case of integral 
membrane GAGs and the molecule contains less carbohydrate. It is 
possible that some peripheral GAGs are derived from integral membrane
components by proteolytic cleavage (Hook et a l . ,  1984).
GAGs of the matrix and of the cell surface are in very close proximity
and it is difficult to clearly separate them. Cells have binding sites for 
hyaluronic acid, each molecule probably binding simultaneously to multiple 
sites at the cell surface and perhaps being involved in important cell
functions such as phagocytosis (Hook et a l . , 1984). GAGs associated with
the cell membrane can function as acceptors for other molecules. Although 
these interactions may be quite aspecific due to the polyanionic nature of
GAGs, the bindings with other matrix components such as structural
glycoproteins and collagen are of interest. Interactions with the 
structural glycoproteins are probably very important for the formation 
and maintenance of the extracellular matrix. These interactions are 
described in detail in the sections on each of these molecules.
GAGs can bind to collagen either directly or by using a structural
glycoprotein as a bridging element and they can modulate (inhibiting or
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stimulating according to conditions) the formation of collagen fibers,
having an effect on their thickness and ultimately on the properties of 
the matrix. GAGs derived from specific sites seem to have specificity only 
for collagens originating from the same tissue compartment, a specificity 
that seems attributable to the core protein (Hook et a l . , 1984).
All GAGs are influenced by the microenvironment, which determines the 
spatial orientation of each repeating disaccharide unit and, as a result, 
the long sugar chains can fold up or extend. Using infrared 
spectroscopy, it is possible to detect such changes in vitro in response 
to varying temperature or the presence of certain ions (Grant et al. ,
1989). Since GAGs present on the cell surface project for some distance 
away from the membrane, this property could be very important in
presenting the cell with a representation of the distant environment and a 
working hypothesis on the role of these molecules on the cell surface is 
that they act as sensing devices (Gallagher, 1989).
The structural glycoproteins
The structural glycoproteins characteristically have asparagine- or 
serine-linked carbohydrate side chains and a structure composed of
globular domains linked by rod like flexible regions. A description of the 
known structural glycoproteins of the sub-endothelial matrix follows.
Fibronectin.
Fibronectin is a large glycoprotein present as fibres in the 
extracellular matrix, as a surface glycoprotein on the cell membrane and in 
soluble form in body fluids. Although the name was originally coined to 
describe the trophism of this molecule for collagen and fibrin (nectere - 
to connect, fibres), lately it has become apparent that fibronectin is
closely involved at a cellular level in a wide variety of adhesive
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phenomena that go beyond its interactions with fibrous proteins.
There are various forms of fibronectin, the two main ones being plasma 
and cellular fibronectin, and indeed some authors refer to them as a 
family of closely related glycoproteins, all of which share the same 
structure where two similar but not identical subunits (each with a of
220,000-250,000) are linked to each other asymmetrically at their COOH 
termini via two disulfide bridges. Strong similarities in structure and 
function exist among fibronectins but they differ in solubility, molecular 
weight, capacity to form mul timers, sugar content and sulfated chains 
(Yamada, 1983; Ruoslahti et al. ,  1982; Yamada et al. ,  1984; Hynes, 1985; 
Mosesson and Amrani, 1980).
Electron micrographs of substratum bound fibronectin show a molecule 
that has a definite V shape with no large globular regions and possessing 
sites of increased flexibility, probably corresponding to the polypeptide 
sections between structured domains. In its prevalent conformation 
fibronectin is probably a folded and asymmetrical molecule (Engel et a l ., 
1981; Hynes and Yamada, 1982), Each subunit has 9 structured regions or 
domains, connected by flexible regions and the dimer they form is an 
extended molecule with two long arms (~ 60 nm each) usually folded but 
capable of expanding when electrostatic interactions are disrupted (Hasty 
et al., 1986; Hynes and Yamada, 1982; Yamada, 1983; Hynes, 1985).
Plasma fibronectin can undergo a limited amount of sel f - association, 
particularly at low ionic strength at 4° C and will form filaments 2 nm or 
more in thickness, resembling fibronectin fibrils observed in vivo. In the 
collagen binding region there may be a self-association site for a 
complementary COOH terminal site. This polymerization is enhanced by 
polyamines and by heparin (which inducepolymerization at physiological 
ionic strength). Factor Xllla or disulphide bonding cause polymerization at 
the cell surface, promoted by proteoglycans. It is thought that multimeric
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fibronectin is required in cell-cell adhesion (Yamada, 1983; Grinnell, 1981).
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Figure 7: Structure of the fibronectin molecule.
Secondary structure of the three types of homologous repeats of
fibronectin (top) and mapping of the homologous and non homologous
(arrows) repeats in the fibronectin subunit (bottom). Regions of 
heterogeneity are marked by dotted lines: there is a 18 aminoacid
fragment in the III domain, the 8^  ^ and 14*** type III repeats may be
absent and there is a further variable segment of up to 120 amminoacids
in the VII domain. All differences between fibronectins seem due to post- 
translational changes of the nRNA. A fibronectin molecule (dimer) is
usually formed by two subunits of unequal lenght.
As shown in figure 7, more than 90 % of the primary structure of 
fibronectin is made of a series of repeats of three different homologous 
sequences known as type I, type II and type III repeats (Hynes, 1985). It 
is believed that alternative splicing of nRNA accounts for most of the 
differences in mobility on SDS PAGE, in pi, in solubility and in the
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capacity to form mul timers and fibrils that fibronectin subunits . and 
fibronectin molecules as a whole show (Yamada, 1983; Hynes, 1985).
Carbohydrates represent between 5 and 9.5 % of the weight of the 
molecule. Unglycosylated fibronectin is assembled and secreted normally 
and is fully functional so the main role of the carbohydrate chains seems 
to be stabilization of specific regions of the molecule against proteolytic 
attack (Yamada, 1983; Hynes, 1985; Mosesson and Amrani, 1980).
Fibronectin has numerous effects on cell morphology and function. It 
promotes phagocytic activity, mediates cell attachment and spreading on 
various substrata and stimulates cell movements as well as participating in 
fibrillogenesis within the extracellular matrix and fibrin gel (Mosesson and 
Amrani, 1980; McCarthy et a l . ,  1985; Grinnell, 1981; Schwartz et al. ,  1985; 
Doolittle, 1984). All these activities are the result of interactions between 
various ligands and discrete domains within the molecule. The mapping of 
these domains has been achieved by proteolytic fragmentation of the 
entire molecule. The subdivision of the molecule into domains is a purely 
functional one and is not related to gene architecture. Indeed a domain 
may be envisaged as a part of the molecule resistant to proteolytic
digestion, probably due to a highly structured tertiary conformation of 
the peptide, connected to other domains by flexible and protease sensitive 
segments (Hynes and Yamada, 1982; Yamada et a i . , 1984). A map of the 
domains, their relationship to the primary structure and the binding sites 
is shown in figure 8.
Fibronectin has two heparin/heparan sulfate binding sites, one in the
first and one in the seventh domain. The binding of these ligands at the
first domain is of lower affinity and can be inhibited by 0.25 M NaCl or
physiological concentrations of Ca^"*" (but not of other divalent cations). 
The binding site of domain VII is of higher affinity, is not modulated by 
divalent cations and requires 0.5 M NaCl to cause dissociation from its
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ligands (Hayashi and Yamada, 1982; Yamada, 1983; Ruoslahti and Engvall, 
1980). The binding of heparin stimulates the fibronectin-mediated uptake 
of gelatinized particles by macrophages and both heparin and heparan 
sulphate enhance the affinity of fibronectin for denatured collagen types I 
and III. Heparin-binding of fibronectin in cold plasma results in
precipitation of fibronectin-fibrinogen complexes (Ruoslahti and Engvall, 
1980; Yamada, 1983; Ruoslahti et a l . ,  1982), Heparin binds to fibronectin 
with a Kd between 10  ^ and 4 x 10*"® M and although the interactions seem 
to be electrostatic in nature, the binding is competitively inhibited only 
by heparin and heparan sulphate. Macromolecular heparin promotes the 
release of fibronectin from tissues and of fibroblasts from collagen 
(Yamada, 1983).
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Figure 8: Map of the functional domains of fibronectin (from Hynesj
1985, modified).
In addition fibronectin may bind actin, myosin, tropomyosin, alpha-
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actinin and vinculin although with such low affinity as to call into
question the significance of these interactions. It is likely that
fibronectin has a role in the clearance of cytoskeletal proteins and
aggregates by scavengers (Yamada, 1983).
Fibronectin also binds to bacteria and is of key importance for the
opsonization of microorganisms and foreign bodies. In human plasma there 
are 5 fibronectin isomers having the same molecular weight but differing 
in their isoelectric points (pi between 5.6 and 6.1). Only the isomer with 
the highest pi seems capable of binding to bacteria and inducing their 
opsonization. Purified fibronectin contains ~15 % of the pi 6.1 isomer and 
there is a marked loss of this isomer upon storage in the cold (Bougfaton
and Simpson, 1984; Boughton, 1987).
There are three bmding sites for fibrin on each fibronectm subunit.
The bindmg site in the first domain possesses the highest affmity. In
the eighth domain there is the second binding site for fibrin, but of lower
affinity than that of the first domain. In the second domain there is a
third and very weak binding site for fibrin adjacent to the collagen
bindmg site and quite sensitive to pro teases. Neither of the two major
bmding sites for fibrin is of particularly high affinity, at least at 37® C,
and factor Xlla mediated crosslinking is quite important m stabilizmg the 
mteractions with the fibrin gel, which are otherwise relatively labile.
Nevertheless, the affinity of fibronectin for fibrm increases at lower
temperature (Hynes and Yamada, 1982; Yamada, 1983). Similarly, fibrinogen
is not a ligand of fibronectin at 37° C but binds to it at 4° C, causmg 
precipitation of the complex. This property gave fibronectm the name of 
cold insoluble globulin (GIG), because fibrinogen contaminant produced 
precipitates when the preparation was stored m the cold (Grinnell, 1981;
Mosesson and Amrani, 1980).
The second domain contains the collagen binding site. Fibronectin
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binds to a site on the collagen alpha-1(1) chain between residues 757 and 
791 and a similar site in the alpha-2(I) chain. These are the least stable 
regions of the collagen triple helix and in fact contain the only site of 
attack of vertebrate collagenases (Yamada, 1983). Fibronectin also binds 
to denatured non helical collagen but with a somewhat higher affinity 
when compared to the corresponding native collagen and the for
denatured collagen varies between 2 and 5 x 10"® M, depending on the 
type of collagen. For the type I collagen this is a significant 200 fold 
increase, while in the case of type III collagen the difference is minimal
(2-6 fold) (Yamada, 1983). After binding to this domain of fibronectin, 
collagen can be covalently crosslinked to the first fibronectin domain by 
factor Xllla (Mosesson and Amrani, 1980).
There are at least 3 cell-binding sites on fibronectin: one is a RGDS
sequence placed in a hydrophilic loop in the sixth domain (Hynes, 1985); 
the other two, LDV and REDV, are found in the 8*'’ domain (Humphries et 
a l . ,  1990). It is probable that these are not the only sites used by 
fibronectin in its interactions with cells. In fact, membrane bound GAGs
are probably very important as fibronectin ligands, and there are reports 
of the existence of at least two different cell-binding sites on the 
fibronectin molecule (McCarthy et a l . ,  1986). Interestingly, the RGDS- 
containing domain has also one of the three regions of variability of the 
fibronectin molecule in the form of the 14*^  type III repeat.
Fibronectin binds to hyaluronic acid with moderate affinity (Kd= 10'^  
M) via a binding site different from that used to bind to heparin and this 
binding is not inhibited by 2 M NaCl. The localization of the domain 
responsible for this interaction has not been possible since fibronectin 
probably needs to be in its polymeric form to bind effectively to this
ligand, suggesting the presence on each subunit of a low affinity site. In 
human fibronectin this activity is present only in cellular fibronectin
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(Hynes and Yamada, 1982; Yamada, 1983). Hyaluronic acid interferes with 
some enhancement effects exerted by heparin on fibronectin function. 
Chondroitin sulfate proteoglycan (but not the free chondroitin sulfate 
chains) interacts with fibronectin and enhances fibronectin binding to
collagen type I (Yamada, 1983). Overall it seems that proteoglycans may act 
as modulators of fibronectin-cell and fibronectin-extracellular matrix 
interactions (Yamada, 1983).
Laminin
Laminin is the most abundant glycoprotein present in basement 
membranes and has a between 850,000 and 10®. It consists of three 
disulphide linked subunits which are synthesized from different mRNA but 
show regions of similarities. There is one A-chain (or beta-subunit) with 
Mr 350,000-440,000 and two B-chains (or alpha-subunits) with Mr" 220,000.
Two different types of B-chains can be distinguished: a B1-chain with Mr
225,000 and a B2-chain with Mr 205,000 (Martin and Timpl, 1987; von der 
Mark and Kuhl, 1985; Paulsson e t a l . , 1986; Ekblom et a l . ,  1986; Yamada,
1983).
Although laminin has been reported to exist in many different forms, a 
typical complete laminin molecule (as for instance isolated from tumour 
tissue or placenta) is an A-B1-B2 assembly. Electron micrographs of 
substratum adsorbed, rotary shadowed preparations of laminin show a 
cross-shaped structure with one long arm and three short ones (Engel et  
a l . , 1981; Martin and Timpl, 1987; McCarthy et a l . , 1985; von der Mark 
and Kuhl, 1985; Yamada, 1983).
Digestion studies and analysis of cDNA clones reveal that laminin has a 
multidomain structure (Martin and Timpl, 1987), A map of the domains of 
the B1 chain is shown in figure 9. Domains I and II are alpha-helical 
coils and between the first and second domain there is a 30 amino acids
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segment (segment alpha), cysteln-rich, which represents a region of 
difference between B1 and B2 chains. Domains III and V are formed by 
repeats of homologous cysteine-rich segments, each "50 amino acid
residues long. Both the sixth (NHg terminal) and fourth domain are "250
amino acid residues long and have a globular structure. The B2 chain 
possesses the same overall structure but is shorter than the B1 chain by
" 100 amino acid residues, lacking the segment alpha and having a lower 
number of repeating homologous sequences in domains III and V. Data on 
the structure of the A chain are incomplete but it is believed that the NH^  
terminal segment (the third short arm of the laminin molecule) is similar to 
the correspective segments on the B chains; at the COOH terminus the A 
chain has a large globular domain, known as the "foot", which is formed 
by five loops or "toes" (Martin and Timpl, 1987; von der Mark and Kuhl,
1985; Paulsson et a l . ,  1986).
An A-B1-B2 assembly has the NHg terminus of each chain forming the 
three short arms. The chains are then linked by disulphide bonds at the 
centre of the cross where the A chain probably runs within a coiled-coil 
alpha-helix " 50 nm long made by the two B-chains. The B chains are 
then linked at their COOH termini by a single disulfide bond while the 
COOH terminus of the A chain forms the globular structure at the end of
the long arm (Martin and Timpl, 1987; Yamada, 1983; McCarthy et a l , ,  1985;
Paulsson et a l . ,  1986; von der Mark and Kuhl, 1985).
Carbohydrate content is 13 % w/w and the oligosaccharide chains are 
all asparagine-linked. Their role is unknown since they do not seem to 
confer resistance against proteolytic attack, they are scarcely involved in
ligand interactions, and they do not appear to be important for the 
assembly or the secretion of the mature molecule (Martin and Timpl, 1987; 
Yamada, 1983).
Laminin is now regarded to be a molecular family of similar molecules
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that are separate gene products. One of this, called S-laminin, is thought
to be a macromolecular assembly (Mr> 10®) of a single polypeptide of
190,000 homologous to the B1 chain (Hunter et al. ,  1989). Another member 
of this family, called merosin, is very similar to the traditional laminin 
molecule but is a B1-B2-M assembly, the M chain having much homology 
with the A chain and a very similar tertiary structure (Leivo and Engvall, 
1988). The laminin produced by invertebrates has a long arm of 110 nm. 
Schwann cells and oocytes produce only B chains which are assembled in 
a Y-shaped dimer. Only after the two cell stage, do embryos contain 
laminin with A chains (Martin and Timpl, 1987; von der Mark and Kuhl, 
1985; Yamada, 1983; Kleinman et a l . ,  1984).
There is an heparin/heparan sulfate binding site in the large globular 
domain at the end of the long arm (Yamada, 1983; von der Mark and Kuhl, 
1985; Martin and Timpl, 1987; McCarthy et a l . ,  1985). It is known that the 
glycan chains of high density heparan sulfate bind to laminin, but the 
binding is very weak (K<,> ICT® M). Low density heparan sulfate also 
binds laminin but there are no data on the strength and sites of these 
interactions (Martin and Timpl, 1987).
Collagen type IV binds to the globular domains at the end of the short 
arms of the laminin molecule and an additional binding site is present in 
the globular domain at the end of the long arm. For the binding, the 
triple helical structure of collagen must be intact (Martin and Timpl, 1987; 
Yamada, 1983; McCarthy e t a l . ,  1985; von der Mark and Kuhl, 1985).
A binding site for nidogen (see page 44) is found in one of the 
globular domains of the short arms near the centre of the cross. The 
interaction with nidogen is very strong (K<,< 10 nM) and is dependent on
divalent cations (chelating agents readily dissociate this binding). The role 
of this interaction is unknown, but it is thought that nidogen helps in 
stabilizing the structure of the basement membrane and it may also
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modulate the activity of a cell-binding site present in the central part of 
the laminin molecule (Martin and Timpl, 1987; von der Mark and Kuhl,
1985). Nidogen is present in an equimolar ratio with laminin in the
basement membranes of some tumours as well as those of normal cells (von
der Mark and Kuhl, 1985; Paulsson e t a l . ,  1986).
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Figure 9: top left: the A chain ”foot”; bottom left: a map of the B1 chain;
right a model of laminin. (from Martin and Timpl, 1987, modified)
Laminin also binds a small glycoprotein (Mr= 40,000) present in 
basement membranes and referred to as BM-40, osteonectin or SPARC 
(Martin and Timpl, 1987; Paulsson et a i . ,  1986). The binding to laminin is 
divalent cation independent although BM-40 is a calcium-binding protein
4 2
and calcium causes changes in the alpha helical conformation of this
molecule (Martin and Timpl, 1987). Other ligands of laminin include the 
complement components C 3  and C l q ,  plasminogen, plasminogen activator, 
sulfatides and gangliosides although there are no indications on the
physiological significance of these interactions (Martin and Timpl, 1987;
1Yamada, 1983).
Laminin is capable of forming large polymers that possess a definite 
structure. Dimers and trimers of laminin can be assembled even in the
presence of chelating agents but the presence of divalent cations seem
necessary for further polymerization. There are two regions for self 
association: one involves domains at tlie end of the short arms, a second
one occurs between the globular domains of the long arms (Martin and 1
Timpl, 1987).
So far two different cell-binding sites have been identified on the 
laminin molecule. One is the pentapeptide Tyr-lle-Gly-Ser-Arg (YIGSR),
located in the third domain of the B1 chain, the other Is a RGD sequence 
located in the rod like region near the centre of the cross (Aumailiey e t
a l.,  1990). A receptor for the YIGSR sequence has been isolated from
various cell types (Martin and Timpl, 1987). The receptor molecule is an
integral membrane protein with a hydrophobic domain. It has, depending 
on the cell of origin, a Mr between 67,000 and 70,000 and is extractable 
from different sources using different procedures (Malinoff and Wicha,
1983; Rao e t a l . ,  1983; Martin and Timpl, 1987; von der Mark and Kuhl,
1985). Despite these differences indicating heterogeneity in the receptor 
structure, cells seem to possess comparable numbers of free acceptor sites
for laminin (between 5 and 10 x 10'* per cell) and their receptors have â
similar dissociation constants (Kq= 1.5-2 x 10'  ^ M) (Martin and Timpl, 1987; 
von der Mark and Kuhl, 1985). In normal epithelial cells this receptor is 
found only along the basal side of the membrane while its distribution in
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tumour cells is less organized (Martin and Timpl, 1987). The solubilized 
receptor appears not to have high affinity for its ligand nor high 
specificity, showing some binding to immobilized fibronectin and collagen 
type I or IV. Nevertheless, when reconstituted into liposomes (or even 
when adsorbed onto nitrocellulose), it acquires specificity as well as an 
affinity for laminin comparable to that exhibited by whole cells (von der 
Mark and Kuhl, 1985; Ekblom et a l . , 1986). The receptor has been shown 
to bind actin and induce its polymerization (Martin and Timpl, 1987; von 
der Mark and Kuhl, 1985) but, because of the large number of molecules 
that can bind actin, the existence of a transmembrane link between 
extracellular matrix laminin and the cytoskeleton can, at the moment, only 
be postulated. What is known is that on the internal surface of the 
membrane the receptor is in association with, or actually contains, a 5’ 
nucleotidase whose activity is stimulated several fold upon binding of 
laminin to the receptor, a fact which supports the hypothesis of the 
existence of a mechanism to translate laminin binding into an intracellular 
signal that could result in shape changes as well as triggering other 
cellular events such as differentiation (von der Mark and Kuhl, 1985).
Nidogen
This molecule is a single chain protein capable of binding laminin and 
collagen type VI and is probably identical or very similar to entactin, a 
Mp 158,000 sulphated protein (Ekblom et a l . ,  1986). In its intact form 
nidogen has a Mp of "150,000 but a series of fragments with Mp 130,000
100,000 80,000 and 40,000 are produced as a result of stepwise degradation 
at the NHz terminal end of the protein by the tissue proteases (Paulsson 
et al . ,  1986).
In rotary shadowed preparations of nidogen, the molecule possesses a 
dumbell shape with a large and a small globular region connected by a
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thin rod. The region responsible for the interaction with laminin seems to 
reside either in the small globular region or in the rod-like segment
proximal to it (Paulsson et al., 1986), Nidogen also binds to the globular
NCI domain of collagen type IV and this binding only occurs when the NCI
domain is rendered divalent, either by crosslinking of purified NCI 
fragments or by the use of intact crosslinked collagen IV (Paulsson et
a l . ,  1986). j
It is probable that this molecule serves as a stabilizer of the basement j
membrane structure by binding to both laminin and collagen IV and, since I
nidogen seems much more sensitive to proteolysis than any other basement 4
Imembrane protein, it perhaps allows cells to manipulate the supramolecular j}
structure of the basement membrane by means of proteolytic enzymes iI(Ekblom et al., 1986; Paulsson et al., 1986). Nidogen also contains a RGD |
and a LDV sequence which could be used to interact with cells (Humphries =1Iet al . ,  1990; Nagayoshi et a l . , 1990) j
Thrombospondin
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Thrombospondin was first identified by Baezinger and co-workers II(1971) as a molecule released by platelets upon thrombin exposure. It is a |1large glycoprotein with a Mp of 450,000 involved in cell-cell and cell-matrix I
Îiinteractions. As shown in figure 10, thrombospondin is composed of three jIidentical subunits and is capable of interactions with a number of I
molecules including collagen type IV, plasminogen, laminin, fibrinogen, I3fibronectin, histidine-rich glycoprotein (HRGP) and heparin (Lawler, 1986; |
jFrazier, 1987). Thrombospondin is a true multifunctional protein, with |
■Iindependent domains mediating various activities, but a striking feature of 
this molecule is its Ca^  ^ dependent structure. Thus, changes in the 
concentration of the cation in the microenvironment can lead to
modulations of its shape and function (Lawler et a l . ,  1985, Lawler, 1986;
J'
Frazier, 1987),
It has been shown that thrombospondin production is not limited to 
platelets and megakaryocytes: endothelial cells, vascular smooth muscle
cells, fibroblasts from a variety of somrces, alveolar type 11 epithelial 
cells, monocytes, peritoneal macrophages, as well as cells from many
tumours, including B16 cells, all produce thrombospondin, secrete it and 
incorporate it into the extracellular matrix in variable quantity (Raugi e t 
a l ., 1982; Mumby e t a l . ,  1984 a; Jaffe e t  a l . ,  1985; Lawler, 1986).
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Figure 10: A model of thrombospondin.
Thrombospondin consists of three subunits, each of M,. 145,000 ,
joined together by disulfide bridges in a region close to the NHg terminus 
of these chains. Electron microscopy of surface adsorbed, rotary 
shadowed preparations reveals a structure composed of three large 
globular regions, three long, thin connecting rods, a knot where tlie three
4 6
chains are crosslinked and a small globular region close to it (Coligan and 
Slayter, 1984; Lawler et a l . ,  1985; Lawler, 1986; Frazier, 1987).
Each large globular region is between 118 and 170 A in diameter and 
represents the COOH terminal part of each subunit and is in fact called 
globular region C. The small globular region consists of the NHg terminal 
ends of the three chains and is called globular region N. This globular 
region can sometimes be resolved into three separate smaller structures. 
The thin connecting rods are very flexible and may adopt a variety of
orientations, furthermore their length, which in the presence of Ca*^  is 
between 160 and 290 A, increases to 383 A when the Ca^  ^ is chelated. 
This increase in length is related to the decrease in size of the globular 
region C (Margossian et a l . ,  1981; Coligan and Slayter, 1984; Lawler et
a l . ,  1985; Frazier, 1987).
The heparin binding site on thrombospondin resides in the globular 
region N. Thrombospondin binds avidly to heparin and the binding is 
disrupted with high (0.45 M) concentrations of NaCl (Raugi et a l . , 1984;
Dixit et a l . , 1984). Thrombospondin in the extracellular matrix has been 
demonstrated to be associated with fibrils containing GAGs, and both 
fibronectin and heparin can inhibit thrombospondin incorporation in the 
matrix (Majack et a l . , 1985).
Thrombospondin interacts with the surface of activated platelets by 
binding to fibrinogen. The affinity for this ligand has an in vitro
Kd= 3 .4  X 10“® M and is inhibited by glucosamine, mannosamine and 
arginine, as indeed is the case for the lectin-like activity of platelets. 
The binding site for fibrinogen resides near the globular region C (Leung
and Nachman, 1982; Frazier, 1987). Controversial reports indicate that the 
affinity of immobilized thrombospondin for soluble fibronectin is much
lower than for soluble fibrinogen, but soluble thrombospondin has a
comparable affinity for both these ligands when they are in solid phase
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(Lahav et a l . ,  1984). As well as by binding to fibrinogen, thrombospondin 
can interact with the cell surface via two known adhesive sequences, RGD 
and LDV (Humphries et al. ,  1990)
Thrombospondin also binds to collagen with a binding site located in a
region of the connecting arms close to the interchain knot (Mumby et a l .,
1984 b). Monomeric collagens possess only one low affinity binding site so 
their interactions with thrombospondin in vitro are very weak and only 
type V collagen seems to have a second binding site, which is of much
higher affinity (Mumby et al . ,  1984 b; Frazier, 1987). Such preferential
affinity for collagen type V may not be representative of the in vivo
interactions of thrombospondin with collagen in the matrix since
thrombospondin would find a high number of binding sites (albeit of low 1
.]affinity) in fibrillar collagen. i
The interaction of thrombospondin with plasminogen, which occurs jIprobably via the lysine binding site on this molecule, has a of |
j3.5 X 10 M, while the binding of thrombospondin with HRGPhas a of i
6.2 X  ICT^  M. These molecules (thrombospondin, plasminogen and HRGP) |
can form a trimolecular complex that is capable of binding to heparin and 1ithat serves as a substratum for plasminogen activator (Silverstein et al. ,  |j1985; Leung et al . ,  1984). It is possible that, by forming this complex, |
thrombospondin enables the insertion of plasminogen into the fibrin clot q
'j
and therefore serves as a regulator of plasmin dependent proteolysis i
within the clot.
Thrombin forms a stable complex with thrombospondin. This complex |
forms very rapidly and then is stabilized by thiol disulphate exchange ^
(Danishefsky et al. ,  1984). Thrombospondin also binds laminin, von 
Willebrand factor and low density lipoproteins, as well as factor DQ and 
factor X, for which it can serve as a substratum (Lawler, 1986).
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Vitronectin
Vitronectin is an alpha-1 globulin present in serum, amnio tic fluid and 
urine as well as being found on the cell surface and in the extracellular 
matrix (Hayman et a l . ,  1983; Barnes e t a l . ,  1985; Tomasini and Mosher,
1986). Its concentration in plasma is quite variable, ranging from 140 to 
700 ug ml"*. In plasma it is present in at least 2 forms, a native one, 
that has a M^  around 78,000 and its cleavage product, with a Mr of
65,000-70,000 , together with a Mr”* 10,000 fragment (Jenne and Stanley, 
1985; Silnutzer and Barnes, 1984 a).
Vitronectin was first described two decades ago by Holmes (1967), but 
remained poorly characterized until it was shown not to be a fragment of 
fibronectin (Knox and Griffiths, 1979). Originally identified by its ability 
to mediate cell attachment and spreading and termed serum spreading 
factor, it was later named vitronectin because of its ability to mediate cell 
adhesion on glass surfaces and because of its affinity for glass (glass- 
bead chromatography was indeed used for its purification - Bames et al. ,
1984). Lately it has been found that an independently characterized 
glycoprotein, named S-protein, with binding properties for the complement 
complex C5b-7 has the same biological, immunological and physicochemical 
characteristics as vitronectin and comparisons of their primary sequences 
has confirmed that S-protein and vitronectin are one and the same
(Suzuki et al. ,  1985; Tomasini and Mosher, 1986; Jenne and Stanley, 1985).
The polypeptide backbone of vitronectin consists of 458 amino acid 
residues having a calculated M^ of 53,132. It possesses three potential
sites for glycosylation and if the vitronectin carbohydrate content is 
confirmed to be in the region of 34 % w/w, the side chains would account
for the difference between the experimentally determined and the 
calculated molecular weights (Suzuki et al. ,  1985).
Vitronectin binds to anti thrombin III, to the complement lytic complex
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C5b-7..9 and to heparin (111 and Ruoslahti, 1985; Pytela et a l . ,  1985; Jenne 
et a l . ,  1985; Hayashi et a l . ,  1985; Preissner et a l . , 1985; Barnes et a l . ,
1985). The amino acid sequence of vitronectin can be divided into regions 
of functional significance: the first 44 NHg terminal amino acids are the
somatomedin B molecule. Somatomedin B was originally described as a 
growth hormone dependent polypeptide which stimulated glial cells to 
undergo mitosis, but recently it has been found that such activity was 
due to a small quantity of contaminant epidermal growth factor co-purified 
with somatomedin B. In view of this  ^the polypeptide should not qualify
for such nomenclature but the term somatomedin B is still widely used to 
refer to this sequence (Jenne and Stanley, 1985). The somatomedin B
region is rich in cysteine and contains four disulphide bridges which fold
it into an independent domain (Jenne and Stanley, 1985; Suzuki et al. ,
1985).
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Figure 11 : A map of vitronectin (^ = positively charged amino acids,
clusters of hydrophobic residues).
In positions 45-47 there is the familiar cell binding sequence RGD found 
in many other molecules (see section on fibronectin). Interestingly, the
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somatomedin B polypeptide is generated by proteolytic cleavage at the R-G 
bond (in vivo probably the result of the action of thrombin which cleaves
a similar R-G bond in fibrinogen) which depletes the molecule of its cell
binding activity (Jenne and Stanley, 1985).
After the cell binding site there is a long (~ 300 amino acids) region
which contains the three asparagine residues, in positions 67, 149 and 222, 
possible sites of attachment of N- linked sugars. This is a region rich in 
proline, with densely scattered hydrophobic residues and probably having 
an unusual secondary structure (Jenne and Stanley, 1985).
Between residues 364 and 396 there is the heparin binding site (Jenne 
and Stanley, 1985). Among these 32 residues there are 14 positive
charges, two hydrophobic residues and no negative charges. This site 
could also be involved in the binding of vitronectin to the C5b-7..9
complex and the ability of vitronectin to inhibit the heparin induced
stimulation of the inactivation of thrombin by anti thrombin III probably
derives from interactions with heparin at this site (Jenne and Stanley,
1985; Preissner et al. ,  1985).
At position 402 there is a site for proteolytic cleavage that generates a 
COOH terminal fragment with of 9,400. Partial vitronectin cleavage is 
undertaken in plasma where a fragment of 10,000 from the COOH
terminus is detected. In vitro, purified vitronectin is rapidly cleaved at
this site by trypsin (Jenne and Stanley, 1985).
Although only one gene has been found for vitronectin, the existence
of different length mRNAs and the heterogeneity in molecular weight that
vitronectin preparations show upon electrophoresis with the presence of 
large bands, would suggest that vitronectin molecules of slightly different
molecular weights originate from a unique nRNA by splicing (Suzuki et 
a l . ,  1985; Jenne and Stanley, 1985).
Native vitronectin does not have the heparin binding site exposed.
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becoming able to bind this ligand only when activated. This activation
normally occurs during coagulation, and serum vitronectin (but not plasma
vitronectin) expresses the heparin binding site (Tomasini and Mosher,
1986; Bames et a l . ,  1985; 111 and Ruoslahti, 1985; Hayashi et a l . ,  1985;
Silnutzer and Bames, 1984 b). It has been shown that the presence of
active thrombin is necessary for activation, even though it is not known
whether the action of thrombin is a direct enzymatic one on the
vitronectin molecule (Silnutzer and Bames, 1984 b).
There are other agents that can expose the heparin binding site on
vitronectin: treatment of the molecule with acids or short exposure to
100® C or 8.0 M urea, all activate the heparin binding site, although many 
other denaturing agents fail to do so (Hayashi et a l , ,  1985). It is
interesting to note that not all vitronectin molecules can be induced to
bind heparin, but once the heparin binding site is exposed the molecule
loses its ability to be adsorbed to the substratum (Bames et a l , ,  1985). 
Vitronectin in which the heparin-binding site is exposed is unable to 
support adhesion and spreading of cells in the usual assays, but only
because of its lack of substratum binding. In fact the integrity of the 
cell binding site can be demonstrated if the molecule is anchored to the
substratum by other means.
It seems that the two serum forms of vitronectin have different 
affinities for heparin, it having been reported that at physiological pH the 
binding of the Mr 78,000 form to heparin is dissociated by 0.12 M NaCl 
while 0.5 M NaCl is needed to dismpt the interactions of heparin with the 
Mr 65,000 form (Hayashi e t a l . ,  1985; 111 and Ruoslahti, 1985). This is 
likely to be related to different affinities of the two forms for the
thrombin-antithrombin III complex (the Mr 65,000 form does not seem able
to bind anti thrombin III) and the influence of such complex on the 
heparin-vitronectin interactions.
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enhancement of thrombin inactivation by anti thrombin III induced by
heparin. If vitronectin is added to an already formed thrombin- 
antithrombin III complex it will still bind to the complex but will not
modulate the activity of anti thrombin III (111 and Ruoslahti, 1985; Preissner 
et a l , ,  1985; Jenne et a l . , 1985). It is probable that the region of
vitronectin involved in the binding to anti thrombin III and the C5t,-7..9 
complex is not readily available in the native molecule but becomes
exposed during purification (Dahlback and Podack, 1985).
When vitronectin binds to the nascent 05^-7 complex this cannot be 
inserted into the cell membrane. Membrane insertion of the complex is 
necessary for the inclusion of C8 into the complex which in turn promotes 
the insertion of C9 in the membrane and its polymerization, which leads to
Vitronectin binds to anti thrombin III only after the latter has been 
activated and their interactions may be important in the regulation of the
coagulation process (111 and Ruoslahti, 1985; Jenne et a l . ,  1985). jJAnti thrombin III acquires affinity for vitronectin once it is complexed to j
thrombin. Adsorption to plastic or iodination has the same effect, |
1suggesting the presence of a cryptic site for binding to vitronectin which i
Iis exposed by a change in the tertiary structure of the molecule (111 and 1Ruoslahti, 1985). Accordingly, vitronectin is not associated with -|
ianti thrombin III in plasma, while in serum it is found in a complex that 3
1usually includes also thrombin (Jenne et a l . , 1985; 111 and Ruoslahti, 1985). iThe binding to anti thrombin III is independent of divalent cations and a
heparin does not influence either the formation or the stability of the i
1complex (111 and Ruoslahti, 1985). |
The binding of vitronectin to the nascent thrombin-antithrombin III i
complex results in the suppression of the inhibition of thrombin, which is }Itherefore still able to exert its amidolytic and proteolytic action, albeit at j
ja somewhat slower rate. Vitronectin is also able to mitigate the 1
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membrane lesion (Podack and Muller-Eberhard, 1979; Preissner et al. ,  1985; 
Jenne and Stanley, 1985). When bound to an already formed C5b-C9
complex, vitronectin also inhibits C9 polymerization and the dissociation of 
vitronectin from the lytic complex results in restoration of the lytic
activity (Preissner et al . ,  1985). Vitronectin could represent a very 
effective protection for bystander cells from complement-mediated lysis 
and in fact its low constant of inhibition for the C5b-7 complex (Ki= 0.55 
uM) compares favourably with the concentration of vitronectin in plasma 
(" 5 uM) (Dahlback and Podack, 1985; Preissner et a l . ,  1985).
Von Willebrand factor
Von Willebrand factor is a large circulating, cell stored and matrix 
bound glycoprotein produced exclusively by endothelial cells and 
megakaryocytes (Hoyer, 1981; Reinders et a l . , 1985). It is composed of two 
apparently identical subunits assembled into a homodimer which can 
polymerize to form multimers containing up to 40 dimers or more. Von 
Willebrand factor exists therefore as an array of molecules of increasing 
Mr ranging from the 450,000 of the basic dimer to 2x10® or more of the 
largest mul timers (Wagner and Marder, 1984; Spom et a l . ,  1987).
Two important functions in the maintenance of haemostasis seem to be 
related to von Willebrand factor. The first concerns its association with
the antihaemophilic factor VIIIzC. V<m Willebrand factor serves as a
plasma carrier of VlllrC, to which it is non covalently bound and acts to
significantly increases its circulatory half life (Ginsburg et a l , ,  1985; 
Lynch et a l . ,  1985). Such a circulating assembly is called FVIII complex 
(Hoyer, 1981). The other function is related to platelet adhesion and
fibrin deposition during thrombus formation. Thus, von Willebrand factor
is secreted from endothelial and platelet granules to promote interactions 
between the activated platelets and the damaged endothelium or the
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exposed sub-endothelial matrix (Bockenstedt et a l . ,  1986; Hada et a l . ,  
1986; Spom et a l . ,  1987).
The concentration of von Willebrand factor in human plasma is 
estimated to be 5-10 ug ml~^ , which is approximately 100 times greater 
than that of FVIII:C (Hoyer, 1981).
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Figure 12: Distribution of the repeating sequences along a subunit of von 
Willebrand factor.
The mature von Willebrand factor subunit has a of approximately
270,000 , as calculated from its primary structure, 18.7 % of which is 
carbohydrate side chains (Titani e t a l .  , 1986). The polypeptide backbone 
is made of 2050 amino acid residues, 75 % of which are arranged in 
repeating sequences, implying a complex evolutionary history of its gene 
with internal duplication, in a manner reminiscent of other characterized 
molecules involved in cell-matrix interactions. There are five types of
repeating sequences, named A, B, C, D and E (Sadler et a i . ,  1985;
Shelton-Inloes et a l . ,  1986), and their distribution along the subunit is
shown in figure 12.
Von Willebrand factor is synthesized as pro-subunits containing the
2050 amino acid residues of the mature subunit, together with a NH% 
terminal sequence of approximately 700 amino acid residues known as pro­
polypeptide (Titani et a l . ,  1986). The pro-polypeptide, which is cleaved
before secretion, is thought to encourage mul timer formation (Spom et
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a l . ,  1986; Wagner and Marder, 1984; Wagner et a l , ,  1987). Von Willebrand 
factor is very rich in cysteine, with 169 half cysteine residues, all of 
which are engaged in inter- or intra-chain disulfide bonds (Titani et a l .,
1986).
In endothelial cells, after passing through the Golgi apparatus, von 
Willebrand factor is secreted, principally as a dimer (60 % of all von
Willebrand factor secreted) or low molecular weight mul timer (Spom et
a l . ,  1986). A small proportion, estimated to be less than 10 %, is stored 
in specific structures called Weiber-Palade bodies (Spom et a l . ,  1986).
Far less von Willebrand factor is produced in megakaryocytes. This is 
thought to be almost exclusively for storage and is found in the alpha-
granules (Ginsburg et a l . ,  1985).
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Figure 13: Subunit, dimer and different terminations of the 5 isomers of 
each mul timer of von Willebrand factor (see text).
Although in megakaryocytes von Willebrand factor is stored together
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with many other cell products, including fibronectin, thrombospondin and 
thrombin (Reinders et a l . ,  1985), in endothelial cells there seems to be a
specific mechanism for separating von Willebrand factor from other
synthesized molecules. Weiber-Palade bodies contain only von Willebrand
factor and von Willebrand antigen-II (the pro-polypeptide which, once 
cleaved from the rest of the molecule, has a 92,000-98,000 and is also
present in plasma). This mechanism is very sensitive to slight shifts of 
the pH of culture medium (Reinders et a l . ,  1985; Spom et a l . ,  1986;
Wagner et a l . ,  1987; Shelton-Inloes et a l . , 1986). Multimerization
continues even after storage and in fact the stored material is rich in
high molecular weight mul timers (Spom et a l . , 1986; Wagner et a l . ,  1987).
Weiber-Palade bodies are specific granules of endothelial cells (Reinders
et a l . ,  1985). They are bound by a unit membrane and appear as rod
shaped organelles of about 2 um in length and 0.5-1 um in width, of
variable electron density, often clustered at the periphery of the
cytoplasm and occasionally associated with the Golgi region from which 
they seem to originate (Spom et a l . ,  1986). Within them, Weiber-Palade 
bodies contain an average of 10-20 tubules 150 A in width, which are
likely to be von Willebrand factor molecules in a highly condensed form. 
Indeed, they are similar to tubular structures present in certain regions
of platelet alpha-granules known to contain von Willebrand factor (Spom
et a l . ,  1986).
Analysis of quasi-elastic light scattering of von Willebrand factor in 
solution and of electron micrographs of substratum adsorbed von
Willebrand factor indicate that the predominant native structure is that of
a flexible polymer coiled upon itself. The shape of the coiled polymer is
usually oval for the loosely coiled dnes, with the long diameter measuring 
an average 200-300 nm. The more extensively coiled polymers have a 
shape that tends towards the sphere, with a somewhat smaller diameter.
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Non-coiled von Willebrand factor seems to represent less than 15 % of the 
total and it is predominantly of low molecular weight (Fowler et al. ,  1985; 
Slayter et al. ,  1985).
Von Willebrand factor polymers are a linear assembly (no branching has 
ever been observed) of a repeating unit called a protomer. A protomer
represents one dimer and its structure is outlined in figure 13 (Fowler et
a l . , 1985). Polymers are end to end assemblies of protomers and there
seems to be heterogeneity in the way in which they terminate. The 
extreme flexibility of the molecule at its COOH terminus allows the dimer 
the wide range of movements that are necessary for coiling of the polymer 
(Fowler et al. ,  1985; Slayter et al. ,  1985).
Electrophoretic separation of von Willebrand factor shows that each 
multiple of the simple unit (dimer) can be resolved into up to 5 different 
bands, separated by an overall difference in electrophoretic mobility
corresponding to a of approximately 150,000 (Fowley et a l . , 1985;
Zimmerman et a l . , 1984). In fact multimers composed of the same numbers 
of protomers (isomers) but having different end morphology could account
for the heterogeneity of molecular weight of each isomeric cluster (Fowler 
et al. ,  1985), as shown in figure 13.
The binding of von Willebrand factor to platelets occurs via two 
independent receptors on the platelet membrane designated glycoprotein Ib 
(gplb) and glycoprotein Ilb/Illa complex (gpIIb/IIIa) on the basis of their
electrophoretic mobility. Von Willebrand factor has a binding site for gplb
localized in a 50,000 tryptic fragment, part of the large globular
region. The binding of von Willebrand factor to gplb is Ca^  -independent 
(Shelton-Inloes et a l . , 1986; Houdijk et a l . , 1986). The RGDS sequence in 
von Willebrand factor is localized very near to or within the central 
globular domain. This sequence, being part of a very hydrophilic region, 
Is most likely to be localized on the outer surface of the coiled molecule.
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thus needing no activation step prior to binding (Shelton-Inloes et a l .,
1986; Titani et al. ,  1986) Von Willebrand factor also possess a LDV 
sequence (Humphries et al., 1990).
Although von Willebrand factor has the potential to bind to gpIIb/IIIa 
of activated platelets in vivo, the role that soluble von Willebrand factor 
secreted by endothelial cells plays in platelet aggregation (gpIIb/IIIa is
responsible for this phenomenon) is likely to be very marginal if not 
irrelevant. In fact, all the molecules that bind to gpIIb/IIIa can displace 
each other in a competitive manner, all binding via the RGD sequence 
(Pytela et al. ,  1986). Because of the overwhelming molar excess of 
fibrinogen in plasma the binding of soluble von Willebrand factor to 
gpIIb/IIIa is minimal, if it occurs at all (Parker and Gralnick, 1986). 
Nevertheless von Willebrand factor released from platelet alpha-granules 
does bind to the platelet surface complex gpIIb/IIIa (Parker and Gralnick,
1986), probably because of the high concentration of von Willebrand factor 
localized at the platelet surface during degranulation. Similarly, the 
binding of Weiber-Palade body-derived von Willebrand factor to the
surface of the endothelial cells, which express gpIIb/IIIa complex upon 
stimulation, probably happens because of the transient high concentration 
of von Willebrand factor near the cell membrane during secretion. The 
endothelium releases the content of Weiber-Palade bodies both towards the 
luminal side and into the sub-endothelial matrix, and a great part of 
released von Willebrand factor remains bound to the cells or to the
collagenous matrix (Spom et al. ,  1986; Spom et a l . , 1987).
Collagen is indeed likely to be the main acceptor of von Willebrand 
factor in the basement membrane (Sadler et a l . , 1985). The collagen
binding site in von Willebrand factor resides in a M,. 48,000 tryptic digest 
of the large globular region (Houdijk et a l . , 1986; Shelton-Inloes et a l . ,
1986). Von Willebrand factor binds to collagen with high affinity and it is
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not displaced by either fibronectin or fibrinogen. Although the binding to 
fibrillar collagen is Ca^ ’^-independent, the crosslinking that follows 
requires Ca^ (Bockenstedt e t a l . ,  1986).
Unlike fibronectin, which actually has an increased affinity for 
denatured collagen, von Willebrand factor does not bind to gelatin
(Bockenstedt e t a l . ,  1986). Von Willebrand factor is a substratum for a 
transglutaminase reaction catalysed by factor Xllla and can be covalently 
crosslinked to the fibrin alpha-chain (Hada e t a l- ,  1986). To date there 
are no reports on the role of von Willebrand factor during the arrest of 
circulating cells, be it leukocytes/lymphocytes or metastasizing tumour 
cells.
In te grins
The interactions of cells with the extracellular matrix are mediated by a 
variety of cell surface molecules- Some of these are glycosaminoglyeans, 
fibronectins and perhaps also other structural glycoproteins which may
have an additional transmembrane domain or be bound to phospholipids 
and gangliosides of the cell membrane and that could provide a link with
the extracellular environment because of their ability to bind a number of 
different ligands. Cells also possess an array of receptors of more 
conventional type which have a ligand binding site in their extracellular 
portion, a transmembrane domain and an intracellular part which may be 
linked with the cytoskeleton and mediate signals from the extracellular 
environment.
Fibrinogen, laminin and collagen receptors have been Identified in the 
past. These are small molecules witii 30,000-80,000 and are unrelated
to each other (von der Mark e t a l., 1984; von der Mark and Kulil, 1985;
Buck and Horwitz, 1987; Levesque e t a l . ,  1990) but, more recently, 
investigators from two separate fields (cell biology and immunology) have
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independently uncovered the existence of a number of related receptors 
for the extracellular environment. In view of the structural and
functional similarities shared by these molecules, it is believed that they 
are all members of a super family of cell surface receptors which have 
been termed "integrins".
In evolutionary terms the integiin family is very ancient, in fact in
Drosophila there are homologous structures implicated in development 
called position-specific (PS) antigens (Kishlmoto et a l . ,  1989). The basic 
structure of integrins is an alpha-beta heterodimer, non covalently linked, 
with Mr usually approximately 250,000. The beta subunit has a high 
cysteine content and is composed of an extracellular domain, a
transmembrane domain and a cytoplasmic domain; overall there is between 
35 and 45 % aminoacid identity between beta subunits, with particularly 
high conservation in the transmembrane and cytoplasmic domains 
(Kishlmoto et a l ., 1989). The alpha subunits are integral membrane
proteins with a long extracellular domain, a hydrophobic transmembrane 
domain and a short cytoplasmic region; the polypeptide backbones are all
of similar size and the differences in Mr could be due to the number of
potential glycosylation sites; each alpha subunit contains three putative 
metal binding regions which are highly conserved. There is strong 
homology (>47 %) among the alpha ,^ alpha,, and alpha  ^ and among the 
alphav, alphaiib and alphai..?, but the homology drops to 27 % between 
these two groups. The alpha-beta heterodimer has a talin binding site in 
its cytoplasmic tail (Buck and Horwitz, 1987).
Probably the first of such molecules ever identified is the platelet 
membrane glycoprotein Ilb/IIIa, whose discovery dates from the mid 1970' 
despites the fact that its functional identity was unveiled much later, but 
the work that lead to the present body of knowledge about integrins 
derived from a new approach used to search, in the early 1980', for the
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cell receptor for fibronectin- The fibronectin molecule was digested into 
different fragments using a series of proteases and, after a small cell
binding portion was identified and mapped, short synthetic peptides of 
this fragment were studied and it was found that cells specifically 
recognize and bind to a tripeptide sequence of the fibronectin molecule:
arginine-glycine-aspartic acid (arg-gly-asp; RGD - Pierschbacher and 
Ruoslahti, 1984). Using affinity chromatography on immobilized cell
binding fragments of fibronectin, a fibronectin receptor was isolated from 
cell membrane extracts (Pytela et a l . , 1985).
RGD LDV
Fibronectin Fibronectin
Thrombospondin Thrombospondin
Nidogen* Nidogen
von Willebrand factor von Willebrand factor
Fibrinogen Fibrinogen
Osteopontin N-CAM
HLA-B associated (BAT-2)^ L-CAM
Vitronectin 03
Laminin Collagen alpha,. (I)
Tenascin Collagen alpha, (III)
Endoglin^ Collagen alpha, (IV)
Collagen IV Collagen alpha, (XI)
BSP-2*
VP-1 (foot and mouth disease virus)®
Trigramin (snake venom)®
TP (bacteriophages phi29 and M2)^
Filamentous hemagglutinin (B. pertussis)®
Table 1: adhesive molecules containing an RGD or LDV sequence.
From : Humphries et a l . ,  1990. Additional references: 1 Nagayoshi e t al . ,
1989; 2 Banerji e t a l . ,  1990; 3 Gougos and Letarte, 1990; 4 Ruoslahti, 1988;
5 Fox et a l . ,  1989; 6 Huang et a l . ,  1989; 7 Kobayashi e t a l . ,  1990;
8 Reiman e t a 1 . , 1989.
The notion that three aminoacids were all that was needed for cells to 
specifically adhere to fibronectin was innovative and;, searching through 
the data bank of already sequenced proteins ^  it was found that many 
molecules contained the adhesive sequence RGD in a position accessible for 
interactions with a receptor (a list of adhesive molecules containing this
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sequence is shown in table 1). More RGD-binding molecules were being 
found, all quite similar to each other but many showing preferential
binding to one or more RGD-containing ligands (Pytela e t al., 1985b; 
Pytela e t  al., 1986; Pytela e t al., 1987; Buck and Horwitz, 1987.). The
emerging consensus was that RGD functions as specific "glue" while the 
adjacent aminoacids conferred the ligand specificity and the integrins
molecules were termed RGD-binding proteins. Only later it became 
apparent that RGD is not the only sequence that can act as glue, since 
some of the integrins ligands like the 1C AMs do not have this sequence
(Warwryk e t al,, 1989) and that LDV and REDV are two other short
sequences that can be recognized by some integrins (Humphries e t al., 
1990; Garcia-Pardo e t a l . ,  1990). In table 1 there is a list of some of the 
LDV-containing molecules implicated in cell adliesion; it is probable that 
other recognition and glueing sequences will be identified in the future.
To date 12 alpha and 6 beta subtmits have been identified and so far 
tlie integrin superfamily consists of 18 different receptors, although it is 
very likely that these numbers will be much larger in a not Loo distant 
future. According to the current classification, integrins can be separated 
into six families, each with a common beta subunit, as shown in table 2. 
The beta, molecules, also known as the VLA (very late antigen) group, 
mediate cells to extracellular matrix adliesion. The betag group molecules
are also known as the leucocyte integrins or the CD 18 cluster; these 
integrins mediate cell-cell interactions and are important in leukocyte
function. The tliird family (betag) comprises of the vitronectin receptor 
and the platelet gpIIb/lIla, both RGD ligands; a shorter betag subunit has
been recently demonstrated (Krissansen et al., 1990) and therefore this 
family has been divided into betag^ and betag^ subgroups. The fourtli 
type of beta subunit (beta^) is an unusual beta chain with a much higher 
Mr (400,000) and a much larger cytoplasmic domain than those of other
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beta subunits; this beta chain has 4 type III repeats homologous to those 
of fibronectin and is linked to an alpha  ^ chain to function as a laminin 
receptor (Suzuki and Naitoh, 1990), The fifth beta subunit (betap) is 
engaged with an alpha* subunit to form one of the two lymphocyte-Payer's 
patch adhesion molecules (LPAM-1) involved in cell adhesion to the 
postcapillary venules of Payer's patches; LPAM-2 is a member of the first 
family of integrins (betaj alpha*). Lastly a betas subunit, linked to an 
alphav chain, forms the only member of the sixth group.
J
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subunitsM, X 10"^ ligandsrecognition sequence Other nam es
alpha,
130 ISOfl, alphag130Bi alphag
130
B, alpha*130 ISO
B, alphas
130 140B, alphas
130 140B, alpha?
130 200B, alphay
130 150B, alpha,.
130 180
Bg alphat95 180
Bg alphaw95 170
fig alphax95 ISO
Baa alphav120 150
Bsa alphajjb120 U S
flsb alphav®100 ISO
C oi,C ojv,I-'in  
Coi^Coji ,Co,;, ,Coiv,Covi jGe ,Lm,?Fn 
Coi,Lm,Fn,Iv  ^
Fnait,VGAM-l®
LDV or REDV
Fn,Iv*
RGDLm,Iv*
Lnineu^
Vn®,Fn
RGD9
VLA-1 
VLA-2, gpla-lla 
VLA-3 
VLA-4, LPAM-2'* 
VLA-5, FnR, gplc-lla 
VLA-6, gplc’-lla
ICAM-l,ICAM-2
Fx,C3b*,Fb
9
Vn,Fb,Op/BSP-1 ,vWf ,TSP''
RGD
Fb,Fn,Vn,vWf,(TSP^)
RGD
9
CD „a/C D ia,LFA -l 
CDun/CDiB,Mac-l ,Mo-1 ,OKM-1 ,CR3 
CDuc/CDia,pl50/95,CR4,LeuM5
VnR 
gpIIb/IIIa 
(? Bg-alphaV)
fl* alphas400 140 Lm 
PP-PCVE 
Vn,Fn
RGD
Integrins not as yet fully characterized: SQMP
Bp alpha»
130 160
fig alphav"ISO
LPAM-i'*
(? fiab-alphaV) 
LRI“ , Gap b3' .^
Table 3: the integrin super family.
Abbreviations: BSP= bone sialoprotein; Co= collagen; CR3= complement
receptor for C3; C3b,= complement component 3b*; Fb= fibrin(ogen); Fn= 
fibronectin; Fna,t= Fn alternatively spliced; Fy= coagulation factor X; Ge= 
gelatin ICAM= intercellular adhesion molecule; Iv= invasin (Yersinia 
pseudo tuberculosis); LFA= lymphocyte function associated; Lm= laminin; 
Lmnw= neuron b.s. of laminin; LPAM= lymphocyte-Payer's patch adhesion 
molecule; Op= osteopontin; PP-PCVE= post capillary venule endothelium of 
Payer's patches; TSP= thrombospondin; VCAM= vascular cell adhesion 
molecule; VLA= very late antigen; Vn= vitronectin; VnR= vitronectin 
receptor; vWf- von Willefrand factor;
From :Ruoslahti and Giancotti, 1989; Kishimoto et al., 1989; Sonnenberg et  
a l . ,  1990. Additional references: 1 Staatz e t a 1 , , 1990; 2 Isberg and
Leong, 1990; 3 Elices e t a 1 . , 1990; 4 Holzmann and Weissman, 1989; 5 
Ignatius and Reichardt, 1988; 6 Bodary and McLean, 1990; 7 Lawler and 
Hynes, 1989; 8 Krissansen e t a 1 . , 1990; 9 Freed e t a 1 . , 1990; 10 Wong et  
ai . , 1990; 11 Gresham et a l . ,  1989; 12 Tsuji e t a 1 . , 1990.
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The extracellular matrix is thus an environment very rich in adhesive
stimuli. However, most of the molecular components of the subendothelial 
matrix so far described can also be found on the surface of the 
endothelium and on other cells. Many molecules interact directly with the 
cell surface and, in fact, it is at times very difficult to understand 
whether these are part of the extracellular matrix or of the cell surface.
To add to this, the same type of molecule can either form fibrils (the
scaffolding of the matrix) or be an integral component of the plasma 
membrane. All these molecules are able to interact with each other in 
many different combinations and, when present on the cell surface, 
enhance the adhesive potential of the cell. Additionally, it is possible to 
envisage how each molecule present in the extracellular matrix may have a 
number of different sites specific for different cell surface receptors
(integrins or non integrins) and mediating different and independent 
functions and messages. However, in spite of the fact that there are no 
distinct boundaries between cells and extracellular matrices and that the 
environment is full of an array of multivalent molecules, cell adhesion is a 
well disciplined phenomenon of fundamental importance. Future research 
should focus on understanding which of these interactions are of 
physiological importance and how they are regulated.
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The B16F10 cell line
To investigate the process of metastasis various model systems have 
been developed in the past. Before the introduction of cell culture
techniques, most of the work on metastasis was done using transplantable 
tumours. In those days there was little awareness of the immunological 
problems associated with non-syngeneic transplantation and indeed many 
experiments were based on models using human tumours in experimental 
animals. Additionally, some systems were based on chemically-induced 
tumours and the data obtained from them had a great deal of inherent 
variation.
It was only with the introduction of cell culture techniques and the 
understanding of the mechanisms underlying the rejection of transplants, 
that better model systems were developed. The BI6 malignant melanoma is 
probably the most widely used model for investigating metastasis. The 
cell lines used in this model are derived from a transplantable malignant 
melanoma that arose spontaneously in a mouse of the C57B16/J strain in 
1954 (Green, 1968). This tumour, called BIB melanoma, was later adapted 
by Fidler (1970) to in v itro  growth.
Subsequently Fidler (1973) selected from the B16 population through 
repeated in vivo passages in syngeneic mice a series of sublines with 
differing abilities to form lung colonies when injected as single cell 
suspensions into the tail vein. From this original work two cell lines 
emerged which were used in a large number of studies. They were called 
B16F1 and B16F10 because they were obtained after 1 and 10 in vivo 
passages respectively (for review see Nlcolson, 1982).
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Stackpole (1981), in a carefully conducted study, demonstrated that the 
B16 population contains distinct metastasizing and colonizing phenotypes 
and suggested that within the sublines selected in vivo for lung colony 
formation (like the B16F10) there may be absence of the metastasizing 
phenotype.
When introduced directly into the blood stream as single cell 
suspensions, either by injection into the left ventricle or into the tail 
vein, the B16F10 has a high colonizing efficiency for the lungs, but rarely 
produces extrapulmonary foci. The B16F1 on the other hand, although
Although the B16F1 and B16F10 are established lines that were 
extensively manipulated during the selection procedure, they are widely 
used for their ability to preferentially colonize tissues according to 
determined patterns when injected intravenously into syngeneic mice. The 
cell lines have therefore been used as a tool to study the spread of 
métastasas via the circulatory system.
In this respect many investigators have given the impression that the 
use of intravenous injections of B16 cells in syngeneic mice represents a 
model for metastatic spread via the blood (Fidler, 1975; Winkelhake and
Nicolson, 1976; Rieber and Castillo, 1984; Poste and Nicolson, 1980; Hart et ;|1a l . ,  1980; Liotta et a l . ,  1980; Kimura and Xiang, 1986; Kawano et a l . , I
I1986; Miner et a l . , 1982; Poste et a l . , 1982). In reality this is merely an
assay for colonization, since, during metastasis formation, tumour cells |
ijmust somehow gain access to the circulation, while this important phase of i
the process is bypassed in the B16 model. Furthermore it is unlikely that 1
a tumour suddenly releases a large number of single cells directly into |:,jthe circulation (the standard inoculum consists of 10® cells), not to j
mention the artefactual systemic and localized effects of the significant ^
haemodilution that arises from the sudden introduction of a volume of |l
'1fluid corresponding to ~ to of the mouse blood volume. À
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producing fewer lung colonies, disseminate more easily to various other 
sites such as the brain, the ovaries, the liver, the digestive system and 
the subcutaneous tissue (Fidler and Nicolson, 1976; D’Arrigo et a l . ,  1985). 
Because the B16F1 cells, when injected into the systemic circulation,
exhibit a propensity to establish foci of growth in many tissues, various
authors have subsequently selected from their population a series of 
different sublines having enhanced ability to give a certain pattern of
colonization. The selection procedures were in most cases adaptations of
the original strategy used by Fidler (1973),
Sublines with enhanced colonizing ability to the liver (B16L - Tao et 
a l, 1979), the ovaries (B16O10 - Brunson and Nicolson, 1979), the brain 
(B16B14b - Miner et a l, 1982), as well as sublines with increased ability to 
penetrate some structures such as the bladder wall (B16BL6 - Poste et
a l . ,  1980) or blood vessel wall (B16BV8 - Poste et a l . ,  1980) are examples 
of some of the sublines selected.
It has been shown that these colonization patterns do not merely
reflect the adaptation of some tumour cells to grow in specific
environments but are rather the result of the selection imposed by the
entire colonization process, which involves survival, arrest, invasion and
growth at discrete sites (Nicolson, 1982). In fact attempts to obtain a
B16F10-like subline from the parent B16 cells using an injection protocol
that allows non-discriminating mechanical lodging in the lung circulation 
(as is the case in the work of Nicolson and Custead, 1982, who injected 
cells attached to microcarrier beads of 180 um of diameter) resulted in
failure to select a subline with a high lung colonizing potential.
Within the B16F10 subline, as well as other sublines selected from the
original B16 line, there is evident heterogeneity, not only for biochemical 
markers such as melanin content, but also for colonizing potentials and
malignant phenotype (Elvin and Evans, 1985; Tao and Burger, 1977;
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Stackpole, 1981). Even within an individual lung colony cells with different 
colonizing ability exist, although the clonal diversity found in each colony 
is substantially less than that found within the subline. This would 
suggest that each lung colony originates from a single cell and, in fact. 
Poste and co-workers (1982), using cells bearing resistance to various 
drugs, found that the majority of lung colonies (> 90 %) were monoclonal 
in origin.
After intravenous injection, B16F10 cells that colonize the lungs 
extravasate and are fomid growing witliin the parenchyma of this organ. 
This is in contrast with their colonizing habits in other sites. If these
cells are injected in the portal vein a widespread colonization of the liver 
results but the colonies are rather the consequence of intravascular 
growth and tumour cells do not migrate tlurough the endothelium, at least
not within the first few days (Nicolson, 1982).
Wlien cloned, tumour cells from either the original BIG line or from any
of the selected sublines may be relatively stable in short term cultures 
but with time they diverge to reform a heterogeneous population. Within
the population there seem to be mechanisms to regulate the growth of
each different phenotype, as was shown by Miner and co-workers (1982)
who found that three clones with brain colonizing . ability were unstable 
following in v itro  culture, losing their ability to colonize the brain, while
retaining this colonizing property when co-cultured.
That tlie reason for the BIGF 10 lung colonizing habits resides on the
surface of these cells can be shown by transferring fragments of cell
membrane from B16F10 cells to a subline with lower Incidence of lung 
colonies, such as tlie B16F1. This can be done by fusing purified vesicles
shed by B16F10 cells (shedding occurs spontaneously both in vivo and in 
v itro ) to B16F1 cells, as done by Poste and Nicolson (1980), who showed 
that the lung colonies formed by B16F1 cells with integrated fragments of
7 0
B16F10 membrane were significantly increased. Such an effect is 
nevertheless transient and correlates with the natural turnover of 
membrane components.
Fidler (1975) showed that the adhesion to host lymphocytes was more 
pronounced within the B16F10 population than within the B16F1. When the 
B16F10 cells were selected for survival against lymphocyte killing, he was 
able to obtain a subline, called B16Lr6, which was no longer susceptible to 
lymphocyte-mediated cytotoxicity (Fidler et a l . , 1976). The cells of this 
line exhibited reduced lymphocyte binding and limited ability to form lung 
colonies.
Cells from B16 sublines also show an increased propensity to establish 
heterotypic adhesion with cell suspensions from the preferred organs of 
colonization and in some cases it has been possible to demonstrate 
enhanced adhesion to endothelial monolayers derived from target organs 
(Nicolson, 1982; Roos, 1984). Investigations of the specific density of the 
cells forming the populations of various B16 sublines, as determined by 
isopycnic density gradients of colloidal silica (Percoll), indicate that a 
correlation exists between lung colonizing ability and cell density. B16F1 
cells have a higher mean density than the B16F10 and the population of 
the original B16 line shows a broad distribution of density, with cells from 
low density fractions exhibiting a higher ability to form lung colonies than 
cells from the higher density fractions (Baniyash e t a l., 1981).
B16F10 cells produce a variety of enzymes that can degrade components 
of the sub-endothelial matrix. Matrix-bound fibronectin and perhaps also 
laminin are dissociated from the matrix by means of proteolytic activity by 
these cells, and heparan sulphate and other sulfated giycosaminoglycans 
are solubilized in greater quantities by B16F10 cells than by B16F1 cells 
(Nicolson, 1982).
B16F10 cells produce and release several lysosomal enzymes such as
71
acid phosphatase, many glycosidases, cathepsin D and cathepsin B. 
Cathepsin B is present in quantities three to four times higher in the 
B16F10 than in the B16F1 cells and its secretion has been shown to be
increased in malignant neoplasms of the breast when compared to benign
tumours or normal breast tissue (Nicolson, 1982). Cathepsin B seems to 
activate procollagenases and helps in the degradation of proteoglycans. 
The B16F10 cell population is also a source of collagenases against various 
types of collagens, of endoglycosidases, of plasminogen activator, a serine 
protease that converts plasminogen into plasmin, as well as of an inhibitor 
of such an activator (Liotta et al. ,  1980; Hart, 1979; Nicolson, 1982).
Prostaglandins are produced in different amounts by different sublines: 
PgD2 is produced more abundantly by B16F1 cells than by B16F10 which 
also produce PgEg and PgFz* (Fitzpatrick and Stringfellow, 1979).
Production of PgDg has been implicated in influencing the colonizing
phenotype because of its anti- thrombogenic action (Stringfellow and 
Fitzpatrick, 1979). It has been suggested that platelet aggregation and 
thrombus formation to cover the tumour cells which have arrested in the 
pulmonary circulation is important in the establishment of a focus of 
growth (Stringfellow and Fitzpatrick, 1979).
Macromolecules such as fibronectin and thrombospondin are produced 
and promptly released by these cells. It has been calculated that within 
48 hours cultured B16 cells secrete " 36% of their newly synthesized
macromolecules and shed 44% of tumour associated antigens (Nicolson, 
1982). The rapid release of synthesized material, especially macromolecules, 
is not peculiar to tumour cells but seems to be also a characteristic of 
normal cells.
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C oncluding rem arks
The arrest phase at the metastatic site is probably one of the most 
critical steps of the spread of tumours via the blood stream. The
mechanism of arrest is not known. The circulating tumour cell could form 
a thrombus with platelets or an embolus with other tumour cells and
arrest simply by lodging in a smaller diameter vessel. On the other hand 
the phase of arrest could rely on specific tumour cell-blood vessel wall 
interactions with an underlying mechanism similar to the one involved in 
lymphocyte recirculation (Bjerknes e t a l.,  1986). This mode of arrest, as 
opposed to mechanical lodging, would rely on ligand-receptor interactions 
and can therefore be called specific arrest. If specific arrest does occur, 
tumour cells must possess a machinery that enable them to adhere to the 
surface of the vessel wall in a very short time and with enough strength 
to resist detachment by the flowing blood.
This study was an attempt to establish whether tumour cells have 
adhesive properties of the kind required for specific arrest. In order to 
establish this it was decided to use an in v itro  assay to assess rapid
adliesiori. It would be impossible to recreate with any accuracy in an in
v itro  assay the hydrodynamic forces and the environment that tumour 
cells encounter during the arrest phase. In this sense, any in v itro  
assay to investigate this phenomenon has the limitation that some of the 
parameters of the assay may not compare closely enough to the in vivo
situation. Since the assessment of adliesion is strongly dependent on
factors like the timescale available to the cells to establish contact with 
the substratum or the quality and quantity of the forces that act towards
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the disruption of adhesion, in v itro  assays will always represent an 
approximate assessment of the phenomenon. On the other hand, in v itro  
work allows freedom to interfere with the system and manipulate it under 
carefully controlled conditions, and the generation of interpretable data 
represent at this stage a reasonable compromise.
The second purpose of this study was to assess the suitability of 
various components of the blood vessel wall to promote tlie adhesion of 
tumour cells. A third aim was to introduce into the assay system factors 
that would enhance or diminish the adhesion of tumour cells and study 
their effects on various substrata in order to establish whether the
adhesion of tumour cells to the endothelium can be attributed to any of 
the adhesive molecules produced by the endothelial cells.
Since the in v itro  adhesion assay gives indications only on interactions 
that occur In the first few minutes of the process, this study utilized also 
a second in v itro  assay to monitor the long term fate of the adhesive
interactions. This second assay assessed the ability of tiumour cells to
flatten and spread on various substrata. Spreading results in an increase 
of the number of adliesion points that a cell establish with the substratum 
(or in an increase in the area in which these points are contained) and
this may be accompanied by secretion of extracellular material and 
enzymatic modification of the substratum. The suitability of a substratum 
for such activity may be relevant to the phenomenon of specific arrest.
The final part of this study was the extraction, partial purification and 
characterization of an endothelial cell-derived adhesion factor. The 
adhesive properties of tlie extracted material was studied and compared 
with other adhesive substrata using in v itro  adhesion and spreading 
assays.
The cells used in this work were the FI, FIO and BL6 variants of the 
B16 mouse malignant melanoma and the BAE cells (bovine aortic endothelial
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cell). The use of BAE cells gave us the convenience of working with 
continuous cell lines, avoiding the need to establish primary cultures 
periodically. There are some inherent complications associated with the 
use of primary cultures, such as less reproducible results because of
inevitable differences between batches, tlie increase in the risk of occult 
infections that would render the interpretation of the results very 
difficult and the increased work load. The tumour cells lines were chosen
because they were known to possess suitable characteristics for use in
our assay systems. In fact these cells are capable of arresting in the 
microcircuiation when injected in vivo. Moreover single cell suspensions 
can be prepared without resorting to the use of enzymes which could
denude the cell surface of important molecules involved in the binding to 
the endothelium- Above ail our laboratory has years of experience in the 
manipulation and behavioiur of all these ceil lines.
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P la s t ic  and g la ssw a re
Tissue culture grade plastic Petri dishes of 3 cm (cat.no. 1-53066), 6 cm
(cat.no. 1-50288A), 9 cm (cat.no. 1-50350A) and 14 cm in diameter (cat.no.
1-68381A), tissue culture grade plastic multidish clusters with 24 wells
(cat.no, 1-46485A) and tissue culture grade plastic microdish plates with 72 
wells and Terasaki configuration (cat.no. 1-36528A) were all Nunc products 
and purchased from Gibco.
Two litre borosilicate glass roller bottles with a surface area of 750 cm^  
(Wheaton, USA) were obtained from Flow Laboratories (cat.no, 60-210-00).
Screw cap 1.8 ml polypropylene tubes for storage of cells in liquid
nitrogen were purchased from Gibco (cat.no. 3-63401A). Sterile centrifuge 
tubes with a conical base, screw cap and a capacity of 10 ml (polystyrene, 
cat.no. 144AS), 25 ml (polystyrene, cat.no. 128A) and 50 ml (polypropylene, 
cat.no. 36050) were purchased from Sterilin.
Polypropylene microcentrifuge tubes with integral caps and a capacity 
of 1.5 ml (cat.no, LW 2075) and 0.5 ml (cat.no. LW 2072) were purchased 
from Alpha Laboratories, UK.
Sterile polypropylene 2 ml micro tubes with a conical bottom, flat base 
and screw cap with O-ring were purchased from Sarstedt, West Germany 
(cat.no. 72.694.006).
Sterile flat bottom polystyrene tubes with screw cap and a capacity of 
5 ml (cat.no. Z6744) and 10 ml (cat.no. Z9944) were purchased from Teklab 
Medical Laboratories, UK.
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G en era l p roced u res and ch em ic a ls
Sterilization by filtration was achieved in a system pressurized with
inert gas (nitrogen) using durapore (polyvinylidene di fluoride) membrane 
filters (Millipore Co.) with pores of 0.22 um in diameter- Glassware was 
dry heat sterilized in an oven at 250° C for 4 hours. Glass bottles, filter
membranes and pipette tips were sterilizeid in an autoclave at 121” C for
40 minutes.
All chemicals were of analytical grade, unless otherwise stated, and 
were obtained from BDH or Sigma Chemicals. The water used throughout 
this study was glass double distilled from deionized tap water and 
sterilized by filtration.
Minimum Essential Medium (MEM) of Eagle (modified), with Earle's salts
was purchased from Flow Laboratories (cat.no. 10-101-24) as premixed
powder. It was reconstituted with the appropriate volume of distilled 
water, supplemented with 2 g/1 NaHCO] and buffered with COg to pH 7.2. 
It was then sterilized by filtration and stored in 100 ml aliquots at 4" C. 
Each batch of medium was tested for sterility and used within 60 days.
Phosphate buffered saline (PBS) and Ca^  ^ and Mg'"*-free PBS (D") were
prepared according to Dulbecco's formulae (see Flow Laboratories, 1987 
catalogue, page 57) to a pH of 7.2, sterilized by filtration, stored in 100 ml 
aliquots at 4” C and used within 60 days.
A 100 times concentrated solution of non-essential amino acids for 
Eagle's MEM of was purchased from Flow Laboratories (cat.no. 16-810-49), 
stored in 1 ml aliquots in 5 ml Teklab tubes at 4” C and used within 60 
days.
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L-glutamine was purchased from Flow Laboratories (cat.no. 15-801-15),
dissolved in PBS to a concentration of 200 mM, filter sterilized, stored in 1 
ml aliquots in 5 ml Teklab tubes at -20° C, and used within 3 months.
Hepes was purchased from Sigma Chemicals as free acid (cat.no. H 3375)
and as the sodium salt (cat.no. H 7006). A I M  solution with a pH of 7.4
at 37° C was prepared, sterilized by filtration, stored in 1 ml aliquots in 5
ml Teklab tubes at 4° C, and used within 6 months.
Insulin was purchased from Sigma Chemicals (cat.no. I 5500), prepared 
to a concentration of 12.5 lU ml’^  in PBS, sterilized by filtration, stored 
in 5 ml Teklab tubes in 1 ml aliquots at 4° C, and used within 60 days.
A 100 mM solution of Na-pyruvate was purchased from Flow 
Laboratories (cat.no. 16-820-49), stored in 1 ml aliquots in 5 ml Teklab 
tubes at -20° C, and used within 3 months.
A 100 times concentrated solution of vltamins for MEM of Eagle was
purchased from Flow Laboratories (cat.no. 16-014-49), stored in ! ml
aliquots in 5 ml Teklab tubes at -20° C, and used within 3 montlis.
BP (Glaxo, UK) and streptomycin sulfate BP (Evans,
UK) were dissolved together in PBS at a concentration of 5000 lU mi'' and 
5 mg m f  respectively, sterilized by filtration, stored in 1 mi aliquots in 5 
ml Teklab tubes at -20° C, and used within 3 months.
Endothelial cell growth supplement was purchased from Sigma Chemicals
(cat.no. E 2759), dissolved in PBS at a concentration of 0.5 mg ml*', stored 
in 1 ml aliquots in 5 ml Teklab tubes at -20° C, and used within 3 months.
Mycoplasma and virus-free fetal calf serum (FCS), sterilized through a 
membrane filter with pores 0.1 um in diameter, was obtained from Gibco 
(cat.no. 011-6290), and stored in 10 ml aliquots in 10 ml Teklab tubes at
- 20° C. Because of the variability even within the same batch with
regards to the ability to support the growth of BAE cells, an aliquot from 
each 500 ml bottle received, from Gibco was tested for this purpose and, if
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found positive, used to supplement BAE cell medium,
Ethvlenediaminetetra-acetic acid, disodium salt (EDTA) was purchased 
from BDH (cat.no. 10093) and dissolved in D* at a concentration of 2 mM.
The solution was filter sterilized, stored in 9 ml aliquots in 10 ml Teklab 
tubes at 4° C, and used within 60 days. This solution is here referred to 
as EDTA-DL
Bacto-trypsin was obtained from Difco and dissolved in D" at a
concentration of 0.5 % w/v. The solution was filter sterilized, stored in 1 
ml aliquots at -20° C, and used within 3 months.
Bovine__serum albumin (BSA) was purchased from Sigma Chemicals
(cat.no. A 7906) and dissolved in distilled water at a concentration of 21 % 
w/v. The solution was then sterilized by filtration tlirough an assembly
of five membranes with mean pore diameter decreasing from 8 um to 0.22 
um. The concentration of BSA was estimated by reading the optical
density (O.D.) of the solution in a spectrophotometer (Pye Unicam SP 1800) 
at 280 run in quartz cells of I cm light path (Hellma type 6000-Blue), 
Icnowing from published work (Larson et a l . ,  1986) that a BSA solution of 
1 % w/v has an Eicm.zoo- 6.7 . The concentration of the solution was then 
adjusted to 20 % with distilled water. One ml aliquots were stored in 2 ml
Sarstedt tubes and stored at 4" C. Working solutions of BSA of lesser
strength were prepared by diluting this BSA solution in an appropriate 
buffer.
Laminln was purchased from Bethesda Research Laboratories (cat.no.
6260 LA). Purified polyclonal anti-laminin antibodies (IgG), raised in
rabbits, were purchased from Collaborative Research Inc. USA 
(cat.no.40023),
Polyclonal antibodies against human fibronectin. a gift of Scottish
Antibody Production Unit (cat.no. S037-205), were raised in sheep. The 
antibody preparation was purified by gel filtration on a 24 ml column
80
(12 cm X  2 cm^) of Sephadex G-75 M using PBS a s  eluent. The 
preparation was sterilized by filtration, the protein content was 
determined according to Bradford (1976), and samples were stored at 4° C.
The synthetic pent apep tide GRGDS (L-glycyl-L-arginyl-L-glycyl-L- 
aspartyl-L-serine) was obtained from Sigma Chemicals (cat.no. G 4391), 
reconstituted in 20 mM tris-HCl buffer containing 150 mM NaCl at pH 7.4, 
filter sterilized, stored at 4° C, and used within 30 days.
A monoclonal antibody against vitronectin was the gift of Dr. Ruoslilati 
(La Jolla Cancer Research Institute, La Jolla, USA).
Tunicamvcin was purchased from Sigma Chemicals (cat.no. T 7765). It 
was dissolved in 0.01 M NaOH at 10 ug mT', sterilized by filtration, stored 
in 1 ml aliquots in 5 ml Teklab tubes at -20° C and used within 30 days.
Leupentin was purchased from Sigma Chemicals (cat.no. L 2884).
Gelatin from bovine skin was purchased from Sigma Chemicals (cat.no. G
9382), dissolved in PBS at a concentration of 1 mg ml*', and sterilized by 
filtration. A solution of 95 % collagen t^me I and 5 % collagen type III 
extracted from bovine derma and suitable for tissue culture was prepared
by TM Collagen Corporation and obtained from Flow Laboratories (Vitrogen
lOOTM, cat.no. 60-000-49). Collagen___J:ype IV was purchased from
Collaborative Research Inc. (cat.no. 40233).
Von Willebrand factor purified from human blood was the gift of Dr. 
Nick Hunter (MRC SNBTS Blood Components Assay Group, Edinburgh).
Chondroitin sulfate from bovine trachea (cat.no. C 8529), derrnatan 
sulfate from porcine skin (chondroitin sulfate type B, cat.no. C 4259),
heparin-Na from porcine intestinal mucosa (cat.no. H 7005), heparan sulfate
from bovine kidney (cat.no. H 9637), keratan sulfate from bovine cornea 
(cat.no. K 3001) and hyaluronic acid from human umbilical cord (cat.no. H 
1751) were all purchased from Sigma Chemicals.
Single stranded deoxyribonucleic acid (DNA) from calf thymus (cat.no. D
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8899) and ribonucleic acid (RNA) from calf liver (cat.no. R 7250) were 
obtained from Sigma Chemicals.
Haemoglobin from bovine erythrocytes was purchased from Sigma 
Chemicals (cat.no. H 2625); it was dissolved in PBS, and sterilized by 
filtration. The protein concentration was determined according to 
Bradford (1976), and the preparation was stored at 4° C.
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Cell culture
For the model systems the source of endothelial cells were two 
continuous cell lines, both established from the endothelium of bovine 
aorta. The first line, a clonal derivative called BAED, was the gift of Dr.
Jean Starkey (University of Washington, Washington, DC, USA). BAED cells 
produce FVIII and form confluent monolayers in v itro  with the 
morphologic attributes of the endothelium. The second endothelial cell 
line, called BAES, was established by Dr. Schwartz (University of 
Washington, Washington, DC, USA) and obtained from Dr. Starkey 
(Gajdusek and Schwartz, 1983).
B16F10 and B16F1 cell lines were used as sources of tumour cells.
These were obtained from Dr. I. J. Fidler (Frederick Cancer Research I1Centre, Frederick, MD, USA). i
1
All cells were routinely handled in a horizontal sterile laminar air flow |
hood using sterile glass pipettes, a pipette pump and an aspirator. All dIplasticware was disposable and sterile. I
V JB16F10 and B16F1 cells were routinely cultured on a three day cycle. |
Only cultures which had been submitted to less than 20 passage cycles
were used. Samples containing cells with low passage number were kept
in a liquid nitrogen freezer in 1 ml aliquots containing 2 x 10® cells in
complete medium (see below) + 10 % v/v dimethyl sulfoxide (BDH
Chemicals). Freezing and thawing were performed according to published 
procedures (Freshney, 1983).
The medium used for routine cultures was Eagle's MEM, supplemented
with 10 % v/v of FCS, 1 mM Na-pyruvate, 2 mM L-glutamine, 50 lU mT* 
benzylpenicillin-Na B.P., 50 ug mT^  streptomycin sulfate B.P., 1 % v/v MEM
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non-essential aminoacids and 1 % v/v MEM vitamins. This supplemented 
medium is here referred to as complete Eagle's medium.
Cells were harvested according to the following routine. The spent 
medium was aspirated and the dish was rinsed with an equivalent volume 
of D~. The rinsing solution was aspirated and 0.8 or 2 ml of detachment 
medium (EDTA-D') were inoculated into Petri dishes of 6 or 9 cm in 
diameter respectively. After 1 minute of incubation at room temperature, 
the action of the detachment medium was neutralized by addition of 2.5 
volumes of complete Eagle’s medium and the cells were dislodged from the 
dish by gently squirting the medium onto the adhering cells using a 5 ml 
pipette. The cell suspension was transferred to a 10 ml centrifuge tube 
and submitted to 200 x g for 3 minutes in a refrigerated centrifuge (MSE 
Chilspin). After centrifugation the supernatant was discarded and the 
pellet resuspended in complete Eagle's medium using 1 ml of medium for
every estimated 10^  harvested cells. A single cell suspension was
obtained by passing the cells through the orifice of a 5 ml pipette and a 
series of 10 such passages was enough to obtain a suspension with > 90 % 
single cells. Cell concentration was determined by an electronic count of 
a 40 ul sample diluted in 20 ml of isotonic solution (Isoton II, Coulter 
Electronics, U.K.). Two readings of the number of suspended particles 
contained in 0.5 ml of the isotonic cocktail were performed using a Coulter 
Counter (model ZB 100, Coulter Electronics, U.K.) mounted with a probe 
having an orifice of 100 um diameter. In order to maximize the accuracy 
the following settings were used: attenuation = 64, aperture current =
0.177, upper threshold = 86, lower threshold = 10. The distribution of the 
counted particles was analyzed using a channelyzer (model Cl000, Coulter
Electronics, U.K.) set on a base channel threshold of 5 and a window
width of 100. This procedure was used both to eliminate sub threshold 
counts in order to obtain a more accurate evaluation of the density of the
1
84 j
cell suspension and to check the size distribution of cells within the
sample. Cells were seeded in Petri dishes of 6 or 9 cm of diameter, 
containing 3.5 or 10 ml of complete Eagle’s medium respectively, at a 
concentration of 3.6 x 10^  cells cmT^ . The plates containing the cell 
inocula were gently shaken to disperse the cells in the medium and then
placed in a Heraeus incubator (type B5060 EK/COg, Heraeus GmbH, West
Germany) at 37° C in a humidified atmosphere containing 95 % air and 5 %
COg.
BAE cells were routinely cultured in a variety of tissue culture plastic 
dishes and in pyrex roller bottles. The cells were kept on a 3 days cycle 
and used for up to 20 passages. Storage, freezing and thawing of these 
cells were as described for the B16 cell line. The medium used for 
routine cultures was complete Eagle’s medium (containing FCS which could
support BAE cell growth) further supplemented with 5 ug ml"' of 
endothelial cell growth supplement and 0.125 lU mi"^  of insulin. This 
medium is called complete BAE medium.
BAE cells were harvested following a routine similar to that used for 
the B16 cells, the only differences being that the monolayer of BAE cells 
was incubated with the detachment medium for 3 minutes at 37° C and 
that such detachment medium also contained 0.05 % w/v of trypsin. This
detachment medium is referred to as T-EDTA.
BAE cells were plated at a concentration of 9 x 10^  cell cm~^  in 9 or 14
cm diameter Petri dishes or in 750 cm* roller bottles containing 10, 25 and
117 ml of complete BAE medium respectively. Petri dishes were placed in 
an Heraeus incubator, as for the B16 cells, while bottles were gassed with
a mixture of 95 % air and 5 % COg and incubated in a hot room at 37° C 
rolling at 0.7 rpm. j
BAE cells to be used in adhesion assays were seeded 3 days prior the
-iassay in 24-well plates at the somewhat higher concentration of 2.5 x 10®
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cells cm * in order to obtain a confluent monolayer. Briefly, cells, 
harvested as per usual, were resuspended at a concentration of 5 x 10® 
cells mr' in complete BAE medium and 1 ml of this suspension was 
inoculated into each well of the 24-well plate. The plates were then
placed in a Heraeus incubator as described previously. After 48 hours
the medium was carefully aspirated and substituted with an equal volume 
of fresh complete BAE medium containing 10 mM Hepes buffer and the 
plates returned to the incubator where cells were allowed to grow for a 
further 24 hours.
Cell viability was measured using the trypan blue dye exclusion test. 
Trypan blue solution (Sigma Chemicals, cat.no. T 9520) was diluted in PBS 
to a concentration of 0.2 % w/v. A chamber was constructed by attaching
two strips of proprietary adhesive tape parallel to the shorter side of a
glass slide leaving a gap between each strip of ~ 1.25 cm. Twenty ul of
dye solution were mixed on the glass slide with 20 ul of cell suspension.
A cover glass was then placed on top of the liquid and, using a light 
microscope with a 200 x magnification, at least 200 cells were scored for 
their ability to exclude the dye. In isotonic medium and at physiological 
pH, trypan blue diffuses freely across cell membranes but viable cells 
actively transport it extracellularly. Failure to do so results in 
intracellular accumulation of the dye and therefore non viable cells are 
stained blue (Freshney, 1983),
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A d h esion  a ssa y
B16 cells were cultured as described earlier and harvested as per
usual, when subconfluent, after three days of growth. Cells were
resuspended in complete Eagle's medium containing 10 mM Hepes and
diluted in a 25 ml centrifuge tube to a concentration of 4 x 10® cells ml*'
in a volume of 4 ml. Before the assay, the cell suspension was incubated
at 37° C for 10 min in order to equilibrate the temperature of the 
suspension to that used during the assay. Monolayers of BAE cells grown 
to confluence in a 24-well plate, were transferred to a hot air cabinet
heated at 37° C and spent medium was carefully removed with the help of
an aspirator immediately before the addition of the tumour cell suspension. 
Inocula of 0.2 ml of B16 cell suspension were carefully and rapidly 
delivered using a repetitive syringe (Eppendorf, West Germany, Multipette 
mod. 4780, with a 5 ml syringe tip) into each well and into two vials
containing isoton. These two vials were used to accurately determine the 
number of cells inoculated into each well.
Following inoculation, each well was sealed with an appropriately 
modified 10 ml plastic syringe bearing an inlet and an outlet tube (see
figure 14). The inlet tube was connected to a reservoir containing an 
isotonic buffered salt solution (Hepes-HCl 20 mM, NaCl 0.9 % w/v, pH 7.4) 
and capable of delivering a constant volume per unit of time under the 
principle of the Mariotte flask. The reservoir was placed on a laboratory 
jack and flow rate was regulated by lowering or raising the reservoir 
relative to the outlet tube. After a set time each inlet flow valve was 
opened and the well flooded with isotonic solution, which was collected at
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the end of the outlet tubes in a set of plastic coulter vials (Coulter 
Electronics, U.K.) of uniform weight. The volume of isotonic solution 
contained in each vial was determined by weight. The cell concentration 
was determined by electronic counting using the same apparatus and 
settings described in the section on cell culture techniques.
ou t <1.5 mm l.d.)
In <1 mm l.d.)
air Inlet
Inlet tubes (12)
M ariotte  f la sk  V taps
outlet tubesyringe plugisotonicb u ffer
laboratory Jack for  
height adjustment coultervialsbaseplate 24-well plate
Figure 14; Apparatus for the adhesion assay. A syringe plug is shown at 
the top.
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For each experiment a well was inoculated with 0.2 ml of medium not 
containing cells and, by processing it as per usual, tlie number of 
endothelial cells detaching from the monolayer was determined 
Furthermore, a vial containing isotonic solution plus medium alone was 
counted so as to take into account any background noise introduced into 
the assay and this result was subtracted from all measurements obtained.
Vials were counted twice and the overall number of cells contained in
each of them determined according to the volume of isotonic solution 
collected. The total number of cells inoculated into each well was 
estimated by averaging the number of ceils inoculated directly into two
vials at the start of tlie assay. The percentage of adhering cells was
determined according to the formula:
% adhering ceils = (T - NA)/T x 100 
where T=number of cells inoculated and NA-number of non-adhering cells.
Each experiment t)/pically used a row of 6 wells, 5 of which received an 
inoculum containing tumour cells while one received medium alone. The 
five wells were sequentially washed at 1 minute intervals for 30 seconds 
with 15 ml of isotonic solution and a time-dependent curve of the adhesion 
kinetics was constructed. In each curve all point measttrements were
obtained during the same experiment. Alternatively, end point
measurements were performed by washing non adhering cells after 5 
minutes incubation. The apparatus was later modified so that 12 wells 
could be washed at the same time, thereby speeding up the procedure of 
screening for the adhesive fractions purified from the material extracted
From the endothelial monolayer.
When testing the adhesion properties of selected molecules or extracted 
material rather than endothelial monolayers, the wells of the plates were 
incubated at 37° C with 0.2 or 0.5 ml of the solution to be tested. An 
incubation time of 1 hour was chosen in order to achieve adsorption of
the molecules under test to the plastic substrata. Following this
incubation the solution was aspirated and the remaining free sites on the 
plastic were saturated by addition of 0.5 ml of a 1 % w/v solution of BSA 
in PBS and incubated at 37° C for a further hour. Following this 
treatm ent tlie BSA solution was aspirated and the wells washed three times 
with PBS before being used for the assay, which was performed as per 
usual.
Antibodies and peptides:
In some experiments antibodies were used in order to try to block the 
adhesiveness of endothelial monolayers or molecular substrata. For this 
purpose, the substrata were adsorbed with the adhesive molecules and the 
remaining free sites on the plastic were blocked with BSA, as already 
described. Alternatively, endothelial monolayers were seeded and grown to 
con fluency as described previously. The supernatant was then gently
aspirated and replaced with a medium containing I mg ml'  ^ of the 
antiserum to be tested. Following an incubation period of 1 hour tlie 
antiserum was removed and the well rinsed with three volumes of medium
before the adhesion assay was performed as per usual.
In other experiments the competitive effect of the fibronectin-derived 
pentapeptide GRGDS were studied. For this purpose, immediately before 
the addition of the tumour cells suspension, 100 ul of GRGDS solution was
inoculated into each well, quickly followed by an equal volume of a 
suspension of 8 x 10^  tumour cells ml" .^
Tunicarnycin, leupeptin and trypsin:
When the role in adhesion of the glycosylated proteins present on the 
surface of tumour cells was evaluated, B16F10 cells were cultured in the 
presence of the antibiotic tunicarnycin. This substance Inhibits the
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transfer of N-acetyl-glucosamine-1-phosphate to the dolichol
monophosphate unit at the end of the carbohydrate side chains of proteins 
during the processing of newly translated molecules, thereby blocking the |
glycosylation process (Duksin and Mahoney, 1982). Cells were cultured in I
Itheir usual medium and 3, 6, 12, 18, 24, 30, 36, and 48 hours before iiharvesting (that is 69, 66, 60, 54, 48, 42, 36 and 24 hours respectively i
;|after plating) 450 ul of tunicamycin solution were added to the medium to !1
give a final concentration of 0,45 ug ml"^ . The plate was then returned j
to the incubator. In other experiments cells were incubated in the J
presence of tunicamycin for 36 hours as described, after which the |1medium was carefully aspirated and substituted with complete Eagle's 1medium. The cells were then allowed to recover from the exposure to %
iItunicamycin for a period of 6, 12, 18 and 24 hours before the adhesion "N1assays. In further experiments cells were incubated with tunicamycin for |136 hours as described before together with the enzyme inhibitor leupeptin I
(acetyl-L-leucyl-L-leucyl-L-argininal) which was present in the culture
medium at the final concentration of 100 uM, 200 uM, 400 uM, 600 uM and 
800 uM. Following this treatment, adhesion assays were performed as per 
usual.
When the ability of trypsin to digest active molecules on the tumour 
cell surface was tested, B16F10 cells were harvested as per usual and
resuspended at a concentration of 8 x 10® cell ml'*'. Four ml of this cell
suspension was transferred to a 25 ml centrifuge tube and washed three
times with PBS or D~. The pellet was then resuspended in 1 ml of a
solution of trypsin 0.05 % w/v in PBS or D” and incubated at 37° C for 
various lengths of time. The reaction was stopped by the addition of 7 ml 
of warm complete Eagle's medium containing 10 mM Hepes and the adhesion 
assay performed as per usual.
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Formaldehyde, low temperature and EDTA:
In some experiments either the tumour cells or the endothelial
monolayer were fixed prior to the assay. To achieve this, B16F10 were 
harvested as per usual, resuspended in formol saline (4 % w/v
formaldehyde 0.9 % w/v NaCl, BDH cat.no. 23077 7A) and left for 45 minutes 
at room temperature, after which cells were centrifuged as per usual and 
resuspended in complete Eagle's medium with Hepes 10 mM. To obtain
substrata of fixed endothelium, the medium was aspirated from BAES 
monolayers ready for the assay and an equal volume of formol saline was 
added to the wells. After incubation at room temperature for various 
lengths of time the fixative was removed and complete BAE medium with 
Hepes 10 mM was added. Assays were then performed as usual.
When the adhesion kinetics of B16F10 cells on various substrata were 
studied at a temperature of 4° C, the apparatus for the assay was
transferred into the cold room beforehand and both the cell suspension 
and the substrata were precooled to 4° C,
In some experimentis the effect of EDTA on the adhesion of tumour cells 
to various substrata was tested. B16F10 cells were harvested as per 
usual with the exception that the medium used was EDTA-D containing
0.05 % w/v BSA and that the monolayer was washed three times with D 
before exposure to EDTA. Cells were then resuspended in EDTA-D + 0.05 
% BSA and the assay performed as usual.
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Spreading assay
For this assay B16F10 cells, grown for three days in 6 cm diameter 
Petri dishes as described, were harvested as per usual but with the 
following modifications:
1 The dishes were washed three times with 4 ml of D* before addition 
of detachment medium.
2 The medium used for the assay was complete Eagle's medium without 
fetal calf serum and with 0.05 % w/v BSA. This medium was called
complete BSA medium.
3 After dislodgement, cells were transferred to a centrifuge tube 
containing 0.2 ml of a 1 % w/v BSA solution in PBS.
Plastic tissue culture Terasaki plates were used in the spreading assay. 
The substratum was conditioned by the addition of 5 ul of solution
containing the agent to be tested, followed by incubation for 1 hour at
37° C. At the end of the incubation the spent solution was removed, 10 ul
of a solution of 20 % w/v BSA was added and the plate incubated for a
further 1 hour at 37° C in order to block the remaining reactive sites on 
the plastic. After washing with excess PBS 3 times, the plate was ready to
receive the cell suspension. This was 
at a concentration of 2 xlO"' cells ml"' 
and was inoculated into each well in 
10 ul aliquots. The plate was placed 
in a Heraeus incubator, as described, 
for 1 hour, after which the amount of 
spreading was determined by using a 
phase contrast inverted microscope 
(Olympus) and a magnification factor
of lOOx. With the help of a graticule,
Microphbtograph of round (arrow) 
and spread cells.
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all cells a t the bottom of each well were counted and scored subjectively 
as spread or round. For examples of spread (arrows) and round cells see 
the photograph on page 93. Parameters used Included: surface area
occupied by tlie cell and its shape, nucleus to cytoplasm ratio, presence of 
perinuclear or cytoplasmic glare, nucleoli and cytoplasmic opacity. Results
were expressed as percentage of spread cells.
When agents that could interfere with cell spreading (such as specific 
antibodies) were tested, three different procedures were followed after 
adsorption and blocking of the plastic substratum and subsequent washing 
of the wells:
1 Five ul of the test agent solution were added to the wells and 
incubated for 1 hour at 37° C, following which the solution was
aspirated, the wells washed tlrree times with PBS and cells added as 
per usual.
2 After incubation with 5 ul of test agent for 1 hour at 37° C, the 
solution was left in the wells and 5 ul of cell suspension were
added. Since the presence of ~ 200 cells per well was required for
the assay, the cell suspension was prepared at 4 x 10'* cells rni*'.
3 In some cases it was desirable to observe the effects of the test
agent when added at the same time as the cells. In such cases, 5
ul of test agent solution and 5 ul of a suspension of 4 x 10“ cells
ml”‘ were added simultaneously.
For all of these tliree methods, after the inoculation of the cell
suspension the assay was carried out as described before.
Wlien the kinetics of cell spreading were investigated, the assay was
performed as per usual but the incubation period was reduced 
accordingly. In this case, for each experiment data from several plates 
were used, since determining the number of spread cells after a set time
interval involved interrupting the incubation.
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Extraction from the endothelial cell monolayer
For the extraction, endothelial monolayers were grown for 3 days in 
roller bottles as described before.
Usually the extract from 6 roller bottles was prepared at the same time.
Medium was decanted and each bottle was gently washed 3 times with an 
equal volume of warm Ca^ "*° and Mg^ '*’ -free Tris buffered saline (Tris-HCl 
20 mM, NaCl 150 mM, pH 7.5, here called T®), then 10 ml of a solution of 2 
mM EDTA in T- were added and the bottles were returned to the hot room 
and incubated rolling as per usual. After 30 min the extracted material 
was transferred to a 25 ml conical tube and centrifuged at 200 x g for 5 
minutes in a refrigerated centrifuge (MSE Chilspin) in order to pellet |
detached cells. The supernatant was then transferred to a second conical 
tube and centrifuged as before but at 1500 x g for 30 minutes. The pellet 
was discarded and the supernatant sterilized by filtration and stored at 
4° C.
Production of extract from medium.
For this extraction, bottles, seeded according to the procedure used to 
obtain endothelial monolayers but without the addition of cells, were 
processed as described for the preparation of the endothelial extract. The 
extract from the medium constituted in effect a control for the endothelial 
extract.
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Liquid C h rom atograp hy
For preparative and experimental chromatography a low pressure 
system was used. The system was assembled around the liquid 
chromatography controller of a fraction collector (Fraction collector FRAC- 
100, Pharmacia, Sweden) and comprised an optical gradient maker 
(Ultrograd 11300 gradient mixer, LKB, Sweden), a fixed wavelength (280 
nm) photometer with a quartz flow cell (Single path monitor UV-1, 
Pharmacia, Sweden) and a plotter (Recorder REC-481, Pharmacia, Sweden).
Fluid drive was obtained by means of a peristaltic pump (Pump P-1, 
Pharmacia, Sweden) or by gravity feed using Mariotte flasks (LKB,
Sweden).
Borosilicate glass columns of three different cross sectional areas (0.78,
2.0 and 5.3 cm^ ) and various lengths, featuring adjustable end pieces in 
order to enable the reversing of the direction of flow, were obtained from 
Pharmacia (C-column system, Pharmacia, Sweden).
The gel filtration media Sephadex G-15, Sephadex G-25 M, Sephadex G- 
25 F, Sephadex G-50 M, Sephadex G-75, Sephadex G-lOO, Sephadex G-150, 
Sephadex G-200, and the ion exchange media Q Sepharose fast flow and S 
Sepharose fast flow were all obtained from Pharmacia, Sweden. For affinity |
Ijchromatography Affi-Gel-Gelatin (Bio-Rad Laboratories, cat.no. 153-6125), -iIHeparin-Agarose (Sigma Chemicals, cat.no. H 5380) and poly-L-lysine- I1Agarose (Sigma Chemicals, cat no. P 6893) were used. All these media ]
were hydrated, handled and packed under flow according to the
1manufacturers’ instructions and flow rates and operating pressures never I1exceeded the recommended values.
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All eluents were filter sterile and degassed by vacuum and a 5 um 
nylon mesh filter (obtained from Henry Simon Ltd, UK) was mounted in 
line at the inlet of the column.
Columns packed with gel filtration media were equilibrated in the 
buffer of choice and a standardization run was performed to determine the 
volume of the stationary phase and the void volume of each column. For 
such runs a mixture of high (2 x 10®) dextran (Blue Dextran, Sigma
Chemicals, cat.no. D 5751) and tyrosine (Sigma Chemicals, cat. no. T 3754) 
was applied to the top of the column, typically at a concentration of 0.1 
mg ml"' in an appropriate buffer. The elution profile of these standards 
allowed us to check that the chromatographic medium was correctly packed 
and that the experimentally determined values were in accordance with the 
estimated ones. Column parameters were calculated according to published 
procedures (Gel filtration, theory and practice, Pharmacia Fine Chemicals, -W
Sweden).
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Fibronectin purification
Flbronectin was purified from human plasma. Forty ml of peripheral
blood were obtained by venipuncture in the antecubital fossa and rapidly 
mixed with 4 ml of anticoagulant containing EDTA-Na  ^ 40 mM and Tris-HCl 
buffer 200 mM, pH 8.3. Plasma was obtained by centrifugation of the 
anticoagulated blood for 20 min at 1500 x g in a refrigerated centrifuge 
(MSE Chilspin). The supernatant layer of plasma was carefully removed 
using a plastic pipette and applied to a 25 ml column (4.5 cm x 5.3 cm^ ) of 
Affi Gel-Gelatin previously equilibrated with Tris-HCl buffer 20 mM pH 8.3. 
Application flow rates never exceeded 5.5 ml cm’® K*‘. The column was 
first washed with application buffer and then with the same buffer 
containing NaCl 1.0 M. Fibronectin was eluted, after flow inversion, with 
Na-acetate buffer 50 mM, NaBr 1.0 M, pH 5.0 at a flow rate of 5.5 ml cnT® 
1T\
The eluted material was collected and applied, with a flow rate of 225 
ml cnf® h’*, to a 150 ml column (28 cm x 5,3 cm®) of Sephadex G-25 M
previously equilibrated with Tris-HCl buffer 20 mM, pH 7.5. In order to
exchange the buffer, tris-HCl buffer 2 mM, pH 7.5 was used for the 
elution.
After buffer exchange the eluted material was applied with a flow rate 
of 225 ml cnT® to a 16 ml column (8 cm x 2 cm®) of Q Sepharose fast
flow previously equilibrated with Tris-HCl buffer 20 mM, pH 7.5. The 
column was washed with the same buffer until the O.D. returned to within 
2 % of the baseline. The material retained in the ion exchange column was 
eluted with NaCl 0.15 M in the same buffer. The elution of a sharp peak
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followed the change in eluent and once the O.D. at the outlet returned to 
within 2 % of the baseline the flow was reversed and the remaining
material retained in the column was eluted with Tris-HCl buffer 20 mM, 
NaCl 0.25 M, pH 7.5 at a flow rate of 1.1 ml cmT® h“*.
The material eluted with 0.25 M NaCl was filter sterilized through a 0.22, 
um pore diameter durapore filter (Millipore Co), protein concentration was 
estimated according to the dye binding assay (Bradford, 1976) and, if 
necessary, the solution was diluted to less than 0.5 mg ml“^ . Aliquots
were stored in 2 ml Sarstedt micro tubes at 4° C and the activity of the 
preparation tested in spreading and adhesion assays.
All fractions were tested for the presence of fibronectin in immuno-dot
blots on 0.45 um pore diameter nitrocellulose membrane (Millipore Co., 
cat.no. HAHYOOlO) as reviewed by Towbin and Gordon (1984). A template 
(the top margin of a 96-well cluster, Nunclon, Gibco) was pressed on 
nitrocellulose membranes in order to obtain a pattern of separate rings. 
The samples were applied to the centre of each ring in volumes of 2 ul 
and the dots were allowed to dry at 37° C. The membrane was blocked 
with a solution of BSA 2 % w/v for 30 minutes at 37° C after which the 
membrane was rinsed 3 times in TBS, allowing the buffer to equilibrate for 
5 minutes during each rinse. A working solution of sheep polyclonal
antibodies anti-human fibronectin in TBS, prepared at the lowest dilution 
recommended in the batch instructions, was incubated with the membrane 
for 30 minutes at 37° C. The membrane was then rinsed 3 times as before 
and incubated for 30 minutes with a solution of horseradish peroxidase- 
conjugated donkey polyclonal antibodies anti-sheep IgG (a kind gift of the 
Scottish Antibody Production Unit) in TBS, prepared at the lowest dilution 
recommended in the batch Instructions. After rinsing in TBS, the 
membrane was stained with a solution of 3 mg mM of 4-chloro-1 -naphthol 
(Sigma Chemicals, cat.no. C 8890) in methanol (BOH Chemicals, Aristar,
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cat.no. 45102) to which 5 volumes of a 0.018 % solution of HgOg (BDH 
Chemicals, cat.no. 28519) in cold TBS were added. The colour was allowed 
to develop for 10 minutes at room temperature, after which the reaction 
was stopped and the membrane washed several times in distilled HgO. 
Results were visually evaluated immediately after development against 
dilutions of positive and negative controls.
1 0 0
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P u r if ic a t io n  o f  f ib ro n ectin
Part 1 : Background
Although fibronectin is now commercially available from many sources, 
purity of the preparation and functional activity can be quite poor. For
this work it was decided therefore to undertake purification of the 
molecule in our own laboratory.
Plasma from human peripheral blood was chosen as source of 
fibronectin for convenience and availability and a protocol of purification
was devised to overcome the pitfalls of various published methods. The
purification technique exploits the property of fibronectin to bind to 
denatured collagen. Investigations on the nature of this interaction have 
shown that the binding is inhibited even at low ionic strength (27 %
inhibition in the presence of 50 mM NaCl at pH 7.5), but once established 
it is not disrupted even when the NaCl concentration is increased to 2.0 M 
(Vuento et a l . ,  1982). However, molar concentrations of specific cationic 
compounds readily dissociate the complex (Vuento and Vaheri, 1978; Dessau 
et a l . ,  1978).
The formation of the gelatin-fibronectin complex has an optimum pH 
between 7.0 and 9.0, with very low binding at pH below 6.0 and with a 
sharp fall off above pH 9.5, with the highest binding occurring at pH 8.5. 
Furthermore the reaction, even in the presence of excess gelatin, is not
rapid, reaching equilibrium after 15 to 30 minutes (Vuento et a l . ,  1982).
EDTA was chosen as the anticoagulant in view of the fact that the 
plasma was used immediately after preparation, without storage. The use
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of heparin or protamin-SH was avoided since heparin is a known modulator 
of the gela tin- f ibr onectin interation as it binds to fibronectin; there would 
also be the possibility that heparin or protamine-SH could be still present 
as contaminants in the final fibronectin preparation, with obvious risk of 
providing a source of bias in the work that followed since they could both 
be involved in modulation of cell adhesion. The use of acid citrate 
dextrose was also avoided in order to maintain the plasma pH weakly basic 
and so maximize fibronectin binding to gelatin. To ensure this, the 
anticoagulant also contained Tris-HCl buffer at pH 8.3.
Plasma was slowly applied to a column of gelatin-agarose; the affinity 
ligand used had a capacity to bind 1 mg of fibronectin per ml of gel. The 
column was never theoretically loaded above 25 % of its maximum capacity, 
given a concentration of fibronectin in plasma of 0.3 mg mM.
Part 2: Findings
When plasma was applied to the gelatin column no fibronectin could be 
detected immunologically in the not bound fraction (first peak of the trace 
on the left in figure 15). Following application of 1.0 M NaCl at pH 8.3,
some material was eluted from the column (second peak in figure 15).
This peak did not contain fibronectin as determined immunologically and
did not possess any adhesion-promoting activity as determined in an
adhesion assay. A peak containing fibronectin and adhesion-promoting
activity was eluted using 1.0 M NaBr at a pH of 5.0 (third peak, left chart, 
figure 15).
This eluate was then applied to a column of Sephadex G-25 M for a
rapid exchange of the buffer (figure 15, middle chart). To produce this
figure and show the separation from low molecular weight material, a low
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tracer with low (tyrosine, 0.5 mg) was added to the NaBr eluate prior 
to application to the Sephadex column. The second peak of the middle 
chart of figure 15 was negative when immunologically tested for 
fibronectin, and contained no adhesion-promoting activity. The first peak,
which represents the desalted NaBr eluate, contained both fibronectin and 
adhesion-promoting activity.
When this peak was applied to a Q-Sepharose column, some material was 
not retained by the column (figure 15, first peak of the chart on the 
right); such material was not fibronectin as determined immunologically nor 
did it contain adhesion-promoting activity. The column was then washed 
with 0.15 M NaCl which caused the elution of a peak (second peak, same 
chart) containing material which was not immunologically related to 
fibronectin nor had adhesion-promoting activity. The application of 0.25 M 
NaCl resulted in the elution of a large peak containing both fibronectin 
and adhesion-promoting activity. Gel electrophoresis on SDS containing 
polyacrylamide (5-20 % linear gradient) of this last peak showed the
presence of three bands, one with an estimated of 450,000 and two with 
Mr 200,000. As estimated with the dye binding test (Bradford, 1976) the 
total amount of protein contained in the last peak was 7.12 mg. The 
adsorption at 280 nra was 9.52 O.D. (0.272 O.D. mM, 35 ml). The 
extinction coefficient for a 1 mg mM solution of fibronectin is 
Eaeo ic*=1‘28 (Dessau et a l . , 1978), so the amount of fibronectin recovered 
would be 7.44 mg as deduced from its extinction coefficient. According to 
these calculations, the initial plasma sample used contained between 0.31 
and 0.32 mg mM, which is in general agreement with published estimates.
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Figure 15: Purification of fibronectin from human plasma.
Plasma (23 ml) was applied to a column of gelatin (left). Bound material
not containing fibronectin was eluted with 1 M NaCl at pH of 8.3. The
remaining bound material, containing fibronectin, was eluted with 1 M NaBr 
at a pH of 5.0 and applied to a 150 ml column of Sephadex G-25 M for 
buffer exchange (centre). Such desalted material was then applied to a 16 
ml column of Q-Sepharose (right); bound material not containing
fibronectin was eluted with 0.15 M NaCl while fibronectin was eluted with
0.25 M NaCl.
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A d h es ion
Part 1 : Background.
The purpose of this work was to investigate the molecular interactions 
between circulating tumour cells and endothelial cells which may occur 
during the vascular arrest of tumour cells at a distant metastatic site. To 
accomplish this task a convenient model system was developed based on 
the observation that B16 melanoma cells in suspension adhere to an 
endothelial monolayer when they are left to settle on it (Kramer and 
Nicolson, 1979).
The adhesion assay was developed from the collecting lawn assay of 
Walther and coworkers (1973). In their paper, these authors showed how a 
suspension of tumour cells adhered to a monolayer of endothelial cells in a 
time dependent fashion. To study and quantify this phenomenon the cells 
were radiolabelled. The non-adherent cells were washed away and, in 
order to determine the number of adherent tumour cells, the radioactivity 
retained by the monolayer was counted after solubilization.
Most authors working with similar assays measure adhesion after 
relatively long periods of incubation, sometimes even up to 2 hours or 
more (Tao and Johnson, 1982; Winkelhake and Nicolson, 1976), Long 
incubation times do not offer the opportunity to study adhesive 
phenomena of the kind that might allow a circulating tumour cell to arrest 
at a distant site in order to produce a metastasis. Such adhesion, in fact, 
needs to be established in a relatively short time (certainly not hours), 
since tumour cells may have perhaps only very brief contacts with the
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endothelium before being forced to progress by the blood flow. 
Furthermore, during long incubation times cells usually secrete and 
deposit extracellular material on the substratum (Clark e t a l . ,  1986; 
Grinnell and Feld, 1979; Jaffe e t a l . ,  1983; Raugi e t a l . ,  1982), rendering 
it more suitable for adhesion. Alternatively, cells may modify the 
substratum using, for example, enzymes. All this would provide misleading 
information with regards to the role of the substratum under test in early 
adhesive interactions.
Part 2: Modifications to the adhesion assay.
In our hands this assay has been developed and made more reliable. 
The use of radiolabelled cells was avoided. Labelling of the tumour cells 
is a procedure that subjects tlie cells to unnecessary manipulation and 
introduces a possible source of artefact. Furthermore there are the added
cost and safety disadvantages of working with radioactive material. To 
determine the number of adlierent cells, the non-adherent cells (i.e. those
remaining in suspension) were collected and counted using an electronic
particle counter. This method proved to be extremely practical, enabling 
us to have the results within a few minutes of each experiment, as well as 
being reliable and precise.
Another modification of the original method was the way in which non­
adhering cells were harvested once the incubation was completed. We 
recognized the need to wash the monolayer under controlled conditions 
with regards to tlie amount of fluid used, the flow rate  and the duration 
of the wash: it is possible that tumour cells have a wide range of
adhesive potential to tlie endothelium regarding the ability to resist
dissociation and therefore even slight changes in the washing routine
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would Introduce significant variability between experiments. To perform a 
controlled wash, an apparatus was developed which was capable of
delivering fluid in a sealed circuit under gravity feed. The coupling of
electronic cell counting of non-adhering cells with the controlled washing 
of the monolayer proved very successful and made it possible to use this 
assay to study rapid adhesion.
Our assay gave us the opportunity to look at events occurring earlier
tlian was possible with any other published method, being able to
determine the number of adhering cells even after only 1 minute of
incubation. We were able to select the parameters of the controlled wash
so that the adhesion developed after 5 minutes by tlie majority of the
tumour ceils with the endothelium would be of sufficient strength to resist 
detachment induced by the flow of washing solution. The assay was 
subsequently adapted to measure the adhesion of tumour cells to an
adsorbed layer of molecules. This enabled us to compare the endothelium 
and specific molecules with respect to their function as an adhesive 
support for the tumour ceils.
Part. 3: Findinyrs.
•  X . A d h esio n  to e n d o th e liu m .
In the initial experiments, the adliesion of BIGF 10 cells to a monolayer 
of endothelial cells was studied over a period of 60 minutes. As shown in 
figure 16, adhesion is time dependent and the kinetics has two phases. 
During the first 7-8 minutes there is a rapid increase in the number of 
adherent cells up to approximately 80 %. Following this, there is a second 
phase where the number of adhering cells slowly increases to almost 100 % 
in 25-30 minutes. Monitoring ahdesion for up to 60 minutes showed that
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the initial adhesion was not short lived and that tumour cells remained 
attached to the endothelium for the duration of the assay. Visual
inspection of the wells at the end of the assays, showed an intact 
endothelium with few tumour cells still visible over its surface, while a
large proportion of the tumour cells had migrated through the monolayer 
and was lying between the endothelium and the bottom of the well.
Since this part of the study was related to the initial adhesion that 
circulating tumour cells may form with the endothelium in order to arrest, 
it was decided to monitor only the first five minutes of the adhesion 
kinetics. Indeed, if different substrata were to be proven more or less
adhesive for tumour cells, it would be in this part of the curve (where
the number of adhering cells increased rapidly) that the greatest
differences would be detected.
Because of the nature of the experiments, it was not always possible to 
run adhesion assays in close succession and most of the work was spread
out over a period of 12 months. Since it is essential to compare 
experiments that were performed many months apart, it is important to
assess the internal consistency of the assay. For this purpose, adhesion 
experiments to unmodified endothelium which included a set of five time 
points (1-5 minutes) performed at 37® C in the presence of the normal
medium performed in four different months (January, May, August and
October) were grouped and statistically analyzed. A multivariate analysis
of variance indicated that there is no significant difference between the 
four groups (p= 0.49), as shown in figure 17.
Some experiments were performed in order to characterize the nature
of the adhesion of B16F10 cells to BAE monolayers. As shown in figure 18, 
this was dependent on the presence of divalent cations and could be 
inhibited by lowering the temperature of the assay to 4® C. Such
temperature-dependent inhibition was reversed on return to 37® C. To
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investigate the relative contribution toward adhesion of the two cell types, 
experiments were done using dead cells. As shown in figure 19, when the 
endothelium was killed by fixation, B16F10 cells were still able to adhere 
to it, although at approximately half the normal rate. When the tumour 
cells were treated with the fixative, there was virtually no adhesion. 
Although this pointed towards an active role of tumour cells during
adhesion, it could be envisaged that live tumour cells are only needed to
give the endothelium an initial trigger and that, once the endothelium is 
activated, it would conduct the adhesion process itself. If this was the 
case, probing the endothelium with a mixture of live and dead tumour cells 
would result in adhesion of all the cells used. In these experiments 
adhesion was exactly half that of the controls, indicating that only the 
live cells were adhering to the endothelium.
Exposure of either the endothelium, the tumour cells or both to EDTA 
for up to 15 minutes had no effect when adhesion was later tested in the 
normal medium (results not shown). Nevertheless exposure of tumour cells
to trypsin resulted in modulation of adhesion. The extent of such 
modulation depended on the presence or absence of chelating agents and 
on the length of exposure to the enzyme. As shown in figure 20, trypsin- 
EDTA exposure for 10 minutes resulted in an almost total inhibition of 
adhesion, while 2.5 and 5 minutes exposure caused a slight decrease of 
adhesion. When trypsin was used without chelating agents, the reduction 
in adhesion after 10 minutes exposure was less marked and 5 minutes 
incubation had no significant difference over the untreated cells (see 
figure 21). Interestingly though and somewhat controversially, a much 
shorter exposure of the cells to (inactivated) enzyme for a nominal 0 
minutes resulted in a significantly greater adhesion. Such increase in
adhesion was not recorded when fibronectin was used as a substratum.
To investigate possible differences between different sublines of the
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same original B16 population, the adhesion of B16F1, B16F10 and B16BL6 
cells to endothelial monolayers was studied. As shown in figure 22, all 
tumour cell lines adhered rapidly to the endothelium and the kinetics were 
similar for all three cell lines.
b. Adhesion to molecular substrata.
When fibronectin was adsorbed to the plastic, it supported the adhesion 
of B16F10 cells in a concentration dependent fashion. As shown in figure 
23, the kinetics of adhesion markedly improved as the density of this 
molecule on the substratum was increased from 1 to 4 ug cm”*; slightly 
faster kinetics were obtained with concentrations of 5 ug cm”"*, while 
raising the concentration up to 9 ug cm”* resulted in only a marginal 
increase in adhesion. No further improvement beyond this was noted even 
when concentrations as high as 20 ug cm"* were used (results not shown). 
For this reason a concentration of 5 ug cm“* was chosen for all further 
experiments. Similar to results from the experiments of adhesion to the 
endothelium, the adhesion of B16F10 cells to fibronectin was dependent on
the presence of divalent cations and could be inhibited by lowering the
temperature to 4® C, as shown in figure 24. No significant difference 
could be demonstrated when the adhesion of B16F10 and B16F1 cells to 
fibronectin (figure 25) was compared (multivariate analysis of variance, p= 
0.21).
Figure 26 shows the adhesion of B16F10 cells to different 
concentrations of laminin. These results are similar to those obtained for
fibronectin. There was about a two fold increase in adhesion after 5 
minutes when the concentration of laminin was raised from 1.25 to 3.75 ug 
cmT* but only a marginal inciease when the concentration was raised from
3.75 to 6.25 ug cm“* and to 10 ug cnT*. Above 10 ug cm”* the adhesion 
kinetics did not change significantly (results not shown) and a
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concentration of 6.25 ug cm"* was chosen for all further experiments. As 
already observed for fibronectin and endothelium, adhesion to laminin was 
dependent on the presence of divalent cations and could be inhibited by 
lowering the temperature to 4° C (figure 27).
When FCS was tested for its ability to support the adhesion of B16F10 
cells, it was found to be a poorly adhesive substratum and even after 
increasing the concentration up to 500 ug cnT* there was no detectable 
improvement. Figure 28 shows the adhesion kinetic of FCS and the
inhibition brought about by the absence of divalent cations.
A wide panel of different molecular substrata was tested in adhesion 
assays and it was found that many molecules such as collagen type I (800 
ug cm"*), gelatin (100 ug cm"”*), GAGs (heparin, heparan sulfate, 
chondroitin sulfate types A and C, dermatan sulfate, keratan sulfate and 
hyaluronic acid, all used at 100 ug cmT*), low molecular weight von
Willebrand factor (5 ug cm"*), RNA and DNA (100 ug cnf *), anti-fibronectin 
antibodies (500 ug cnf*) and haemoglobin (100 ug cnT*), were not
effective in supporting adhesion of B16F10 cells (results not shown).
In figure 29 the adhesion of B16F10 cells to BAE monolayers was 
compared to their adhesion to a variety of molecular substrata. Adhesion 
to FCS or collagen type I showed relatively slow kinetics, while the
adhesive molecules fibronectin (5 ug cnf*) and laminin (6.25 ug cm"*) 
supported adhesion in a manner comparable to that of the endothelium.
Attempts were made to block the effectiveness of some substrata such 
as fibronectin, laminin and BAE monolayers in supporting the adhesion of 
B16F10 by using polyclonal antibodies against fibronectin and laminin. 
Antibodies were incubated with the substrata for 1 hour after which the 
wells were washed with buffer and the adhesion assays were performed. 
While the anti - f ibr onectin antibodies proved effective in blocking the 
adhesion of tumour cells to fibronectin substrata, they had no effects on
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the adhesion to laminin substrata and only a moderate effect on 
endothelium (some of these results are shown in Figure 30). The anti- 
laminin antibodies had no effect on the adhesion of tumour cells to any of 
the three substrata (results not shown).
c. Effect of tunicamycin.
B16F10 cells were cultured in the presence of the antibiotic tunicamycin 
in order to inhibit glycosylation of newly synthesized proteins. When the 
adhesion of these cells to fibronectin and endothelium was then tested, no 
significant reduction of adhesion was caused by exposure to tunicamycin 
for 6-30 hours and only after 36 hours of exposure a decrease in the rate 
of adhesion was noted (see figures 31 and 32). Prolonging the incubation 
for a further 12 hours (48 hours in total) did not result in additional 
reduction of adhesion, as shown in figure 31.
Conversely, when tunicamycin treated B16F10 cells were used in 
adhesion assays on laminin substrata, a significant reduction in adhesion 
(the adhesion at 5 minutes decreased from 76.2 % to 25.2 %) occurred after 
only 24 hours of exposure to the antibiotic, as shown in figure 33.
In later experiments, B16F10 cells that were exposed to tunicamycin for 
36 hours were allowed to recover in the normal medium not containing the 
antibiotic. These cells were then assessed for their ability to adhere to 
endothelium or fibronectin- As shown in figures 34 and 35, a recovery 
period of 18 hours was necessary to reacquire a level of adhesiveness 
comparable to that of cells not exposed to tunicamycin. Longer recovery 
times did not result in improved adhesion kinetics beyond the control 
levels.
The inhibitory effect of tunicamycin on cell adhesion could be due to 
proteolytic degradation of carbohydrate-stripped molecules, because 
unglycosylated proteins often have an Increased sensitivity to proteolytic
113
digestion. Alternatively, the decrease in adhesion could be the result of
the lack of the glycosylated moiety itself which could be directly involved 
in the phenomenon- In order to investigate this latter possibility, some
experiments were conducted using the enzyme inhibitor leupeptin, which 
would block proteolytic degradation of the unglycosylated molecules. 
B16F10 cells were cultured in the presence of both tunicamycin and 
leupeptin for 36 hours and their adliesion to endothelium or fibronectin 
was assayed. Figure 36 shows that the presence of leupeptin did not 
reduce the adverse effect of tunicamycin on tumour cell adhesion to
endothelial monolayers. On the other hand, as shown in figure 37, 
leupeptin countered the inhibitory action of tunicamycin on tumour cell 
adliesion to fibronectin; the value for 5 minute adhesion was raised from
47.8 % (no leupeptin) to 72.6 % (leupeptin 200 uM), close to tliat of cells 
not exposed to tunicamycin (76.5 %).
d- Adhesion to endothelial cell extract.
Wlien partially purified endothelial cell extract was tested, it was found 
to support the adhesion of B16F10 ceils extremely well. The extract was
still very active (85.6 % adherent cells in 5 minutes) at a concentration of
6 ug cm'*, as shown in figure 38. Extract from roller bottles exposed to
the culture medium but that did not contain any endothelial cells had no 
adiiesive activity (results not shown).
The pentapeptide GRGDS was used to inhibit the adhesion of BIGF 10 
cells to endothelium, fibronectin or endothelial cell extract substrata. It
was found that adhesion to fibronectin was unaffected by the presence of
the soluble pentapeptide (up to 2 mg ml’ )^, while the adliesion to
endothelial cell extract was totally Inhibited and the adhesion to
endothelial monolayers was reduced to approximately 30 %. In further 
experiments adhesion of B16F10 cells to substratum-adsorbed GRGDS (up to
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100 ug cm"*) was tested but this substratum was not adhesive for the 
tumour cells. These results are summarized in figure 38. Finally, 
incubation of endothelial cell extract substrata with anti-fibronectin
antibodies had no effect on the kinetics of adhesion (results not shown).
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Figure 16: Adhesion of tumour cells to endothelial monolayers.
The adhesion of B16F10 cells to BAES monolayers was monitored over a 
period of 60 minutes; n= 5.
In this and all subsequent figipres: bar = S.D.; all S.D. less than 2.5 are not
represented; all curves represent cubic fits.
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Figure 17: Control for internal consistency.
The adhesion of B16F10 cells to BAES monolayers assayed in four different 
months were groupped and statistically analyzed using a multivariate analysis 
of variance. The four groups were not statistically different (p= 0.49). 
o = January (n=7).
A = May (n=12).
□ = August (n=7).
O = October (n-9).
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Figure 18: Adhesion of tumour cells to the endothelium: influence 
of temperature and divalent cations.
The ability of BAES monolayers to support B16F10 cell adhesion in a medium 
depleted of divalent cations or at various temperatures was tested,
o = tumour cells and endothelium at 3TC (n=8).
A = tumour cells and endothelium at 4®C (n=3).
O  = tumour cells and endothelium cooled to 4®C for 15 minutes; 5 minutes
before the assay the temperature was then raised to 37® C and kept 
at this value throughout the assay (n=l; 5 min n=3).
□ = tumour cells and endothelium at 37®C in a Ca^ "** and free medium
(n-3).
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Figure 19: Adhesion of tumour cells to endothelium: effect of fixation.
B16F10 cells or BAES monolayers were fixed with formol saline for 45 minutes; 
subsequently the adhesion of tumour cells to BAES monolayers was tested in 
adhesion assays.
o = neither tumour cells nor endothelium exposed to fixative (n=5).
□ = endothelium exposed to fixative (n=3).
A = tumour cells exposed to fixative (n-3).
O  = 50 % of the tumour cells exposed to fixative (n=2).
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Figure 20: Adhesion of tumour cells to endothelium: effect of exposure of
tumour cells to trypsin in the absence of divalent cations.
B16F10 cells were incubated for various lengths of time at 37° C with 0.05 %
w/v trypsin in the presence of a chelating agent (EDTA 2 mM). The reaction
was stopped by the addition of FCS containing medium and their 
adhesion to BAES monolayers was tested.
O = tumour cells not exposed to trypsin (n=10).
A = tumour cells exposed to trypsin for 2.5 minutes (n=2).
□ = tumour cells exposed to trypsin for 5 minutes (n=7).
O  = tumour cells exposed to trypsin for 10 minutes (n=3).
V = tumour cells exposed to trypsin for 30 minutes (n=2).
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Figure 21: Adhesion of tumour ceils to the endothelium: effect of exposure
of tumour cells to trypsin in the presence of divalent cations.
B16F10 cells were incubated for various lengths of time at 37°C with 0.05 % 
w/v trypsin. The reaction was stopped by the addition of FCS containing 
medium and their adhesion to BAES monolayers was tested.
A= tumour cells not exposed to trypsin (n=9).
O = tumour cells exposed to trypsin for 0 minutes (n=3).
o = tumour cells exposed to trypsin for 5 minutes (n=3).
□ = tumour cells exposed to trypsin for 10 minutes (n=2).
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Figure 22: Adhesion of different tumour cell lines to endothelium.
The adhesion of B16F1, B16F10 and B16BL6 cells to BAES monolayers was 
compared.
□ = B16F1 cells (n=8). 
o = B16F10 cells (n=6).
A = B16BL6 cells (n=3).
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Figure 23: Adhesion 
density.
of tumour cells to fibronectin: effect of ligand
Substrata with various amounts of adsorbed fibronectin 
tested for their ability to suppor B16F1Q cell adhesion.
O = substrata containing 1 ug cm“* of fibronectin (n=2).
A = substrata containing 4 ug cm“* of fibronectin (n=4).
□ = substrata containing 5 ug cm"^  of fibronectin (n=3).
O = substrata containing 9 ug c n f  of fibronectin (n=3).
were prepared and
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Figure 24: Adhesion of tumour cells to 
temperature and divalent cations.
fibronectin: influence of
Substrata containing 5 ug cm"* of fibronectin were prepared and their ability 
to support B16F10 cells adhesion in a medium depleted of divalent cations or 
at various temperatures was tested in adhesion assays, 
o = tumour cells and substrata at 37®C (n=4).
A - tumour cells and substrata at 4°C (n=l; 5 min n=3).
O  = tumour cells and substrata at 37®C and in a Ca**“ and Mg*‘^ -free medium
(n=2; 5 min n=3).
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Figure 25: Adhesion of different tumour cell lines to fibronectin.
The adhesion of BI6F1 and B16F10 cells to substrata containing 5 ug cm"* 
of fibronectin was compared.
A = B16F1 cells (n=3). 
o = B16F10 cells (n=4).
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Figure 26: Adhesion of tumour cells to laminin: effect of ligand density.
Substrata with various amounts of adsorbed laminin 
tested for their bility to support B16F10 cell adhesion.
□ = substrata containing 0.6 ug cm*'^  of laminin (n=4).
A = substrata containing 1.25 ug cmT^  of laminin (n=3).
O = substrata containing 3.75 ug cm“^  of laminin (n=3).
V = substrata containing 6.25 ug cmT* of laminin (n=4).
o = substrata containing 10 ug cm^ of laminin (n=3).
were prepared and
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Figure 27: Adhesion of tumour ceils to laminin: 
and divalent cations.
influence of temperature
Substrata containing 6.25 ug cm“* of laminin were prepared and their ability 
to support B IGF 10 cell adhesion in a medium depleted of divalent 
cations or at various temperatures was tested.
O = tumour cells and substrata at 37® C (n=4).
□ = tumour cells and substrata at 4°C  (n=l; 5 min n=3).
A = tumour cells and substrata at 37®C in a Ca^ and Mg *^ f^ree medium (n=l;
5 min n-3).
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Figure 28: Adhesion of tumour cells to FCS: influence of divalent cations.
Substrata containing 100 ug cnT® of FCS were prepared and their ability to
support B16F10 cell adhesion in a medium depleted of divalent cations was
tested.
0 = tumour cells and substrata in normal medium (n=5).
A = tumour cells and substrata in a Ca^ '*’ and Mg^^free medium (n=2; 5 min
n=3).
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Figure 29: Tumour cells adhesion to different substrata.
of various substrata to support the adhesion ofComparison of the ability 
B16F10 ceils.
A = substrata containing 5 ug cm“* of fibronectin (n=5).
□ = substrata containing 6.25 ug cm"® of laminin (n=4).
o = BAES monolayers (n=7).
O = substrata containing 100 ug cm“® of FCS (n=S).
V = substrata containing 800 ug cm"® of collagen type I (n=3)
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Figure 30: Adhesion of tumour cells to endothelium and fibronectin: effect of
anti-fibronectin antibodies.
Substrata of fibronectin (5 ug cm~*) or BAES monolayers were incubated for 
1 hour with polyclonal anti-fibronectin antibodies, following which their
ability to support the adhesion of B16F10 cells was tested in adhesion assays. 
A = fibronectin substrata not exposed to anti-fibronectin antibodies (n=3).
o = endothelium not exposed to anti-fibronectin antibodies (n=4).
□ = endothelium exposed to anti-fibronectin antibodies (n=2).
O = fibronectin substrata exposed to anti-fibronectin antibodies (n=2).
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Figure 31: Adhesion of tumour cells to endothelium: influence of tunicamycin.
B16F10 cells were cultured 
various lengths of time 
subsequently tested.
^ = tumour cells exposed 
V = tumour cells exposed 
□ = tumour cells exposed 
-o = tumour cells exposed 
o = tumour cells exposed 
O = tumour cells exposed 
O = tumour cells exposed
in the presence of 0.45 ug ml”^  of tunicamycin for 
and their adhesion to BAES monolayers was
to tunicamycin 
to tunicamycin 
to tunicamycin 
to tunicamycin 
to tunicamycin 
to tunicamycin 
to tunicamycin
for 6 hours 
for 12 hours 
for 18 hours 
for 24 hours 
for 30 hours 
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(n=6).
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(n=5).
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(n=4).
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Figure 32: Adhesion of tumour cells to fibronectin: influence of tunicamycin.
B16F10 cells were cultured in the presence of 0.45 ug mF* of tunicamycin for 
various lengths of time and their adhesion to a plastic substratum coated 
with 5 ug cm~^  of fibronectin was subsequently tested, 
o = tumour cells exposed to tunicamycin for 3 hours (n=3).
V = tumour cells exposed to tunicamycin for 6 hours (n=3).
□ = tumour cells exposed to tunicamycin for 18 hours (n=5).
O = tumour cells exposed to tunicamycin for 36 hours (n=3).
132
Adherent Cells
100
80 12 h
18 h60
40
24 h
20
0 1 4 5
Time (minutes)
Figure 33: Adhesion of tumour cells to laminin: influence of tunicamycin.
B16F10 cells were cultured in the presence of 0.45 ug ml*^  
various lengths of time and their adhesion to a plastic 
with 6.25 ug cnf^ of laminin was subsequently tested,
o = tumour cells exposed to tunicamycin for 12 hours (n=2).
A = tumour cells exposed to tunicamycin for 18 hours (n=2).
O = tumour cells exposed to tunicamycin for 24 hours (n=3).
of tunicamycin for 
substratum coated
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Figure 34: Adhesion of tumour cells to endothelium: recovery after exposure 
to tunicamycin.
B16F10 cells were cultured in the presence of 0.45 ug 
36 hours. Tunicamycin was then removed and the 
recover for various lengths of time before testing 
monolayers.
to tunicamycin 
to tunicamycin
□ = 
V =
tumour cells exposed 
tumour cells exposed 
for 12 hours (n=5).
A = tumour cells exposed 
for 18 hours (n=3). 
o = tumour cells exposed 
for 24 hours (n=4).
for 36 hours 
for 36 hours
to tunicamycin for 36 hours
to tunicamycin for 36 hours
mF* of tunicamycin for 
cells were allowed to 
their adhesion to BAES
(n=6).
and allowed to recover 
and allowed to recover 
and allowed to recover
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Figure 35: Adhesion of tumour cells to fibronectin: recovery after exposure
to tunicamycin.
B16F10 cells were cultured in the presence of 0.45 ug ml"^  of tunicamycin for
36 hours. Tunicamycin was then removed and the cells were allowed to
recover for various lengths of time before their adhesion to a plastic
substratum coated with 5 ug cm^ of fibronectin was tested.
A = tumour cells exposed to tunicamycin for 36 hours (n=3). 
V = tumour cells exposed to tunicamycin for 36 hours and allowed to recover
for 6 hours (n=2).
o = tumour cells exposed to tunicamycin for 36 hours and allowed to recover
for 12 hours (n=3).
O = tumour cells exposed to tunicamycin for 36 hours and allowed to recover
for 18 hours (n=3).
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Figure 36: Adhesion of tumour cells to endothelium: protection from the
effect of tunicamycin exposure by the protease inhibitor leupeptin.
B16F10 cells were cultured in the presence of 0.45 ug ml~‘ of tunicamycin for 
36 hours together with various concentrations of leupeptin. Their adhesion 
to a BAES monolayer was then tested.
V  =  o  »
Q  =  
A  =
tumour cells not exposed to tunicamycin (n=6). 
tumour cells exposed to tunicamycin for 36 hours (n=6).
tumour cells exposed
leupeptin 100 uM (n=l; 
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leupeptin 400 M (n=l; 
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leupeptin 600 uM (n=l;
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Figure 37: Adhesion of tumour cells to fibronectin: protection from the effect
of tunicamycin exposure by the protease inhibitor leupeptin.
B16F10 cells were cultured in the presence of 0.45 ug ml"* of tunicamycin for 
36 hours together with different amounts of leupeptin. Their adhesion to a
substratum coated with 5 ug cm”^  of fibronectin was then tested in adhesion 
assays.
#  = tumour cells not exposed to tunicamycin (n=3).
V = tumour cells exposed to tunicamycin for 36 hours (n=3).
o = tumour cells exposed to tunicamycin 
leupeptin 200 uM (n=l; 5 min n=2).
for 36 hours in the presence of
A = tumour cells exposed to tunicamycin 
leupeptin 400 uM (n=l; 5 min n=2).
for 36 hours in the presence of
□ = tumour cells exposed to tunicamycin for 36 hours in the presence of
leupeptin 600 uM (n=l; 5 min n=2).
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Figure 38: Adhesion of tumour cells to endothelial cell extract, fibronectin 
and endothelial monolayers: effect of the adhesive peptide GRGDS.
BAES monolayers and substrata containing 100 ug cnT* of GRGDS, 5 ug cmT* 
of fibronectin or 6 ug cm”* of partially purified endothelial cell extract 
(1.0 M NACl elution of a Q-Sepharose column) were tested for their ability to 
support B16F10 cells adhesion. In some experiments the pentapeptide GRGDS 
was present during the assay, 
o = endothelial cell extract (n=3).
# = endothelial cell extract + 1 mg ml"' GRGDS (n=3).
V = fibronectin (n=4).
V = fibronectin + 1 mg ml“‘ GRGDS (n=2).
□ = BAES (n=7).
■ = BAES + 1 mg mr‘ GRGDS (n=2).
O = GRGDS (n=3).
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C e ll Spreading
Part 1 : Background.
The adhesion assay was designed to assess the immediate responses of 
cells in suspension as they come into contact with the endothelium or 
various molecular substrata. The emphasis was placed on the very early 
phenomena occurring as the cell surface comes into close proximity with 
the substratum because it was assumed that in a dynamic environment
such as the blood stream, cells would either rapidly engage in adhesive
interactions with the vessel wall or tliey would be transported downstream
by the flow, thereby missing the chance to extravasate.
1
During the first stages of adhesion cells retain their spherical shape. 1
I
Although one of the prerequisites for adhesion is the alignment of the |
jsurface that confronts the substratum (probably so as to offer a larger |
1area for interactions), the extent of such flattening is quite limited (Roos, ji1984). Later events of cell-substratum interactions Include the f
1establishment of higher numbers of molecular points of adhesion, probably 'j
of varying nature and often this is accompanied by extensive re- 
organization of the cytoskeleton which causes the membrane of the cell to 
spread parallel to the substratum.
The spreading of cells onto a substratum is a slow event, taking 
several minutes to hours and not seconds. This timescale almost certainly 
exceeds the amount of time available to a circulating cell for initial 
adherence to the vessel wall in order to extravasate (cf. Bjerknes e t a l.,
1986). Nevertheless, after adhering to the vessel wall, cells may need to
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establish stronger interactions with it before being able to extravasate
and this could be accompanied by changes in the cell shape so radical as
to be detectable using low power light microscopy.
Although it may seem at first obvious that all molecular substrata that
cause rapid adhesion will eventually support some degree of cell 
spreading, no systematic studies which correlate the two phenomena have
so far been published. Furthermore, even if the supposition is proved 
right, the contrary may not hold true, namely that substrata unable to
cause rapid adhesion will not support spreading, therefore it was felt that
a spreading assay should be used to monitor this phenomenon.
Several spreading assays have been used in the past by many
researchers, all differing in small details but using the same overall 
principles, and a considerable body of experience has been accumulated in 
the field (for a review see Silnutzer and Barnes, 1984 a). In order to
carry out the proposed work it was necessary to have an assay that
would allow the use of minimal quantities of the molecules to be tested.
Together with this, it was thought to try and design the assay so t.hat we 
could more confidently extract informations about the effect of the density 
of substratum-bound ligand on the entire cell po%)ulation. At ! heir best,
most assays measure the number of cells spread per surface area rather 
than the percentage of spread cells. This is done by employing an excess 
of ceils in relation to the surface area and, at the end of the incubation 
period, fixing and staining of the spread cells. This approach has the
advantage of allowing the processing of a large number of samples in each
experiment, the stained plates being counted at a later stage.
The disadvantages are obvious: firstly, spread cells may accidentally be
detached from the substratum during the staining routine. Secondly, the 4
presence of an excess of cells in suspension may increase the likelihood of
cell-cell interactions and these could in turn interfere with the capacity to
i
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interact with the substratum. Thirdly, cells may adhere and spread on 
already adhering cells or on areas of the substratum previously
conditioned by other cells. Lastly, no information can be obtained on the 
effect of the substratum on the population as a whole.
To overcome these problems, quantification of the spreading at the end
of the assay should be performed on live cells with the aid of phase 
contrast light microscopy rather than on fixed and stained preparations 
and tlie concentration of cells in the suspension should be kept as low as 
possible so that the chances of cell-cell collisions would be minimized.
A plastic substratum was preferred to glass in order to avoid 
derivatization of the glass which is quite time consuming and subject to 
day to day variability. In search of suitable tissue culture-grade plastic 
containers, 35 mm diameter Petri dishes and 24 well plates were discarded 
because of the large surface area that had to be adsorbed with molecules 
that: were sometimes difficult to obtain in large quantities. Another
disadvantage that comes with using large plates is that quantification of 
the assay needs the evaluation of a number of fields (usually between 5 
and 10), since the relative percentage of spread and round cells vary 
quite considerably between different areas of the plate. In fact, ideally, 
the whole surface area should be counted, but this is in practice never 
done with large plates.
Plates with 96 wells, although possessing a much smaller surface area
than Petri dishes or 24-well plates, have the disadvantage of a poor
geometry for use with phase contrast light microscopy, so 72-well plates 
with a Terasaki configuration were chosen. The design of Terasaki plates, 
originally developed for immunological work (e.g. mixed lymphocyte 
reaction), has recently been improved by Gibco (Nmiclon) with the 
introduction of tapering low profile walls that render the optical 
properties of the wells extremely good for use with phase contrasted light.
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The wells have a very small surface area (0.01 cm*) and a minimal volume 
(10 ul) and this makes them ideal for our assay. By using an appropriate 
magnification (between x 100 and x 160) the whole surface area of a well 
can be fitted into a microscopic field and all cells can be counted and 
scored for spreading with ease. Because of this we were in a position to 
inoculate into each well the minimum ammount of cells to obtain a 
significant count, reducing the possibility of cell-cell collisions. An added 
advantage of avoiding overcrowding is that the fewer the cells that were 
contained in the inoculum, the more single cells, either round or spread 
would be present on the substratum at the end of the assay, making the 
scoring fast and easy.
Part 2: Findings.
During the course of this study it was found that the spreading of
B16F10 cells was dependent on the type of molecules adsorbed on the 
substratum and their concentration. Certain molecules, such as
fibronectin, laminin and endothelial cell extract, induced more than 90% of 
cells to spread; these three substrata had similar values for the 
concentrations that induced half maximum (0.25, 0.25 and 0.2 ug cm'*
respectively) and maximum spreading (0.5, 0.6 and 0.4 ug cm"’
respectively) as shown in figures 39, 40 and 41. Other molecules, like
gelatin, on the other hand, did not induce spreading at any of the
concentrations used, as shown in figure 39. FCS did support the
spreading of the tumour cells, although much higher concentrations were 
required (half max.= 0.5 ug cm'*, max.= 3 ug cm'*), as shown in figure 40.
Spreading was not as success full on haemoglobin, where the maximum
spread (not more than 70 %) was achieved at concentrations above 3 ug
1 4 2
cm'*, as shown in figure 41. Von Willebrand factor (0.001 to 1 ug cm"*)
did not support the spreading of tumour cells (results not shown).
The time dependent nature of spreading was investigated using 
substrata coated with supra- and sub-maximal concentrations of 
fibronectin (1.5 and 0.15 ug cm'*), laminin (2.25 and 0.225 ug cm'*) and
endothelial cell extract (3 and 0.3 ug cm'*). When supra-maximal
cancentrations were used, the maximum amount of spreading was reached 
by 60 minutes. At submaximal concentrations the kinetics were slower and 
cell spreading continued even after 60 minutes of Incubation. These
results are summarized in figures 42, 43 and 44. High concentrations of 
gelatin did not elicit any spreading even after 90 minutes of incubation
(see figure 42). In fact prolonging the assay on gelatin for up to 4 hours
resulted in no spreading.
Since tumour cells produce and express ligands for gelatin (like
fibronectin), the lack of spreading could be due to a defect in the 
adsorb tion of gelatin on the plastic substratum. To Investigate this
possibility, a "sandwich” experiment was performed in which i ug cm'* of 
fibronectin was added to increasing concentrations of substratum adsorbed
gelatin. As shown in figure 45, the tumour cells were now able to spread 
on the gelatin-fibronectin sandwich in a manner dependent on the
concentration of gelatin adsorbed on the substratum. Berxiuse of these:
results, it was conceivable that tumour ceil surface fibronectin was either
poorly expressed or unable to mediate the spreading process. For this 
reason a further experiment was aimed at investigating the role of cell 
surface fibronectin during spreading: a substratum of anti-fibronectin
antibodies was prepared and spreading was tested. Figure 46 shows that
tumour cells spread well on these substrata in a concentration - dependent 
fashion (while a similar preparation of antibodies from non-immune sheep 
serum was unable to induce any spreading - results not shown). Adding
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fibronectin to the antibodies (the soluble fibronectin binding to the
adsorbed anti-fibronectin antibodies) resulted in a small but significant
improvement in the amount of spreading (p= 0.011) as shown in figure 46.
The inhibitory effect of anti-fibronectin antibodies on the spreading of 
tumour cells were studied in a series of experiments where the antibodies 
were used to mask any molecules previously adsorbed on the plastic. The 
excess antibodies were then either washed away or left in the well and 
spreading assays were performed. Figure 47 shows two such experiments 
where a supra-maximal concentration of fibronectin was used to coat the
wells and different amount of anti fibronectin antibodies were later added. 
Similarly to the results obtained with adhesion assays, the antibodies 
inhibited spreading of tumour cells on fibronectin and this inhibition was 
dose dependent. The presence of excess soluble antibodies during the 
assay resulted in further inhibition of spreading from 20-25 % to 0 %.
The antibodies were tested on all the other molecular substrata that 
elicited adhesion and in all cases there was no effect on spreading when 
the excess soluble antibodies were removed, while there was a similar dose 
dependent effect when the excess antibodies were left in the wells (results 
not shown, but an example is given in figure 48). FCS-coated substrata 
constituted the only exception: as shown in figure 49, substrata with
different concentrations of adsorbed FCS were incubated with 50 ug cm”* 
of anti-fibronectin antibodies; when the soluble unbound antibodies were 
removed there was a dose independent increase of spreading to values of 
around 90 % or more. When, however, the unbound soluble antibodies 
were left into the wells, the usual dose-dependent inhibition was seen.
In other experiments, the effect of purification of the endothelial cell 
extract on the ability to induce spreading was studied. When spreading 
on the crude endothelial cell extract was compared to that on the extract 
purified with ion exchange (one step elution with 1.0 M NaCl), no
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significant difference was found (multivariate analysis of variance, p> 
0.09), although the purified extract gave more reproducible results
(compare figures 39 and 50). Such partially purified cell extract was 
fractionated using ion exchange chromatography by means of a linear 
gradient of NaCl between 0.075 and 1.0 M, and each fraction was tested for 
its ability to support the spreading of B16F10 cells. Only two fractions 
(eluted with 0.3 M and 0.9 M NaCl respectively) showed any spreading 
inducing activity and their dose response curves are plotted in figure 50. 
Multivariate analysis of variance show no significant different between the 
the material eluted at 0.3 M NaCl and that eluted at 0.9 N NaCl (p=0.99), 
while both are significantly different from the (one step) 1.0 M NaCl
elution and the unpurified extract (p<0.001).
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Figure 39: Spreading of tumour cells on substrata of gelatin and endothelial 
cell extract: dose dependent responses.
Substrata were coated with different concentrations of the molecules to be 
tested and their ability to support the spreading of B16F10 cells was tested.
•  = endothelial cell extract (not purified, n=5).
▲ = gelatin (n-3).
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Figure 40: Spreading of tumour cells on substrata of laminin and FCS: dose 
dependent responses.
Substrata were coated with different concentrations of the molecules to be 
tested and their ability to support the spreading of B16F10 cells was tested. 
A -  laminin (n=6).
# = FCS (n=5).
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Figure 41: Spreading of tumour cells on substrata of fibronectin and 
haemoglobin: dose dependent responses.
Substrata were coated with different concentrations of the molecules to be 
tested and their ability to support the spreading of B16F10 cells was tested.
• = fibronectin (n=3).
A = haemoglobin (n=3).
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Figure 42: Spreading of tumour cells on fibronectin and gelatin: time
dependent responses.
Substrata were coated with gelatin or with two different concentrations of 
fibronectin and their ability to support the spreading of B16F10 cells was 
tested.
• = fibronectin 1.5 ug cm”* (n=6).
A -  fibronectin 0.15 ug cm"* (n=5).
▼ = gelatin 7.5 ug cnT* (n=5).
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Figure 43: Spreading of tumour cells on laminin: time dependent responses.
Substrata were coated with two different concentrations of laminin and their 
ability to support the spreading of B16F10 cells was tested.
# = laminin 2.25 ug cm“* (n=5).
A = laminin 0.225 ug cnf^ (n=5).
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Figure 44: Spreading of tumour 
dependent responses.
cell on endothelial cells extract: time
Substrata were coated with different concentrations of endothelial extract 
partially purified through a one step elution (1.0 M NaCl) from Q-Sepharose. 
Their ability to support the spreading of B16F10 cells was tested.
•  = endothelial cell extract 3 ug cm"^  (n=3).
A = endothelial cell extract 0.3 ug cm"^  (n=3).
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Ft mire 45: Spreading of tumour celLs on gelatin: effect of fibronectin.
Substrata were coated with different concentrations of gelatin and, after 
blocking the remaining reactive sites on the plastic, the wells were incubated 
with fibronectin (1 ug cm )^. The abilities of these substrata to support the 
spreading of B16F10 cells were then tested.
O = dose of gelatin, no fibronectin added (n=3).
^ = dose of gelatin + fibronectin (n=3).
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Spreading of tumour ceils on anti-fibronectin antibodies.
Substrata were coated with different concentrations of anti-fibronectin 
antibodies. After blocking the remaining reactive sites on the plastic, the
wells were incubated with 1 ug cm  ^ of fibronectin. The abilities of these 
substrata to support the spreading of B16F10 cells were then tested.
0 = dose of anti-fibronectin antibodies (n=3).
A = dose of anti-fibronectin antibodies + fibronectin (n=3).
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Figure 47: Spreading of tumour cells on fibronectin: effect of polyclonal
anti'- Fibronectin antibodies.
Substrata were coated witli 1 ug cm " of fibronectin. After blocking the 
remaining reactive sites on tlie plastic, the wells were incubated with
different concentrations of polyclonal anti-fibronectin antibodies. The
abilities of these substrata to support tlie spreading of B16F10 cells were 
then tested.
O = fibronectin + dose of polyclonal anti-fibronectin. The unbound antibodies 
were removed before the assay (n=3).
A = fibronectin + dose of polyclonal anti-fibronectin. The unbound antibodies 
were not removed from the wells (n=2).
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Figure 48: Spreading of tumour ceils on anti-fibronectin antibodies: effect of
anti-fibronectin an tibodies.
Substrata were coated with different concentrations of anti fibronectin 
antibodies. After blocking tlie remaining reactive sites on the plastic, the 
wells were incubated with different concentrations of polyclonal anti-
fibronectin antibodies. The ability of these substrata to support the 
spreading of B16F10 cells were then tested.
A = 50 ug cm ^ of anti-fibronectin antibodies + dose of anti-fibronectin
antibodies. The unbound second antibodies were not removed from the
wells (n=3).
O = dose of anti-fibronectin antibodies + 50 ug cm * of anti- fibronectin 
antibodies. The unbound second antibodies were not removed from the
wells (n=3).
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Figure £|9.: Spreading of tumour cells on PCS: effects of anti-fibronectin
antibodies.
Substrata were coated with different concentrations of PCS and, after 
blocking the remaining reactive sites on the plastic, the wells were incubated 
witli different concentrations of polyclonal anti-fibronectin antibodies. The 
abilities of these substrata to support the spreading of B16F10 cells were 
then tested.
^  = PCS (5 ug cm + dose of anti-fibronectin antibodies. The unbound 
second antibodies were not removed from the wells (n=3).
O = dose of PCS + anti-fibronectin antibodies (50 ug cm )^. The unbound
second antibodies were not removed from the wells (n=3).
A(--J= dose of PCS + anti-fibronectin antibodies (50 ug cm )^. The unbound
second antibodies were removed before the assay (n=3).
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Fim.ire 50: Spreading of tumour cells on endothelial cell extract: effect of
extract: purification.
Substrata were coated with different concentrations of the preparations to be 
tested and their abilities to support the spreading of B16F10 cells were
tested.
O = endothelial cell extract partially purified tlirough a one step elution
(1.0 M NaCI) from Q-Sepharose (n=3).
O = endothelial cell extract purified through Q-Sepharose and eluted witli a
linear gradient of 0.075-1.0 M NaCI; 0.3 M NaCI peak (n=3).
Y = endothelial cell extract purified through Q-Sepharose and eluted with a
linear gradient of 0.075-1.0 M NaCI; 0.9 M NaCI peak (n=3).
1 5 7
P ro d u ctio n  and p u r if ic a tio n  o f  th e  e n d o th e lia l e x t r a c t
Extraction procedures varied slightly during the course of this study. 
Initially each roller bottle containing an endothelial monolayer was
incubated with 25 ml of extraction buffer (EDTA 2 mM in T~). The
extraction volume was later reduced to 10 ml without any effects on either 
the biological activity or the amount of proteins extracted. Each roller
bottle gave approximately 0.3 mg of protein as determined by the dye
binding test of Bradford (1976).
Attempts to purify the material were made using ion exchange
chromatography, first on ZetaPrep 15 ion exchange disks (LKB) and later
on Sephadex- and Sepharose-based ion exchange media (Pharmacia). Two 
types of ZetaPrep disks were used, a cation exchanger with sulfopropyl 
(SP) groups and an ion exchanger containing diethylaminoethyl (DEAE) 
groups. The SP disk was used at pH 6,0 and no adhesion promoting 
activity was recovered in the bound fraction when this was eluted either
at pH 7.5 or at pH 9.0; conversely, using the DEAE disk at pH 7.5, some 
adhesion promoting activity could be eluted from the column at pH 6.0 
(results not shown).
From these preliminary results an attempt to purify and at the same
time concentrate the activity contained in the extracted material was made 
using a 16 ml column (8 cm x 2 cm^ ) of Q-Sepharose Fast Flow. The
column was first loaded at a pH of 7.5 and the bound material was eluted
with the addition of 1.0 M NaCI. Both the bound and unbound material 
contained adhesive promoting activity. The unbound material was re- 
applyed to the column at a pH increased by 0,25 units and the bound
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material was eluted with 1.0 M NaCI in the same buffer. Bound and 
unbound fractions were tested in adhesion assays and the cycle of pH
increase and subsequent testing was repeated until no activity was 
detected in the unbound fraction. This was found to be the case when 
the loading buffer pH was at 8.5 (results not shown). When freshly 
extracted material was applied to the Q-Sepharose column at pH 8.5 it was 
noted that some adhesion promoting activity was still present in the eluate 
and that this activity would disappear after repeated applications to the 
column in the same buffer (results not shown).
In an attempt to lower the loading buffer pH and improve the 
separation, extracted material was diluted with an equal volume of tris-HCl 
buffer pH 7.5 (this effectively reduced the NaCI concentration to 0.075 M), 
applied to the Q-Sepharose column at a pH of 8.0, 8.25 and 8.5 and eluted 
in the same buffer with the addition of 1.0 M NaCI. Following these 
experiments it was established that, with a NaCI concentration of 0.075 M,
a pH of 8.25 was sufficient to determine the binding of all the adhesion- 
promoting activity of the extract to the column, while, when the pH was 
lowered to 8.0, some adhesion-promoting activity was detected in the 
unbound fraction. Figure 51 shows an example of purification. Extracted 
material from 8 roller bottles was diluted with an equal volume of tris-HCl 
buffer and the pH was raised with NaOH to 8.25. A two step elution was 
performed using 0.5 and 1.0 M NaCI in the same buffer to try and further 
isolate the active material. Eloth peaks contained spreading-inducing
activity while only the 0.5 M NaCI peak had (rapid) adhesion-promoting
activity.
The molecules present in the preparation purified using Q-Sepharose 
and a one step elution (1.0 M NaCI) were separated using gradient SDS- 
PAGE after the extracted material was concentrated. The only major band 
present in the gels had an estimated of ~ 58,000 and, upon reduction.
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it migrated slightly slower and had an estimated of 62,000-65,000.
Since no other bands were immediately evident, it was at first thought
that this band contained the molecule responsible for eliciting adhesion.
Althought this low molecular weight band was a prime candidate for the
adhesive activity of the extract, it was possible that very low amounts of 
adhesive molecules present in the extracted material, such as laminin,
thrombospondin or fibronectin, might be responsible for the adhesion
observed, although at concentrations too low to be detectable with SDS- 
PAGE.
In an attempt to separate this Mr 58,000 molecule from higher molecular
weight components of the extract, gel filtration was used. The extracted
material, purified on Q-Sepharose by application at pH 8.25 and a one-step
elution with 1.0 M NaCI, was then applied to short columns C  15 cm x 2 
cm )^ of Sephadex G-25, G-50, G-75, G-lOO, G-150 and G-200. Typically 5 ml 
were applied to each column and two fractions recovered: one that did not
enter the gel (or excluded fraction) and one that did. These fractions
were subsequently tested for their adhesion promoting activity. In all
these experiments the adhesion-promoting activity was always found in the
excluded fraction and the separation between the two fractions was always
well defined. Examples of these runs are shown in figures 52 and 53.
No h i^  molecular weight material could be detected after SDS-PAGE. 
This could be due to the very low concentration of the putative adhesive
molecule in the extracted material. Therefore a large quantity of extract
was produced from 24 roller bottles, concentrated down to a small volume 
(0,4 ml) and SDS-PAGE was repeated in order to demonstrate the presence
of bands with higher molecular weight. Unfortunately this exercise
proved unsuccessful. Later experiments suggested that an explanation for
this maybe due to the fact that upon concentration, especially at low 
temperature, the extracted material tended to form a precipitate that was
1 6 0
SDS, mercaptoethanol and urea insoluble.
In other experiments, in order to purify the active component(s) of the 
extract, the material was applied in tris-HCl buffer pH 8.25 + 0.075 M NaCI 
to the Q-Sepharose column and eluted with a linear gradient of 0.075-1.0 M 
NaCI in the same buffer- Each eluted fraction was then tested for its 
ability to support the adhesion and the spreading of B16F10 cells. Only 
one fraction eluting at approximately 0.3 M NaCI seemed to have adhesion- 
promoting activity. Two fractions were most active in supporting 
spreading, one being the same fraction that showed adhesion-promoting 
activity, while the other eluted at approximately 0.9 M NaCI (see figure 
54).
Affinity chromatography was used in an attempt to characterize the 
adhesion- and spreading-promoting activity of the extracted material, and 
at the same time to remove extracellular matrix molecules that are known 
to possess such activity. As starting material an extract partially purified 
on Q-Sepharose with a 1.0 M NaCI elution was used. When such material 
was applied on a column of heparin-agarose (see figure 55) the activity 
was not bound to the column as was the case when gelatin-agarose and 
poly-L-lysine-agarose were used.
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Figure 51: Purification of the endothelial extract on Q-Sepharose 
two step NaCI elution.
using
Extracted material from 8 roller bottles was diluted with an equal volume 
of tris-HCl, pH 8.25 and buffered to pH 8.25 with ~ 0.1 ml of NaOH 1 N. 
The sample was then applied to a 16 ml column of Q-Sepharose and eluted 
with 0.5 M and 1.0 M NaCI. Flow rate = 150 ml cm"*^  h“*. Histograms
indicate the ability of the material to support the adhesion (5 min, 
continuous line) and spreading (60 min, discontinuous line) of B16F10 cells. 
Values below 10 % are not represented.
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Figure 52: Characterization of the endothelial extract; exclusion 
chromatography on Sephadex G-50.
A 2.8 sample was applied to a short column (30 ml) of Sephadex G-50 F
with a flow rate of 120 ml cm"* h"*. The sample is in this way separated
into two fractions: the void volume fraction (first peak) and the fraction
of the stationary volume (second peak). The cut-off point of this gel for
globular proteins is ~ 30,000 D.
Sample 1: 0.5 mg of Blue Dextran + 0.5 mg of tyrosine.
Sample 2: Extracted material from endothelial monolayers, partially purified 
using Q-Sepharose and a 1 step elution with 1.0 M NaCI.
Histograms indicate the ability of the material in each fraction to support 
the adhesion (5 min) of B16F10 cells. Values below 10 % are not
represented.
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Figure 53: Characterization of the endothelial extract: exclusion 
chromatography on Sephadex G-200.
A sample was applied to a short column (33 ml) of Sephadex G-200 with a 
flow rate of 6.9 ml cm'  ^ h"‘. The sample is in this way separated into 
two fractions: the void volume fraction (first peak) and the fraction of the 
stationary volume (second peak). The cut-off point of this gel for globular 
proteins is " 600,000 D.
Sample 1: 1.5 mg of Blue Dextran + 1.5 mg of tyrosine in 8 ml of buffer. 
Sample 2: 5 ml of extracted material from endothelial monolayers, partially 
purified using Q-Sepharose and a 1 step elution with 1.0 M NaCI.
Histograms indicate the ability of the material in each fraction to support 
the adhesion (5 min) of B16F10 cells.
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Figure 54: Purification of the endothelial extract on Q-Sepharose using a 
continuous NaCI gradient.
Two ml of extracted material were diluted with an equal volume of tris- 
HCl, pH 8.25 and buffered to pH 8.25 with " 0.1 ml of NaOH 1 N. Such 
sample was applied to a 16 ml column of Q-Sepharose and eluted with a 
0.075-1.0 M linear gradient of NaCI. Fraction size = 4 ml, flow rate = 75 
ml cm“^  h'^ . Histograms indicate the ability of the material in each 
fraction to support the adhesion (5 min, continuous line) and spreading 
(60 min, discontinuous line) of B16F10 cells. Values below 10 % are not 
represented.
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Figure 55: Characterization of the endothelial extract: affinity 
chromatography on heparin-agarose CL-4 B.
Extracted material from 6 roller bottles was diluted with an equal volume 
of tris-HCl buffer. A sample (15 ml) was applied to a column of heparin- 
agarose CL-4 B and eluted first with 0.6 M NaCI and then with 1.5 M NaCI 
+ 8 M urea. Flow rate = 75 ml cm'  ^ h“*. Histograms Indicate the ability 
of the material in each fraction to support the adhesion (5 min) of B16F10 
cells. Values below 10 % are not represented.
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A d h es ion
1: Designing the assay.
The successful development of an easy, rapid and reliable adhesion 
assay was of prime importance to this study and this therefore constituted
a major part of the early work. The approach was centred on two ideas:
1 Adhesion of circulating cells to the vessel wall is an extremely rapid
event (Bjerknes et a l . ,  1986). The assay should therefore be able 
to measure cell adhesion after the shortest possible period of 
incubation.
2 Given such short incubation, the assay must easily discriminate
between the amount of adhesion elicited when using a known 
adhesive substratum and that measured using a substratum that
does not induce adhesion.
Since the original work of Walther and colleagues (1973), various 
studies have been based on the collecting lawn assay principle: single
cells in suspension are confronted with a monolayer or lawn of cells and 
the rate of their adhesion to the monolayer is measured. Although this 
approach can yield valuable information, the original assay as described 
by Walther and colleagues (1973) does have some significant disadvantages, 
as discussed below.
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Static vs. dynamic assays.
Two basic variations of the collecting lawn assay exist: a static one
where the suspension is left to settle and adhere to the monolayer
undisturbed (Nicolson, 1982 b; Varani e t a i., 1980; Tao and Johnson, 1982; 
Pohlman et a l . ,  1986; DiCorleto and de la Motte, 1985; Kramer and Nicolson, 
1979; Murray et al., 1980; Terranova et a l . ,  1982; Vlodavsky and 
Gospodarowicz, 1981;), and a dynamic one, where adhesion occurs under
flow. In the latter version the flow is usually generated by shaking the
plate in an orbital or a linear shaker (Walters et a l . ,  1973; Winkelhake and 
Nicolson, 1976; Nicolson et a l . ,  1981; Alby and Auerbach, 1984) and this is
done in an attempt to simulate the in vivo environment tumour cells would
encounter when adhering to the endothelium. The use of orbital or
reciprocating shakers is quite a crude way to generate flow and some 
attempts have been made to try and achieve a more controlled 
experimental environment. Most of these generally use a flat flow chamber 
that is optically transparent and suitable for microscopy and time lapse
photography studies (Doroszewski, 1980; Forrester and Lackie, 1984; Owens
e t a l . ,  1987).
Flow undoubtedly represents a very important factor that influences in 
vivo cell adhesion to the endothelium. Nevertheless it is extremely
difficult, if not impossible, to make a precise estimate of the forces that 
circulating tumour cells may encounter when extravasating. A discussion 
about the reasons behind this is outwlth the scope of this dissertation but
the main points are:
1 There is no consensus regarding the anatomical location of tumour
cell arrest in the circulation. This might happen in the precapillary 
arterioles, in the capillary bed, in the postcapillary venule or in
larger diameter veins. In each of these locations blood flow has
markedly different characteristics.
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2 Even if we could be sure about the anatomical location of the arrest, 
the geometry of vascular beds varies between organs. The 
capillaries in the liver, for example, present a totally different 
environment to those in the lungs. In the lungs the capillaries 
spread over several adjacent alveoli and branch and anastomose to 
form Intricate networks over the surface of the alveoli. Lung 
capillaries can be compared more to a continuous thin sheath rather 
than a number of individual small tubes connected in parallel. In 
fact there is so much organ individuality that the in v itro  
mimicking of a vascular environment would probably approximate 
only to one particular organ. Besides, our current knowledge of the 
functional anatomy of the microcirculation of many organs is 
somewhat deficient.
3 Blood is a very complex fluid. Its behaviour under flow seems to 
obey physical rules governing Newtonian fluids (constant 
relationship between shear rate and shear stress), but at times it
can behave like a non-Newtonian fluid (shear stress does not 
increase linearly with shear rate).
4 The mechanical properties of the blood are not uniform but change |
idynamically. There are several phenomena that contribute to this, 1
i
such as plasma skimming towards the vessel walls, particle sorting I!
and dynamic haematocrit. Additionally, the flow rate decreases and 
increases as the blood vessel curves, the pattern of flow changes as IIthe blood goes through restrictions, bifurcations or junctions and |
Î
the pressure fluctuates as districts are open or shut. All these |i
contribute to changing the basic pattern of flow from laminar to 
turbulent, and indeed there may be different types of flow within {
' ithe same area of the vessel. In view of all the necessary
iassumptions it is not possible to make a reliable estimate as to the
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likely flow in any given part of the microcirculation.
5 Even if we were to accept these approximations, there are very 
substantial differences between the environment in model systems 
and that in vivo due to the very nature of the biological material. 
Particles suspended in the blood are not rigid spherical bodies but 
asymmetric and elastic, they are able to modulate their shape and 
the smoothness of their surface. Furthermore the blood vessels are 
irregular and elastic and their shape is always changing.
(For a comprehensive discussion on the mechanics of blood flow see the 
book by Caro, Pedley, Schroter and Seed, 1978). Because of the very 
complicated nature of blood flow, all the different dynamic adhesion assays 
developed in the past reproduce environments so far removed from the in 
vivo situation that they have no real advantages over static systems. In 
fact, contrary to initial impressions, these dynamic assays often complicate 
the picture, introducing variables and constraints which can make the 
results more difficult to evaluate. For all these reasons it was thought 
that a static adhesion assay, although not without limitations, would
nevertheless give some insight into the adhesive phenomenon.
Cell density and volume.
A common pitfall of many methods for measuring adhesion is that the 
results are often influenced by many parameters, some of which are 
irrelevant to the biological phenomenon under study. For instance, in a 
static system (like the one used here), two factors are likely to have a 
very significant effect on the results obtained: the amount of cells in the
suspension and the amount of fluid in which the assay is performed.
The effects of cell number is related to the area of substratum 
available to the cells as well as to the influence of cell-cell interactions on 
their adhesion to the substratum. When there is an excess of cells in
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relation to the surface area of the substratum, only a proportion of these
cells would be able to come into direct contact with it, the rest piling up
on each other. This could be a source of bias because cells may prefer to 
adhere to each other rather than to the substratum. They may therefore 
adhere less rapidly or establish fewer molecular Interactions with the 
substratum, which would weaken the strength of cell to substratum 
adhesion. There may also be differences among individual cells of the
suspension, either because of the presence of different phenotypes (that 
are known to arise even within cell lines of monoclonal origin), or because 
of the presence of cells at different stages of the cell cycle. Such
differences are known to alter the adhesive properties of a cell population 
(Elvin and Evans, 1982; 1983). Also, if cells are in excess, phenotypic
differences within the cell population can give further bias. For example,
if the density (mass/volume) of individual cells varies within the
population and the adherent phenotype is preferentially associated with an 
increased or decreased density of the cell, the heavier cells would "sink" 
to the bottom of the settled suspension and into contact with the 
substratum. The assay would therefore record an increased or decreased 
number of adherent cells only because of the presence of characteristics 
associated with the adherent phenotype, not because of an overall
difference in the numerical expression of such adherent phenotype among
the cell population.
When the volume of medium used in the assay is taken into
consideration, one consequence is immediately obvious: the higher the
column of fluid, the longer the cells will take to reach the substratum
while settling through the medium. This has a tangible effect when 
adhesion kinetics are studied. It can be assumed that, within the
suspension, cells are uniformly distributed. If this is the case, some will 
be in direct contact with the substratum and begin to establish adhesive
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interactions with it almost as soon as the assay starts, while others will 
first need to settle through the fluid. When the geometry of the system 
is such that the column of liquid is tall in relation to its base, a high 
proportion of cells will not be in the immediate vicinity of the substratum. 
Additionally, if we were to measure the distance of each individual cell 
from the substratum at the beginning of the assay, it would become 
apparent that the higher the column of fluid in relation to its base, the 
wider the spatial distribution of the cells would be, which would in turn 
result in a large variation of the time of first contact of each cell with 
the substratum. Some adhesion assays have tried to minimize this 
variable, as in the case of Nlcolson and colleagues (1981), who let the cell
suspension settle onto the substratum before starting the assay by raising 
the temperature to 37® C. This is a rather inelegant solution since the 
system will require a considerable and unknown amount of time to reach a 
stable temperature and during this time adhesion will occur and will be 
enhanced in areas that warm up at a faster rate. If very rapid adhesion 
has to be measured, settling of the suspension would significantly bias the 
results and centrifugation onto the substratum could be a way of
minimizing such bias by reducing the settling time. Although this would 
improve the assay in theory, it also poses practical problems with the
shaking of the system during the deceleration of the rotor and the 
transport of the plate to an incubator, as well as introducing changing 
g forces during adhesion and shape changes of the cells as additional 
variables.
Further considerations arise from the fact that cells, while settling, 
collide with each other. An increased frequency of such collisions can be 
induced by raising the concentration of the cell suspension and the
distance cells have to travel in order to reach the substratum. Cell-cell 
adhcision occurring within a cell suspension (aggregation) is a phenomenon
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which is among other things dependent on the number of collisions and on 
the relative speed of the colliding cells (for a discussion on cell-cell 
aggregation see Evans and Proctor, 1978). If aggregates do form, then 
the results could be extremely biased. Each aggregate, in fact, could 
have as little as one cell adhering to the substratum, resulting in a 
marked over-estimation of substratum adhesion.
For these reasons, when developing the assay, efforts were made in the 
attempt to minimize the number of cells relative to the surface area of the 
substratum. Furtermore, the incubation chamber was designed so that it 
would allow the height of the medium to be kept to a minimum (2 mm).
D e te r m in in g  th e  n u m b er  o f  a d h e r e n t  c e l l s .
A n o th e r  im p o r ta n t  a s p e c t  o f  a d lie s io n  a s sa y s  is t lie  m e th o d  e m p lo y e d  to  
q u a n t ify  Ü ie o u tc o m e  o f  th e  e x p e r im e n t . Id e a lly , a f t e r  r e m o v in g  th e  n o n ­
a d h e r e n t c e l l s ,  a c o u n t o f  a ll th e  a d lie r e n t  c e i l s  sh o u ld  be p e r fo r m e d .  
T h is c a n  b e  d o n e  b y  v isu a l c o u n t u sin g  .1 m ic r o s c o p e  (F lig ie l  a t  a l . ,  1985 ; 
S c o t t  e t  a l . ,  1986) b u t i t  is a te d io u s  and  la b o u r  in te n s iv e  task. O th er  
s t r a t e g ie s  a r e  a v a ila b le :  th e  a d h e r e n t c e l l s  c a n  b e  h a r v e s te d  and c o u n te d
w ith  an e le c t r o n ic  d e v ic e ,  a lt e r n a t iv e ly  a r a d io a c t iv e  la b e l  can b e  
in c o r p o r a te d  in to  th e  c e l l s  w h ic h  ca n  b e  la te r  s o lu b il iz e d  and c o u n te d .  
T h is la t t e r  m e th o d  has b e e n  w id e ly  used ui th e  p a s t  (W a lth er  a t  a l . ,  1972; 
V V inkelhake and N ic o ls o n , 1976 ; A lb y  and A u erb a ch , 1984 ; F’o h lm an  e t  a l . ,  
1986X
Labelling of the cells makes quantification easier, a very high number 
of assays can be performed and the amount of radioactivity later 
determined. There are several disadvantages to this technique however. 
Firstly, radiolabelling involves quite a significant amount of manipulation 
of the ceils, especially if labels such as ^^Cr are used. Secondly, there Is 
the possibility that the label (whether or not metabolic) introduced into
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the cells would accumulate preferentially into certain phenotypes rather 
than others. Thirdly, even during a short term adhesion assay such as 
that used in this study, the label may leak out of the cells, may adsorb
onto the plastic or otherwise be internalized by other cells. Fourthly, a 
long incubation with a metabolic label or the incorporation of radioactive 
sources within a cell poses questions about the effects of radiation on cell 
behaviour. Although this last point is often regarded by the mainstream 
researchers as being insignificant, there is no ground for adopting such a
dismissive attitude. On the contrary, there are increasing numbers of 
reports suggesting that very low doses of radiation can have a profound 
effect on selective cell activities (Kimler et a l., 1981; Olivieri et al-, 1984; 
Shadley and Wolff, 1987; Sankaranarayanan et a l., 1989). Cell adhesion, 
like any other cellular activity, is likely to rely on the coordinated
functioning of many different components such as surface receptors, 
cytoskeletal elements, intracellular organelles, degradation pathways and so 
on; the exposure to radiation obviously Increases the risk of interfering 
with any of these components. It is probably for these reasons that some 
authors have tried, more recently, to overcome the possible effects of 
such manipulations by labelling the cells after the assay (Mentzer et a l., 
1986).
Other techniques have been employed in the past, as in the case of the 
use of a vertical pathway photometer after fixation and staining of the 
adherent cells (Piershbacher and Ruoslahti, 1984) or the measuring of the
turbidity before and after removal of non-adhering cells (Grinnell and 
Minter, 1978; Grinnell and Feld, 1979). The first approach offers
advantages over other techniques especially because of its rapidity, low 
cost and the fact that it allows the processing of large numbers of
samples. Personal experience casts doubts as to the reliability of such
measures and no published indications were given by the authors
1 7 5
regarding variations between duplicates nor has any statistical analysis, 
graphical or numerical, been provided. The second (turbidimetric) 
approach is relatively fast and again it offers low cost and reduced 
manipulation of the cells, but, on the other hand, turbidimetry is not a 
reliable estimator of the number of cells in solution and the presence of 
cellular aggregates reduces the accuracy further. In fact, a relatively 
high number of cells in suspension are required (0.5-1 x 10® cell ml"^ ) for 
an accurate reading, with an increased probability of aggregate formation.
As discussed earlier, the assay would benefit from the use of a small 
number of cells in relation to the available substratum. If reliable results 
are to be obtained by visual counting, this has to be performed over the 
entire surface of the substratum. Cells do not distribute on the bottom of 
the dish uniformly, due to, amongst other things, the geometry of the 
system and, in particular, the presence of a meniscus. The visual 
counting should be done as soon as the assay is terminated because 
adherent cells may detach and float, they may divide or they may lyse. 
Although fixing and staining of the adherent cells allows counting to be 
performed at a later date, the quantification of the assay is very labour 
intensive and, therefore, the use of such a technique for investigative and 
screening purposes becomes impractical.
Another way of determining the number of adherent cells would be to 
harvest and resuspend them and count a sample. For some cell lines (like 
the B16 cells) it is possible to use chelating agents for routine 
detachement but the molecular composition of the substratum of an 
adhesion assay is often very different from that of a dish that had cells 
growing to confluency. It is therefore possible that some cells may not 
detach following such gently treatment and, for this reason, it is best to 
harvest the adherent cells using enzymes. Although this method would 
have the advantage of counting only a small proportion of the adherent
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cells either with an haemocytometer or, even better, an electronic particle 
counter (Murray e t a l., 1980; Terranova e t a l., 1982), bias could arise 
from the exposure to enzymes, which may cause lysis among a population 
of cells that have already been harvested, centrifuged, resuspended and 
allowed to adhere again within the last 10-15 minutes.
By counting the number of non-adhering cells, the number of adherent 
cells can be determined with a good approximation. Since at the end of
an adhesion assay non-adherent cells have to be removed anyway, their
collection does not greatly complicate the procedure. Although
haemocytometers can be used for the counting (Varani e t a l . ,  1980), these 
non-adherent cells would be in suspension and would therefore be ideally 
suited for electronic counting. Counting cells with the help of a Coulter 
counter is inexpensive and cell manipulation is kept to a minimum since no 
labelling is required and large numbers of samples can be processed
easily and rapidly. Furthermore, results are available immediately. In our
experience, when the Coulter counter is coupled to a channelyzer, the 
counts obtained are quite reproducible, especially if the cell concentration 
is kept well below the threshold for coincidence (which, using a 100 um
orifice, is ~ 5.5 x 10® cells ml"^ ).
2: Evaluation of results.
From the results of the study four points can be made:
1 Rapid adhesion is temperature and divalent cation dependent.
2 The kinetics of adhesion to a particular molecule depend on the
concentration of the given molecule on the substratum.
3 The adhesion kinetics to endothelial monolayers compare favourably 
with those of the most adhesive molecular substrata.
4 Some molecules are unable to support rapid adhesion regardless of
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their concentration on the substratum.
D iv a le n t  c a t io n s  and  te m p e r a tu r e .
N o t  su r p r is in g ly , ra p id  a d h e s io n  is  d e p e n d e n t o n  th e  p r e s e n c e  o f
d iv a le n t  c a t io n s  in  th e  in c u b a t io n  m ed iu m  and on  th e  te m p e r a tu r e  o f  th e  
s y s t e m  ( s e e  f ig u r e s  18, 2 4  and 2 7 ). T h is is in  a g r e e m e n t  w ith  th e  g e n e r a l  
c o n se n su s  t l ia t  c e l l  a d h es io n  is  Ca^ and  Mg^ -d e p e n d e n t  an d  d e c r e a s e s  a s  
th e  te m p e r a tu r e  d e c r e a s e s .
T h e r e  a re  s e v e r a l  p o s s ib le  e x p la n a t io n s  fo r  th is:
1 T h e  fo ld in g  and u n fo ld in g  o f  th e  lo n g  a rm s o f  s o m e  a d h e s io n
m o le c u le s  is  -d e p e n d e n t. T h rom b osp on d in , fo r  in s ta n c e , h a s
s e v e r a l  b in d in g  s i t e s  fo r  C a“* w h ic h  m o d u la te  it s  te r n a r y  s t r u c tu r e  
(r e v ie w e d  in  F r a z ie r , 1987) and, as a r e s u lt , b in d in g  to  o th e r
lig a n d s m a y  b e  im p a ired .
2 T h e  a f f in ity  o f  so m e  lig a n d s  for  th e ir  r e c e p to r s  a r e  and Mg^^-
d e p e n d e n t (fo r  m o re  d e ta i ls  s e e  th e  p a g e s  2 5 -6 6  o f  th e  in tr o d u c t io n  
a b o u t th e  s u b e n d o th e lia l m a tr ix ) .
3 C a lc iu m  is n e c e s s a r y  for c e l l s  to  d e g r a n u ia te  and  c h e la t in g  a g e n ts
c a n  in h ib it d e g r a n u la tio n . In p la t e le t  a d h esio n  to  th e  e n d o th e liu m  
for  e x a m p le , W 'ib er -P a la d e  b o d ie s  a re  b rou gh t in to  c o n t a c t  w ith  th e  
c e l l  rnemJDrane a llo w in g  th e  g e n e r a t io n  on th e  e n d o th e liu m  o f  p a tc h e s  
c o n ta in in g  v e r y  h ig h  d e n s it ie s  o f  m em b ra n e  b ou n d  von  VVilltibrand 
fa c to r  (Sporn e t  a l . ,  1986 ; Sporn  e t  a l . ,  1 9 8 7 ). If tu m ou r c e l l
a d h es io n  to  e n d o th e liu m  r e l ie s  on e x o c y t o s is  o f  s e l e c t i v e  e n d o th e lia l  
g r a n u le s , th e  p r e s e n c e  o f  c h e la t in g  a g e n ts  m a y  r e d u c e  e x o c y t o s i s  
a n d /o r  th e  b in d in g  o f  th e  g r a n u le  c o n te n t s  to  th e  m e m b r a n e
a c c e p to r  s i t e s  and th e r e fo r e  im p a ir  a d lie s io n .
4  C h e la t in g  a g e n ts  m a y  a f f e c t  th e  c y t o s k e le t o n .  I f  a d h e s io n  d ep en d s  
on  a r e a r r e n g e m e n t  o f  c e l l  s u r fa c e  a d h es io n  r e c e p t o r s  ( lik e  p a tc h in g
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or capping) and if such redistribution is mediated by the
cytoskeleton, adhesion may be inhibited.
5 The divalent cation-free medium could affect the general metabolism 
of the cells, rather than disrupting specific llgand-receptor 
interactions.
Some experiments to evaluate the action of EDTA on the system gave 
results that are in contrast to those published by Kramer and co-workers
(1980). These authors exploited the action of EDTA on endothelial
monolayers to compare the adhesion of tumour cells to confluent
endothelium and to retracted endothelial cell monolayers. In their hands, 
exposure to EDTA for 30 min caused the rounding up and retraction of the
endothelial cells, leaving the underlying extracellular matrix exposed. 
These authors reported that EDTA pre-treatment of the endothelial
monolayer resulted in a ~ 8 fold increase in the number of adhering cells 
after 5 minutes of incubation. They observed that in these conditions 
tumour cells are mostly bound to the exposed extracellular matrix and then 
they proceeded to use these results to support the interpretation, at the
time in vogue, that tumour cell arrest relied on patches of exposed 
subendothelial matrix. In our hands exposure to EDTA prior to testing of
either the endothelium (for 30 min as described in the work of Kramer et
a l . ,  1980), the tumour cells or both, did not alter the kinetics of adhesion. 
Although for these experiments we used B16F10 and not B16F1 cells, in 
our experience these two cell lines behave quite similarly as regards 
adhesion to the endothelium and other substrata (see figures 22 and 25). 
Finally, according to Kramer and his colleagues (1980), adhesion to the 
endothelial monolayer was not as fast as we have reported, with less than 
10 % tumour cells adhering after 5 minutes. These authors used bovine 
aortic endothelial cells similar to those used in our laboratory. There may
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be several reason for the marked difference in the results we obtained,
mainly related to the handling of the endothelial cells. Their endothelium
was, in fact, maintained with a different routine and cultured in a 
different medium. We routinely kept the cells on a strict 3 days cycle
and no aged monolayer was used for adhesion assays, while there is no
mention of these details in their work; their cells were grown in medium
containing 10 % FCS but at confluency this was replaced with a medium 
containing only 5 % FCS; fibroblast growth factor was added every other 
day but no insulin nor other supplements were used. Other differences
relate to the tumour cell suspension, which was ®^Cr-labelled (with the 
inherent artefacts of exposure to radioactive sources and manipulation)
and inoculated into the wells in a volume 2.5 times larger than that used 
in our study (which resulted in a much increased settling time).
The effects of low temperatures on adhesion (which are reversible - as 
shown in figure 18) can be due to an overall slowing down of the
metabolism of the cells. Additionally, at low temperatures, membrane 
fluidity is reduced and this could impair the movement of receptors 
towards the patches of contact with the substratum. In this scenario, the
speed with which ligand receptor interactions are undertaken would be 
much reduced. Low temperatures could also have a significant influence 
on the Kd of the ligands and receptors involved in adhesion. It is known
that fibrinogen, for example, is not a ligand for fibronectin at 37° C but 
its affinity for it increases drammatically at 4® C (Grinnell, 1981, Mosesson 
and Amrani, 1980). If at low temperature the K*, of laminin for its 
receptor increases, this could in turn result in a much slower rate of
formation of molecular bonds between the cell surface and the substratum- 
bound laminin, which would result in a de facto inhibition of adhesion as 
measured with this assay system (see figures 24 and 27).
If the results of the fixation experiments (see figure 19) are considered
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within this context, it would seem that tumour cell-endothelium adhesion 
may require an active and fully functional membrane-cytoskeleton 
assembly, at least on the tumour cells. Generally the cytoskeleton plays a f
central role in cell adhesion, and this is confirmed by the work of Chong
and his colleagues (1987). The absence of divalent cations would affect
the cytoskeleton (Roos, 1984) as well as the fusion of granules to the cell
membrane, while fixation would have the effect of stiffening the cell 
membrane denying the cell the possibility of modifying its shape, 
redistributing its surface molecules or expressing new ligands on its
surface.
That adhesion of cells is a more complex phenomenon than simply 
bringing two particles together and letting their surface molecules create 
a bond is not a new concept. A fundamental step for adhesion to occur 
is, for instance, the alignment of the two confronting surfaces (see Roos,
1984 for a review). This is probably accomplished by the cytoskeleton.
Cells which are unable to align their confronting surfaces will not adhere.
Using anchorage independent cells and normally adherent cells, it has 
been shown how this alignment can be induced by just one of the cell
pair (see Roos, 1984 and references within). It is therefore very 
interesting to note that fixing of the tumour cells completely abolishes 
adhesion while fixing of the endothelium only reduces it. Since adhesion
is dependent on the ability of the confronting cells to align their 
surfaces, in tumour cell adhesion to the endothelium this alignment must
rely predominantly on an active role of the tumour cells rather than the
endothelium.
Concentration on the substratum.
Small differences in the concentration of adhesive molecules on the 
substratum have a great influence on the rate at which cells adhere to it
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(see figures 23 and 26).
Although this in itself seems quite obvious and has been stated in the
past (for a review see Grinnell, 1981), it is surprising how this effect has 
been overlooked by many researchers. Grinnell and Minter (1978),
Pierschbacher and his colleagues (1984) and Nicolson and bis colleagues
(1981), for example, do not give any indications as to the amount of
fibronectin used to coat the dishes. Giancotti and colleagues (1985), on
the other hand, state the concentration of the protein solution used to 
coat the dishes, but not the volume used. Vlodavsky and Gospodarowicz
(1981) reported that tumour cells adhered quite well to endothelial
extracellular matrix (more than 80 % after 30 minutes) but poorly to
fibronectin coated substrata (less than 10 % after up to 1 h). The
fibronectin substrata used, were coated with 10 ug of protein per dish,
but there is no mention of the type of dishes used. If these were 24-well 
plate», the substrata would have been exposed to 5 ug cm~^  of
fibronectin, but if they were 35 mm Petri dishes (as seems more likely
from the volume of medium used) the substrata had a concentration of
fibronectin which, in our experience, is too low (approximately 1 ug cih^) 
to promote adhesion. This lack of reference to the density of adhesion
molecules on the substratum prevents comparison of data from different 
work and at times cast doubts on the validity of the conclusions.
Throughout this study no attempts were made to quantify the amount
of molecules bound to the substratum, although, in retrospect, an effort to 
try and determine the concentration at the substratum should have been 
made. A major problem was the radiolabelling of the adhesive factors
used: it is impossible to determine whether this procedure would alter the
affinity of the molecule for the substratum. In some respects, any
manipulation could results in substantial changes, as exemplified by
anti thrombin III, where iodination exposes a cryptic site for the binding of
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vitronectin (111 and Ruoslahti, 1985). Therefore all the figures quoted 
represent an estimate of the concentration, assuming that all the molecules 
present in the solution at the time of incubation with a clean plastic dish
would bind to the plastic and that there would be an even distribution
across the exposed surface.
There is no real understanding of the mechanisms regulating the 
adsorption of molecules onto plastic substrata but it is useful to
summarize some phenomenological observations related to it:
1 Adsorption of proteins depends on the characteristics of their 
charged groups that can interact with the plastic (Butler, 1981). 
Some proteins may therefore exhibit unique behaviour in this
respect.
2 The binding of molecules to plastic seems to have an initial phase 
where molecules are adsorbed very rapidly to the plastic reaching a 
plateau within the first 45-60 minutes. Beyond that the
concentration of substratum-bound molecules increases significantly 
only if incubation times are extended to 18 hours or more
(Herrmann, 1981).
3 Below a certain threshold, the amount of bound molecules is 
independent of the amount of molecules present in solution. This 
threshold is inversely related to the molecular weight, and for small
molecules it is around 0.15 ug cm~* (Butler, 1981).
4 Above this limit for independent binding there is an apparent 
saturation limit which is above 2 and below 20 ug of protein per 
cm^  of plastic. Below this limit the amount of protein adsorbed is 
proportional to its concentration in solution and for those molecules 
tested is ~ 50 % (Herrmann, 1981).
5 It is possible to bind more molecules to the plastic above the 
saturation limit by significantly increasing the incubation time and
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the concentration of the solution- The efficiency of the process 
decreases dramatically and most of the additional bound molecules 
will be easily solubilized once the coating solution is removed
(Herrmann, 1981).
6 Below the independent threshold most of the molecules are
tenaciously bound to the substratum: salts, chaotrophic agents, acid
treatment, detergents, organic solvents, oxidizing or reducing agents 
all fail to remove the adsorbed proteins. Only boiling in aqueous 
solution for at least 15 minutes may solubilize all the immobilized
molecules (Parsons, 1981).
7 Some molecules seems to be able to displace other molecules already 
bound to the plastic. Fibrinogen is one of these proteins that 
displaces previously adsorbed ones (Parsons, 1981).
8 Given a complex molecular mixture, below the threshold for
independent binding there is no competition for the binding sites on
the plastic. Above the threshold for independent binding, the 
quantity of each of the types of molecules adsorbed to the plastic
may not be representative of the composition of the solution (Butler, 
1981).
9 Below the saturation point the binding seems relatively independent
of pH, temperature and ionic strength, although more and faster
binding occurs at higher temperatures (Parsons, 1981; Herrmann, 
1981).
10 The bound molecules retain some of their biological activities and in
some cases acquire others not displayed when in solution (111 and 
Ruoslahti, 1985).
Since most of these data refer to studies on the binding of selected 
molecules to plastic, it cannot be assumed that all molecules will behave in
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the same way. It is therefore difficult, for instance, to claim conclusively
that B16F10 cells do not adhere to collagen or gelatin since it cannot be 
ruled out that these molecules, once adsorbed to the plastic, lose their 
adhesive activity.
The endothelium as an adhesive substratum.
One of the central aims of this work was to compare the kinetics of
adhesion of tumour cells to the endothelium and to isolated subendothelial 
matrix components. Previous published work suggested that endothelial
cells were not a suitable substratum for tumour cell adhesion and that, in 
fact, tumour cells arrested in vivo by adhering to patches of the vessel 
wall denuded of endothelium. In their paper, Kramer and colleagues (1980) 
reported that endothelial monolayers were poorly adhesive for tumour cells 
and that other substrata, sudhi as immobilized fibronectin or endothelial 
extracellular matrix, were much more effective in eliciting tumour cell 
adhesion. Although their basic adhesion assay ran for 1 h, from the 
published figures we can extrapolate some data of adhesion after 5 min 
incubation: tumour cell adhesion to the endothelium was ~ 7 % while
adhesion to the subendothelial matrix was around 60 % and adhesion to 
fibronectin alone was between 80 and 90 %. The same group (Nicolson et 
a l., 1981) later confirmed these results. Around this time there were 
reports from related research groups supporting the hypothesis that the 
endothelium was a most unlikely target for tumour cell arrest, as shown 
by the work of Poste and Fidler (1980) where tumour cells were allowed to 
adhere to the intact vessel wall or to one denuded of vascular 
endothelium. Reports on the adhesive role of isolated subendothelial
matrix components like laminin and fibronectin, such as those by 
Vlodavsky and Gospodarowicz (1981) and Terranova et a l. (1982), indicated 
that a consensus of researchers gave the subendothelial matrix a prime
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role in the arrest of tumour cell. Indeed in a review paper Nicolson
(1982) stated that tumour cells would be expected to bind preferentially to
regions of injured endothelium.
This supposition must be met with reserve for two basic reasons;
1 The exposed subendothelial matrix is a very potent stimulus for
platelet adhesion. Platelets are extremely numerous (values
fluctuate, but in most vertebrates there are 2-8 x 10® platelets per
ml of blood) and, although no numbers can be reliably quoted for
circulating metastasizing tumour cells, it is safe to say that platelets 
are present in the blood in overwhelming numbers in comparison to 
cells of non-haematological tumours. With this in mind, it seems
unlikely that tumour cells ever come into contact with exposed
subendothelial matrix. Indeed, platelets would rapidly and effectively 
coat the denuded area before any tumour cell could have a chance 
to adhere to it. It can be argued, of course, that tumour cells
adhere to platelet plaques (although the finding of tumour cells
adhering to platelets adhering to the vessel wall is very rare in
electron microscopy studies), but this is not pertinent to the
endothelium/subendothelial matrix debate.
2 The other point to consider is the fact that the arrest and 
extravasation of circulating cells is of common occurrence
throughout the lifetime of every individual. Apart from colonization
of various organs by circulating cells during fetal life (liver, spleen,
thymus, and so on), leukocyte and lymphocyte traffic across the 
endothelium is a physiological phenomenon for which no exposed
subendothelial matrix is required. Indeed, it would be strange if a 
physiological function were to rely on what is considered to be a 
pathological condition (exposure of subendothelial matrix). Since 
tumor cells grow, locomote and function mainly by utilizing
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mechanisms commonly used by normal cells, it is possible that 
tumour cells use the same mechanisms as other circulating cells to 
arrest in the circulation.
For these reasons it was felt that the endothelium itself, rather than
the subendothelium, might be more important in tumour cell arrest. The 
data collected during this study disagree with the previously published 
work discussed above and show that the endothelium is indeed an
adhesive substratum for tumour cells, certainly comparable to some
isolated subendothelial matrix components such as fibronectin and laminin 
(see figure 29). Although the extracellular matrix of the endothelial cells 
(obtained by detergent extraction with 0.1 % Triton X 100) was not
systematically tested in our adhesion assay, pilot experiments had shown 
that adhesion to such a matrix was comparable to that reported in
previously published work (Kramer et a l., 1980; Vlodavsky and 
Gospodarowicz, 1981; Nicolson et a l., 1981), and the kinetics of adhesion 
were similar to those obtained using intact endothelium.
The reason for the differences in tumour cell-endothelial monolayer 
adhesion in our assay as compared with the work of Kramer et a l., (1980), 
Nicolson et a l,, (1981), Vlodavsky and Gospodarowicz (1981), Tao and 
Johnson (1982) and Nicolson (1982 b) is not at first evident, but it is
probable that the endothelium is a substratum which can modulate its 
adhesiveness according to external stimuli. This is supported by reports 
that Indicate how the endothelium can change from an anti-thrombogenic 
to a pro-coagulant surface (see page 20). Indeed, many factors may
influence the final status of the endothelium as an adhesive or non­
adhesive surface. This is shown, for instance, by the work of Nakache 
and colleagues (1985) who found that different substrata onto which the 
endothelial cells were cultured induced changes in the mobility of
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membrane lipids, although no gross shape and size differences were 
noticed. The different fluidity of the lipid bilayer, although not 
necessarily important in adhesion. Is only an example of how the
environment can subtly change the status of an endothelial monolayer. 
The density of the monolayer may also drastically alter adhesion, as shown 
by Di Corleto and de la Motte (1984), who tested adhesion of U937 
monocyte cells to a number of endothelial cell lines of various derivations.
Further support for the notion that the adhesive status of the 
endothelial monolayer has the potential for modulation arises from the
results of the experiments using trypsin (see figure 21) which showed 
that trypsin can induce the endothelium to become much more adhesive for 
the tumour cells.
With this in mind, we can attempt to explain the discrepancies between 
our findings and the published work by pointing out the differences in
culture conditions, cell handling and assay techniques. We had recognized 
the need to culture the endothelial cells using a strict routine and a 3- 
day cycle (although endothelial monolayers could be kept in culture for 
months) in order to avoid the introduction of the effects of culture ageing 
and different cell densities. In their work, Tao and Johnson (1982) 
performed their assays 7 days after seeding of the endothelial cells, while
in both the work of Kramer et a l. (1980) and Nicolson et a l. (1981) there
is no reference to the age of the monolayers used. The culture medium is
also very important, and in our experience even short exposure to slightly 
more acidic pH can cause disruption of the endothelial monolayer after a
delay of several hours. For this reason we decided to maintain as stable
a pH of the medium as possible during the adhesion assay, since a shift of 
the pH could cause modulation of the adhesiveness of the endothelium. 
Culture media usually rely on bicarbonate buffering with COg in the 
incubator and unless COg levels are controlled during the assay, the
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buffering system fails to be effective. Hepes was therefore added to the
medium and cells were allowed to adapt to it for 24 h. Even at the time
of the assay due care was taken to ensure that the endothelium was not
injured as the medium was aspirated and the tumour cell suspension
inoculated. Results have shown that wounding modulates adhesion (Di 
Corleto and de la Motte, 1985), but it is likely that differences can occur 
even if less obvious injuries are inflicted on the endothelium. This could 
happen when, for instance, the medium is aspirated from the wells and the 
monolayers are temporary exposed to the dry heat of the thermostatic 
cabinet before tumour cells are added.
With respect to the comparison between the adhesion to endothelium
and to fibronectin and laminin, it would be of great interest to establish 
what the concentration of these two ligands is in their functional states 
on the plastic substrata and on the endothelium. Endothelial cells produce 
and incorporate many types of adhesive molecules into the extracellular
matrix as well as on their membrane, and it is possible that tumour cell 
adhesion to the endothelium is indeed mediated by one or more of these 
molecules. In this case their concentration on the surface of the
endothelium should correlate with the data obtained using purified
molecules. If in the experiments shown in figures 23 and 26 the
adsorption of laminin and fibronectin occurred below the saturation limit, 
it is reasonable to assume that the real concentration of these ligands on 
the substratum is approximately 50 % of the quoted value. Therefore, if
the binding of tumour cells to the endothelium occurred via laminin or
fibronectin, the endothelium should possess at least ~ 4 ug cmT* of
fibronectin or laminin (confront figures 18, 23 and 26 ).
On the other hand there may be basic differences between an
artificially constructed substratum and a monolayer of cells, the most 
obvious one being that a fibronectin substratum of a given density is
189
probably composed of randomly spaced molecules, while on the cell 
membrane fibronectin may form patches of tightly spaced molecules 
interspersed by large areas which are depleted of fibronectin. In this 
case, although the fibronectin density on the cell surface may be well 
below that of the fibronectin substratum, there will be localized areas of 
the cell membrane where the concentration of this molecule could be as 
high as that on the synthetic substratum (or higher). Rapid adhesion may 
rely on the formation of small adhesion patches with a high density of 
ligand-receptor interactions, therefore the possibility of such diversity 
should be taken into consideration when comparing the results of adhesion 
to endothelial monolayers with those to molecular substrata.
The experiments performed using formaldehyde (see figure 19) allow us 
to formulate some comments on the adhesive process. Because of the total 
inhibition of adhesion when B16F10 cells were exposed to the fixative 
compared with only a partial inhibition when the endothelium was fixed, it 
seems that rapid adhesion depends on the ability of the cell in suspension 
to modify itself as it comes into contact with the substratum.
Rearrangements of surface molecules (capping?), exocytosis and localized 
shape changes (alignment of confronting surfaces?) would be almost 
certainly impaired in a cell exposed to fixative. In this light it is 
interesting to note that fixing of the endothelium resulted only in partial 
inhibition of adhesion. If an overtly active role of the endothelium during
tumour cell adhesion is envisaged, as it would be in the case of adhesion 
and engulfing of circulating foreign bodies, we should have recorded a 
marked reduction of adhesion.
It is important to point out though, that fixation can have far more 
profound effects on the system than merely to cross-link and stiffen the 
cell membranes. It can, for instance, modify the physico-chemical
properties of the surfaces to such an extent that the subsequent adhesion
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observed could be due to totally different kinds of interactions, as
decades of experiments with fixed platelets have shown.
As for the absence of adhesion elicited by von Willebrand factor, the 
preparation tested contained only the basic dimer plus perhaps small
amounts of the low molecular weight multimers. Although it is known that 
von Willebrand factor is an extremely adhesive substratum for cells such 
as platelets, this property seems to reside exclusively in the very high
molecular weight mul timers (Sporn et a l., 1986; Sporn et a l., 1987) and 
therefore the absence of any adhesion (and spreading - see below) 
inducing activity does not rule out an involvement of von Willebrand
factor in extravasation of tumour cells. It is not clear why high molecular 
weight multimers are highly adhesive molecules while the low molecular 
weight ones are not, since they are all assemblies of the same basic dimer 
and no post-polymerization modifications have so far been reported. We 
can only speculate that on the basic dimer there are low affinity binding 
sites for membrane acceptors. The high molecular weight multimers are 
highly coiled polymers (SI ay ter et a l., 1985) and would therefore possess 
a high density of such low affinity binding sites and this would raise the 
efficacy of the molecule to bind to the cell membrane, A similar property 
has been demonstrated for the aggregation factor in the marine sponge 
Microciona proliféra where a very high molecular weight polymer
containing a high density of low affinity cell binding sites promotes the
specific re-aggregation of single cells, with the association constant 
increasing linearly with the molecular weight of the reconstituted polymers 
(Misevic and Burger, 1986).
An Interesting observation in the present study was that von
Willebrand factor coated substrata were completely non-adhesive (no cells
were found on visual inspection, while we always noticed a small (2-7 %) 
amount of cells adhering to BSA-coated plastic). The ' non-adhesive
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property of this molecule could well be worth further investigations in 
view of the possible industrial applications for substrata that are non­
adhesive for blood, bacteria or algae.
Modulation bv antibodies.
Attempts have been made to inhibit adhesion using anti-fibronectin and 
anti-laminin antibodies which were polyclonal in origin. Polyclonal 
antibodies contain a mixture of tens of thousands of different antibody 
sub-populations. Each of these sub-populations is directed against a
different determinant of the target molecule and each individual antibody 
has a fairly high for its determinant. Monoclonal antibodies are
instead directed against a single determinant of the target molecule. In 
the case of monoclonal antibodies, only those with low for the target 
molecule would successfully interfere with adhesion by competing with the 
ligand for the target molecule. This makes monoclonal antibodies more 
likely to react also with similar determinants present in different 
molecules.
Among the various polyclonal preparations against fibronectin tested, 
the one obtained through the Scottish Antibody Production Unit (SAPU) 
was found to exert an inhibitory influence on adhesion and it was used
for further investigations. Although results showed that it causes an 
almost complete inhibition of adhesion when incubated with fibronectin 
substrata (87 % inhibition after 5 minutes), its inhibitory effects on
adhesion to endothelial monolayers was much less (33 % of the total
adhesion in 5 minutes). This could indicate that fibronectin is indeed not 
responsible for mediating adhesion between tumour cells and endothelium 
but some alternative interpretations should be considered. While in the
first instance (fibronectin substrata) there is a well defined and 
comparatively simple situation where it can be envisaged that the
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antibodies coat the fibronectin molecules and in doing so mask either 
directly or indirectly the sites that are involved in adhesion, in the case 
of the endothelium many alternative explanations may apply.
Since the substratum is composed of live cells, it can be hypothesized 
that the antibodies coat the cell bound fibronectin and that, once removed 
from the solution, the endothelium internalizes the bound molecules and 
replenishes its surface with more fibronectin which is then available for 
adhesion. If soluble antibodies are left in the medium during the assay so
that they are still available to coat fibronectin molecules that are recycled
to the membrane, adhesion is abolished. Unfortunately this inhibition is 
totally independent of the type of molecules bound to the substratum, 
being observed also when laminin and endothelial cell extract substrata 
were used. This is likely to be due to the action of the antibodies on the 
fibronectin present on the tumour cell surface. This could be either by
functional blockage of the fibronectin molecule or by less specific means
such as perturbation of the pattern of electric charges on the cell surface 
or because of the injury that can be associated with formation of immune- 
complexes on the cell surface.
The inhibition of tumour cell adhesion caused by the anti-fibronectin 
antibodies on fibronectin substrata is specific since they do not have any
effect on other molecular substrata. The moderate inhibition exerted by
such antibodies on the tumour cell adhesion to endothelial monolayer may 
be explained as having been caused by the formation of immune complexes 
on the surface of the endothelium. It must be remembered that the
endothelial cells may be considered part of the immune system by virtue 
of their phagocytic and antigen presenting-cells activities. It has also
been shown that the anti-thrombogenic status of the endothelial surface
can be subverted very rapidly using a number of stimuli, challenge with 
immune complexes being one of them. For these reasons it is not
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surprising that, although fibronectin may not be directly involved in the 
adhesion between endothelium and tumour cells, exposure of the
endothelial cell surface to anti-fibronectin antibodies causes a slight
inhibition of such adhesion.
Modulation bv enzymes.
Another way of modulating adhesion is by means of exposure of cells to 
trypsin. Such an effect is in itself not surprising, since the enzymatic
digestion of surface molecules directly or indirectly involved in adhesion 
would markedly influence this process.
Some research groups working with B16 cell lines use trypsin for the 
detachment of these cells during routine passaging. From discussion with 
Dr. Vollmers it emerged that B16 cells subjected to such treatment show a 
substantial decrease in the number of lung colonies formed after i.v.
injection after only 3-5 in v itro  passages. Generally our investigations 
pointed towards a reduction of adhesion following trypsin treatment, which 
could explain the methodological difficulties experienced by Vollmers and 
colleagues.
The action of trypsin may be influenced by the presence in the 
incubation medium of divalent cations within the normal physiological 
range, or of chelating agents. In the presence of chelating agents some
molecules unfold part of their tertiary structure revealing sites of the
polypeptide chain more susceptible to proteolytic cleavage. Usually, the 
enzymatic activity of trypsin in the absence of divalent cations is 
therefore enhanced both in term of speed of reaction and extent of the 
damage caused.
Exposure of tumour cells to trypsin (either in the presence or absence 
of divalent cations) caused an inhibition of adhesion to the endothelium. 
This inhibition was dependent on the time of exposure to the enzyme and
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appeared to require longer exposure to the enzyme when divalent cations 
were present (confront figures 20 and 21). These data suggest that the 
structures responsible for the adhesion are proteinaceous. It is also 
possible that the carbohydrate moiety on the cell surface is active in some 
stages of the adhesive process since an effect of the use of trypsin (and 
other proteolytic enzymes) upon the cell surface is the loss of some 
oligosacharides side chains from the polypeptides cores. The differences 
recorded when digestion occured in the presence or absence of divalent 
cations cannot be due the action of the chelating agent per se on the 
tumour cells. Control experiments have, in fact, shown that incubation of 
tumour cells in a divalent cation-free buffer and in the presence of EDTA
for up to 15 minutes did not alter their normal adhesiveness when this 
was later tested in normal complete medium.
Trypsin can also exert a stimulatory influence on the system. In the 
presence of inactivated enzyme, adhesion of tumour cells (not previously !
exposed to proteolysis) to the endothelium was enhanced (35 % increase of |
adherent cells after 5 minutes, as shown in figure 21). Since this |
enhancement was not detected when adhesion was tested on fibronectin j
substrata, these results would point to a possible action of the trypsin |
molecule on the endothelium. This action should not be due to the ienzymatic activity of the molecule, which was blocked, although this may |
not be a correct assumption. Alternatively, contaminants present in the |
trypsin preparation and not trypsin itself may be responsible for this |
enhancement of adhesion. ]
1
Carbohydrate involvement.
Cell adhesion may be mediated by carbohydrate chains of surface 
molecules and indeed it has been proposed that lectins are involved in the 
process of metastasis (Raz et a l,, 1986). Lectins (carbohydrates-binding
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proteins) have been implicated in many aspects of tumour biology, from 
’’contact inhibition” of growth to involvement in tumour cell-platelet
aggregation during metastasis (Raz et a l., 1984 and references within).
There are reports that carbohydrates are involved in cell-cell adhesion 
(for a review see Feizi, 1985) and lectin-resistant variants of B16 melanoma 
cells have been selected to show how the presence of lectin binding sites 
may correlate with the ability to metastasize (Tao and Burger 1982; Tao et 
a l,, 1983).
The adhesion to fibronectin, laminin and the endothelium may be 
mediated by carbohydrate chains present on tumour cell surface molecules, 
as indeed some reports have suggested (Nicolson, 1982 b). Since by using
our adhesion assay we had already obtained data quite dissimilar from the 
published dogma, we decided to investigate the effects of tunicamycin 
treatment on adhesion- For this, tumour cells were treated with 
tunicamycin, which is an antibiotic that blocks the N-linked glycosylation 
by inhibiting the transfer of the first N-acetylglucosamine-phosphate to 
the dolichyl-phosphate molecule.
Results obtained after exposure of cells to tunicamycin (and other
glycosylation inhibitors) are to be carefully evaluated in that, although
the action of the antibiotic is thought to be very specific upon brief 
exposures, it may ultimately inhibit protein syntesis selectively and 
unpredictably. An explanation for this relates to the role of proteins
themselves within the cellular machinery for protein synthesis: some
unglycosylated proteins may have a shorter life or not function properly
and, if the correct components of this machinery are not supplied, a long 
term effect could be disruption of protein synthesis. Proteins are also 
reqired for modulating DNA synthesis, mRNA production and transport, so 
that long term effects of impaired glycosylation may involve the 
perturbation of some genes coding for certain proteins. A different
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explanation put forward is that the antibiotic itself may selectively
interact at the nucleic acid level, thereby impairing the synthesis of some 
proteins. For a review on the inhibitors of glycosylation see Elbein
(1987).
Adhesion of tumour cells to fibronectin or endothelial cells is affected
only after long exposure (36 hours) to the antibiotic, the inhibition was
partial and did not further increase after even longer exposure (up to 48 
hours, see figures 31 and 32). Therefore adhesion of tumour cells to the 
endothelium and fibronectin does not seem to rely on the presence of N-
lihked sugar chains. The partial inhibition observed only after prolonged
incubation with the antibiotic could be accounted for by its effects on
protein, mRNA and DNA synthesis- An alternative explanation is that the 
molecules responsible for adhesion have an extremely slow turnover or 
that there is a substantial stored pool of such molecules that can be used 
before requiring de novo synthesis. This, it must be said, seems an 
unlikely scenario.
The inhibition recorded might be due to the fact that carbohydrate 
groups, although not directly involved in adhesion, could have the 
function of protecting adhesion molecules from proteolytic attack. If this 
was the case, the addition of inhibitors of proteolytic enzymes would
reduce such inhibition. By using leupeptin it is possible to show that, in 
the case of the adhesion to the endothelium, the partial inhibition after 36 
hours of treatment with tunicamycin is not dependent on increased 
enzymatic digestion of unglycosylated proteins (see figure 36). In the 
case of adhesion to fibronectin the use of leupeptin seems to partially 
overcome the inhibition caused by the antibiotic (figure 37). 
Interestingly, when tunicamycin was used to assess the adhesion to 
laminin (figure 33), the pattern of inhibition was found to be different
from that observed for fibronectin and endothelium since there was a
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quite marked inhibition after only 24 hours of exposure to the antibiotic.
This gives a stronger indication that adhesion to laminin, unlike that to 
the endothelium or to fibronectin, may depend on the presence of 
carbohydrate side chains. Certainly these experiments with tunicamycin 
must be interpreted with caution since it is possible that the effects seen 
on laminin may again be due to selective inhibition of the synthesis of 
some proteins rather than to the lack of glycosylation.
A number of cell surface receptors for fibronectin and laminin belong 
to the integrin family (Buck and Horwitz, 1987; Gehlsen et a l., 1988). 
Integrins are composed of a beta subunit which is common to numerous 
receptors in the integrin family, while the affinity for fibronectin or 
laminin is probably given by the ligand-specific alpha-subunlt. Different 
integrins seem to possess similar molecular mechanisms for the recognition 
and binding of the various ligands. These receptors bind to a discrete 
amino acid sequence (usually RGD) on the target molecules, with 
differences in structures adjacent to this sequence probably responsible 
for ligand specificity. If B16 cells adhered to both fibronectin and laminin 
via an integrin receptor, we would have expected similar results when 
glycosylation was blocked, but this was not the case. We can therefore 
postulate that different types of receptors are used during the rapid 
adhesion to fibronectin and laminin by B16F10 cells. Cells possess at least 
one non-in tegrin receptor for laminin (that binds a quite dissimilar 
sequence - YIGSR - see page 43) and have many surface-associated 
molecules that can bind both laminin or fibronectin; these results suggest 
that one of these could indeed be used during rapid adhesion. The 
polypeptide sequence YIGSR was not available and it could not be tested 
for inhibition of adhesion to laminin, but the lack of inhibition by the 
pentapeptide GRGDS suggested that B16F10 cell adhesion to fibronectin is 
not mediated by the RGD sequence. These results are in agreement with
1 98
those of other coleagues (Aplin, personal comunication) but do not imply 
that this adhesion Is integrin independent; there are, in fact, two other 
sequences on fibronectin (LDV and RGVD, see pages 38 and 62-63) 
recognized by cell receptors of the integrin family. The lack of inhibition 
by GRGDS has also been described by McCarthy and colleagues (1986) who 
found that the peptide actively inhibited adhesion to low density 
fibronectin substrata (80 % inhibition) but not when the fibronectin
concentration on the substrata was 5 times as much (20 % inhibition). 
Unfortunately the authors do not give exact Indications of the volume
used to coat the substrata but, by extrapolation from other work by the
same group, we believe the fibronectin concetration was 0.25 ug cnT® and
1.25 ug craT^ , which would be in accordance with our findings.
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Discussion - Spreading
Although the main emphasis of this work was the study of rapid
adhesion, events subsequent to adhesion may be important in the 
metastatic cascade. Of particular interest is the fate of these rapid 
adhesive interactions and three possible outcomes can be envisaged:
1 Cells could continue to maintain only those molecular bonds that 
were established at the time of adhesion.
2 After a certain length of time, cells may decrease their number of 
adhesive bonds with the substratum and eventually even release 
their grip and detach.
3 Alternatively, cells will remain adherent and establish progresively 
more molecular interactions with the substratum.
The outcome of cell-cell or cell-substratum adhesion is important when 
migration and invasion are considered. Although the importance of the 
long term interactions during the metastatic process is undisputed, their
possible interpretations are more controversial. Consider for example the 
possibility that, after rapidly adhering to the endothelium, the tumour cell 
later detaches from it. It can be argued that such a cell will be impaired 
from metastasizing since, by losing its adhesion to the endothelium, it will 
be washed away by the blood flow. Conversely it can be speculated that 
it is indeed such a character that will allow metastasis formation since the 
tumour cell will need to migrate through the endothelium and into the 
tissue: if a strong adhesion to the endothelium is maintained the tumour
cell will be "glued" to the lumen and unable to extravasate.
The concept that cell adhesion is a dynamic process and that the
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a m o u n t  an d  s t r e n g th  o f  a d h e s io n  d ep en d s  on  th e  t im e  e la p s e d  a f t e r  f ir s t  
c o n t a c t ,  c a n  b e  d e d u c e d  fro m  th e  w o r k  o f  F lig ie l  and  h e r  c o l le a g u e s  (1985)
w h o  m o n ito r e d  th e  a d h e s io n  o f  f ib r o sa r c o m a  c e l l s  o v e r  a  p e r io d  o f  4 8
h o u rs  and  s h o w e d  th a t  a d h e s io n  in c r e a s e d  and th e n  d e c r e a s e d  w ith  t im e .
T h e ir  w o rk  a lso  e x e m p li f ie s  th e  im p o r ta n c e  o f  th e  su b str a tu m  in  
d e te r m in in g  th e  lo n g  te r m  f a t e  o f  a d h e s io n , s in c e  la m in in  su b s tr a ta  g a v e  a  
v e r y  d if f e r e n t  p a t te r n  o f  lo n g  te r m  a d h e s io n  w h e n  c o m p a r e d  w ith
im  tr e a t e d  su b s tr a ta .
A f t e r  ra p id  a d h e s io n  h a s  b e e n  e s ta b lis h e d , c e l l s  m a y  d e v e lo p  s o m e  
sh a p e  c h a n g e s , s o m e t im e s  v e r y  o b v io u s , and  c e l l s  m a y  a s su m e  m o r p h o lo g ie s  
th a t  r a n g e  from  e x t e n s iv e ly  f la t t e n e d  to  a lm o s t  s p h e r ic a l .  C e ll f la t t e n in g  
(sp rea d in g ) is b e l ie v e d  b y  s o m e  a u th o r s  to  b e  an e x t r e m e  a t t e m p t  by th e
c e l l  to  p h a g o c y to s e  a p a r t ic le  o f  in f in it e  rad iu s (th e  su b str a tu m ), b u t  th is
is n o t  b y  an y  m ea n s  d e m o n s tr a te d  and  th e r e  m a y  b e  o th e r  r e a so n s  fo r
su c h  b eh a v io u r  (fo r  a r e v ie w  s e e  R o o s , 1984). In a ll c a s e s  i t  m u st b e
r e m e m b e r e d  th a t , a lth o u g h  c e l l  sp r e a d in g  o c c m s  in  v i v o ,  th e  sp rea d in g  o f  
c e i l s  on th e  f la t  s u r fa c e  o f  a d ish  m a y  b e an a c t iv i t y  t h a t  o c c u r s  o n ly  in  
v i t r o ,  and  m a y  h a v e  no b io lo g ic a l  im p o r ta n c e  in  v i v o .
W lrotever  th e  s ig n if ic a n c e ,  c e l l  sp r e a d in g  is a p h e n o m e n o n  d e r iv in g  
fro m  a c o m p le x  s e r ie s  o f  e v e n t s  w h ic h  o c c u r  ov er  a m u ch  lo n g e r  t im e  s c a le  
c o m p a r e d  to  ra p id  adhtunon (a t  le a s t  to  th e  ty p e  o f  rap id  a d h esio n  
d e s c r ib e d  in  th is  s tu d y ). D u rin g  rap id  a d h esio n  c e l l s  s t i i l  m a in ta in  an  
o v e r a l l  round sh a p e , as p e r c e iv e d  th ro u g h  l ig h t  m ic r o s c o p y  o b s e r v a t io n ,
■jw h ile  du rin g  sp r e a d in g , c e l l s  lo s e  th e ir  round sh a p e  an d  ten d  to  f la t t e n  j
io n to  th e  su b str a tu m  and a t  th e  s a m e  t im e  e x te n d  th e ir  m e m b r a n e  to  c o v e r  ^
s e v e r a l  o rd ers o f  m a g n itu d e  m o r e  s u r fa c e  a r e a  th a n  w a s  o r ig in a lly  
in v o lv e d  during  ra p id  a d h e s io n . T h e  n u c le i o f  sp r e a d  c e l l s  b e c o m e  m o r e  
e v id e n t ,  n u c le a r  c o m p o n e n ts  l ik e  n u c le o li  an d  c lrro m a tin  c a n  b e  
a p p r e c ia te d , and th e  c y t o s k e le t o n  c a n  b e  s e e n  in  a s s o c ia t io n  w ith  th e
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formation of pseudo- and lamello-podia and the appearance of ruffled 
edges.
The assay.
Despite the fact that the phenomenon is clearly complex and probably 
relies on a multitude of different events and Interactions, it is relatively 
easy to devise an assay that assesses the ability of a substratum to cause
cells to spread, regardless of the complexity and interrelationship of all 
the events that give rise to the spreading. The spreading assay used in 
this study gives information only on the overall phenomenon and although 
in some cases it was obvious that some substrata induced cells to occupy 
more surface area than others, there has been no attempt to quantify 
such a parameter.
Spreading or, as some authors prefer, attachment assays are widely 
used in tumour cell biology research and many different variations have
been employed in the past. They are all based on the same principle: a
substratum (usually plastic or glass) is coated with a molecular solution 
(very often by passive adsorption but sometimes using cross linking 
molecules or derivatization of the substratum), a cell suspension is then 
inoculated onto the substratum and incubated for a considerable length of 
time (mostly between 1 and 4 hours), after which the number of spread 
cells are determined by microscopy (either with or without removal of 
non-attached cells, and on fresh or fixed and stained preparations). 
Typical of this technique is the work of Ruoslahti and his colleagues
(1982).
The assay we developed used very small surface area polystyrene 
plates treated for tissue culture. During the years there has been a shift 
from the use of large Petri dishes to small-well plates, mainly because of 
convenience as well as the need to economize on expensive attachment
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factors. Recently, microtiter (96-well) plates have been the standard for 
this work, but their use has not been completely satisfactory because of
the poor optical quality in phase contrast microscopy. Because of this 
many authors have included fixing and staining of the attached cells in
their protocols (Giancotti et a l., 1985; Piershbacher and Ruoslahti, 1984;
Ruoslahti et a l., 1982). Evaluation of the assay by phase contrast 
microscopy is desirable because it avoids possible artefacts introduced by 
the fixing and staining procedures and is prefered by many research 
groups such as the one of Grinnell (for a review see Grinnell, 1981). 
Because of this, we experimented with Terasaki plates and found their 
phase contrast optics satisfactory, providing the wells were completely 
filled with medium. The Terasaki plates also give the added bonus of
having a much smaller surface area to coat (~ 1/10 of the 96-well plates,
depending on the volumes used).
Some authors prefer to use polystyrene plates not treated for tissue 
culture (i.e. bacteriological-grade), and one of the main reasons for this is 
that many cell lines do not spread on such a surface, unless it has been 
previously conditioned by a suitable molecule (Ruoslahti et a l . ,  1982; 
Grinnell, 1981). This gives the great advantage that the substratum does 
not need blocking with a non-adhesive molecule after its conditioning.
Despite this, we chose the tissue culture-grade plastic for two reasons: 
firstly we wanted to compare the same substratum for its ability to induce 
rapid adhesion and spreading. Since adsorption of molecules may be 
different on differently treated surfaces and since tissue culture grade 
plastic had already been used for adhesion assays, we chose not to 
introduce a possible variable that could prevent useful comparisons. 
Secondly, in our hands, the B16F10 cells would spread on untreated 
bacteriological-grade plastic (although not as well as on tissue culture- 
grade dishes), therefore the blocking of the plastic would have been
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required in any case.
BSA is a common blocking agent (Grinnell, 1981; Giancotti et al. ,  1985)
although rarely used at concentrations higher than 1 %. In our assay 
this treatment allowed a small number of cells to spread on the plastic. 
We experimented with many different BSA preparations at various 
concentrations and found that high percentages of BSA (15-20 %) were
required to inhibit such spreading. Although longer incubations (perhaps
overnight) with less concentrated BSA solutions would have had the same 
effect, the benefits of streamlining the assay were preferred.
As for the medium used for the experiments, two variations of the
assay exist: one that employs FCS containing medium and one which has
no FCS. By allowing cells to spread in the presence of a complex and
undefined mixture of molecules (FCS), there is always the risk that some
of these molecules interact with the substratum, changing its original
quality. Although arguably, because of the very presence of the cells, it 
is difficult to be sure that the substratum has not been in any way
manipulated, it was thought better to avoid this if at all possible.
Evaluation of results.
Despite the fact that B16 cell adhesion has been the subject of many 
investigations, there are very few reports on the spreading abilities of 
these cells. McCarthy and his colleagues (1986) used B16F10 cell and
fibronectin fragments in an attachment assay and concluded that, in
addition to the RGDS sequence, there may be other attachment sites on the 
fibronectin molecule. They also found that the inhibition of attachment by 
soluble RGDS is inversely related to the concentration of fibronectin or
fibronectin fragments coating the substratum. Terranova and his
colleagues (1982) investigated the role of laminin and collagen in
attachment of B16BL6 cells and showed that these cells spread more
2 0 4
readily on collagen type IV rather than type L B16BL6 ceils spread very 
readily to substratum adsorbed laminin, and soluble laminin improved the 
kinetics of attachment to collagen type IV. Anti-fibronectin antibodies did 
not interfere with their spreading to collagen type IV while anti-laminin 
antibodies inhibited BL6 attachment to collagen type IV. When cells were 
preincubated for 4 hours with cyclohexamide, an inhibitor of protein 
synthesis, there was no inhibition of cell attachment to laminin substrata 
or to substrata of collagen type IV + soluble laminin.
Other interesting information about the spreading phenomenon derive 
from studies with other cell lines. Fliegel and her colleagues (1985) noted
that the spreading of mouse fibrosarcoma cells on laminin was dependent
on the concentration of the ligand and that higher concentrations
produced faster responses. Piershbacher and Ruoslahti (1984) tested the 
ability of various synthetic peptides adsorbed to the substratum to
support the attachment of rat kidney cells and found that only RGD
containing peptides were effective. Gehlsen and colleagues (1988) showed 
that A375M melanoma and RuGli glioblastoma cells attachment to various
substrata including laminin, vitronectin, fibronectin, collagen type I and 
type IV can be selectively modulated by different RGD containing 
peptides. Following on the work of Piershbacher and Ruoslahti (1987), 
these , authors showed how esapeptides based on GRGDxP with different
amino acids in position x could inhibit the binding of fibronectin, collagen 
type I and vitronectin with their specific receptors. When these peptides 
were tested in an amniotic membrane invasion assay, it emerged that
fibronectin was a crucial ligand involved in invasion.
To date no systematic studies of the spreading of B16 cells on different 
substrata has been done and, by using our spreading assay, some useful 
data regarding this phenomenon emerged. These are briefly:
1 B16F10 cells spread readily on a number of substrata ranging from
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fibronectin and laminin to FCS, but do not spread on other
substrata such as collagen, BSA or gelatin.
2 The kinetics and percentage of cell spreading depends on the
concentration of the spreading factors on the substratum.
3 Within a cell population there is a considerable heterogeneity with 
regard to readiness to initiate spreading.
4 Some molecules, although unable to cause rapid adiiesion, can
trigger cell spreading.
The time-dependent experiments (figures 42-44) showed that the first 
cells begin to spread after 10 and before 20 minutes of incubation and 
most cells were spread within 30 to 45 minutes. These observations are 
interesting since, although most of the cells have the ability to spread, 
there are indications that within the population there are cells that are
responding to the spreading stimuli much nujrc readily than others. This 
delay in spreading shown by some ceils could be due to many diverse 
factors. The substratum could be a mosaic of patches with different 
supramolecular organization jf ‘he spreading molecules so that in places 
spreading can he initiated almost immediately, while in others some 
processing of the substratum by the cells may be needed before spreading 
.can be observed. This is, of course, fruité difficult to disprove but there 
are data that point towards an even and regular adsorption of molecules 
on the substratuxn, as shown in the work of Grinnell (1981). A more 
plausible hypothesis is tliat within the population there are a series of 
phenotypes for the character "spreading", some of which can be 
distinguished by the rapidity of their response. Such diversity may only 
be tlie effect of differences related to cell cycle (for tire influence of the 
cell cycle on cell adhesion see the work of Elvin and Evans, 1983) but 
alternatively they could be caused by tire presence of a more stable type 
of phenotypic variation. If this was the case, it would be of interest to
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select from the population the fast responders and assess this character 
for its association with a higher or lower metastatic potential. Selected 
populations could be easily obtained by removing either the fast or the 
slow responders with the help of a micropipette mounted on a 
micromanipulator.
Like adhesion, spreading is dependent on the density of molecules 
adsorbed on the substratum (see figures 39-41), with the difference that 
the concentration of a particular molecule needed to elicit maximum 
spreading is lower (around one order of magnitude) than that needed to 
obtain fast adhesion (confront with figures 23 and 26). In general, the 
concentrations of purified molecules needed to induce spreading was ~ 0.1 
ug cnf* and the maximum effect was noted around 1 ug cnf
It has also emerged from this study that there are molecular substrata 
that, although unable to support adhesion, do allow cells to spread. FCS,
for instance, stimulated a good proportion of cells to spread, as did the
polyclonal antibody anti-fibronectin (figures 40 and 46). Both these 
substrata, and especially the anti-fibronectin preparation, were unable to 
support rapid adhesion.
Because cells do not spread on an immunoglobulin fraction of normal 
sheep serum, it is quite interesting that the anti-fibronectin preparation 
stimulates cells to spread because such spreading must be dependent on 
cell surface fibronectin interactions with the substratum-bound anti- 
fibronectin antibodies. Since no rapid adhesion can be detected, the
kinetics of this interaction is probably far too slow. Nevertheless, the 
binding of cell surface fibronectin to an acceptor on the substratum 
induces the cell to carry out a spreading response which, therefore, does
not rely on a fast reaction.
The role of cell surface fibronectin on cell spreading is intriguing 
since soluble anti-fibronectin antibodies block spreading regardless of the
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type of molecular substratum used. These findings could lead to the 
assumption that cell surface fibronectin plays a crucial part in the 
cascade of events that lead to the spreading of the cell. On the other 
hand, as discussed before, the mere binding of antibodies to the cell 
surface may be a perturbing event: there may be a non-specific coating
effect, there may be the masking of important ligands present on the cell 
membrane near the fibronectin molecules, there may be an injurious 
stimulus to the target cell and, lastly, the binding of these antibodies to 
the cell surface fibronectin may act as a signal to inhibit spreading.
Alternatively, it could be envisaged that, in order to spread, cells must 
deposit extracellular material on the substratum. If fibronectin is a 
crucial component of such material, the presence of the antibodies in the 
medium could prevent fibronectin interacting with other molecules, 
ultimately disrupting the deposition of such extracellular material. I
Although the inhibition of spreading caused by the anti-fibronectin 
antibodies was quite specific for fibronectin, when tested on FCS 
substrata they had the effect of enhancing spreading (see figure 49).
This is quite puzzling since either no effect or an inhibition was originally 
expected and no definite reason can be given for this phenomenon. One 
way of explaining such enhancement is to envisage that within FCS there 
are molecules which are capable of binding immunoglobulins (components of 
the complement system are good candidates), possibly but not necessarily, 
via their Fc tails. In this way the substratum would present a number of 
anti-fibronectin antibodies with their antigen-binding site free to interact 
with the cell surface fibronectin, thereby increasing the density of 
molecules that can mediate cell spreading.
Another interesting observation came from the experiments in which 
gelatin was used (figure 45). Denatured collagen has quite a good affinity 
for fibronectin and in view of the fact that cells do spread on a lawn of
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a n t i - f ib r o n e c t in  a n t ib o d ie s  p r e su m a b ly  v ia  c e l l  s u r fa c e  f ib r o n e c t in  ( s in c e  
th e s e  a n t ib o d ie s  in d u c e  sp r e a d in g  o n ly  w h e n  th e y  h a v e  th e ir  f ib r o n e c t in  
b in d in g  s i t e  a v a ila b le , and  n o t  i f  th e y  a r e  h ea d s d ow n  w it h  th e ir  F c  ta i ls
s t ic k in g  up as w h e n  th e y  c o a t  a  f ib r o n e c t in  su b str a tu m ), i t  w a s  e x p e c t e d
th a t  c e l l s  w o u ld  sp rea d  on  d e n a tu r e d  c o lla g e n  to o . N e v e r th e le s s
d e n a tu r e d  c o l la g e n  w a s  n o t  a b le  to  m e d ia t e  e i th e r  a d h e s io n  or sp r e a d in g ,  
a lth o u g h  i t  w a s  a b le  to  b in d  s o lu b le  f ib r o n e c t in  and, b y  c r e a t in g  su c h  a
sa n d w ic h , c a u s e  c e l l s  to  sp r e a d . A  r e a so n  fo r  th is  is  th a t  c e l l  s u r fa c e
f ib r o n e c t in  c o u ld  b e  d i f f e r e n t  fro m  p la sm a  f ib r o n e c t in  in  Its b in d in g  to
g e la t in  an d , in fa c t ,  p u r if ic a t io n  p r o to c o ls  fo r  c e l l  s u r fa c e  f ib r o n e c t in  u s e  
a  v e r y  h ig h  pH  (1 1 .0 ) to  e n su r e  i t s  b in d in g  to  im m o b iliz e d  g e la t in .
W lie th er  th is  in d ic a te s  a r e a l d i f f e r e n c e  b e tw e e n  th e s e  tw o  fo rm s o f
f ib r o n e c t in  or m e r e ly  d e r iv e s  fro m  m e th o d o lo g ic a l  c o n v e n ie n c e  (c e l lu la r
f ib r o n e c t in  is  sa id  to b e  p o o r ly  s o lu b le  a t  p h y s io lo g ic a l pH) is n o t  c le a r .
It co u ld  a lso  b e  th e  c a s e  th a t  th e  f ib r o n e c t in  o f  th e  c e l l  s u r fa c e  m ay  n o t
h a v e  th e  g e la t in  b in d in g  s i t e  a v a ila b le ,  d u e  to th e  w a y  th e  tw o a rm s o f
rht: m o le c u le  a re  fo ld e d . A lt e r n a t iv e ly  i t  cou ld  b e  p o s tu la te d  th a t  c e i l
s m f a c e  f ib r o n e c t in  is n o t a lig a n d  in v o lv e d  in sp r e a d in g  and th a t  th e
a n t i- f ib r o n e c t in  a n t ib o d ie s  c a u s e  sp r e a d in g  b y  so m e  o th e r  m e c h a n is m .
H o w e v e r , th is  la s t  p o s s ib il ity  s e e m s  u n lik e ly .
In g e n e r a l, and  fo llo w in g  c o m p a r iso n  o f  th e s e  d a ta  w ith  th o s e  d e r iv e d
from  th e  a d iie s io n  a s sa y s , i t  w a s  fou n d  th a t  su b s tr a ta  th a t a llo w  rap id
a d h e s io n  a lso  h a d  th e  c o r r e c t  s t im u li  fo r  c e l l s  to  sp r e a d . N on  - a d lie s i v e
s u b s tr a ta  c o u ld  a lso  in d u ce  sp r e a d in g  a lth o u g h  in s o m e  c a s e s  (e .g . g e la t in )
no sp r e a d in g  w a s  o b se r v e d . It is  in te r e s t in g  to  r e p o r t  h e r e  th a t  in
s im ila r  e x p e r im e n ts  p e r fo r m e d  in  our la b o r a to r y  w ith  d i f f e r e n t  c e l l  ty p e s  
( e n d o th e lia l c e l ls )  s o m e  s u b s tr a ta  th a t  in d u c e d  rap id  a d h e s io n  ( e .g .  BSA ) 
w e r e  n o t  e f f e c t i v e  in e l i c i t in g  sp r e a d in g , a t  l e a s t  n o t  during  th e  t im e  
c o u r s e  o f  t l ie  a s s a y  (60  m in ).
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D iscu ss io n  - E n d o th elia l e x t r a c t
During the course of this study it was apparent that the endothelial 
monolayer provided a good substratum for tumour cell adhesion and 
evidence suggested that this adhesion was not due to fibronectin or 
laminin molecules present on the endothelium. Since the earlier strategy 
to try and identify the moiety present on the endothelial surface 
responsible for such adhesion by raising monoclonal antibodies were 
abandoned, attempts were made to extract material from the endothelium 
that would support the adhesion of tumour cells when it was adsorbed 
onto a plastic substratum.
Many extraction approaches have been used in the past to recover 
activity from a cell monolayer, some are severe and cause cell disruption 
and yield a complex mixture that has to be extensively purified. Some 
rely on the use of various enzymatic treatments which lead to the 
solubilization of far fewer molecules from the cells but carry a higher risk 
of inactivating the molecules under investigation. This would therefore 
render functional identification quite difficult. Some milder treatments 
include the use of chelating agents that release material from the cell 
layer in two ways: either by disrupting interactions within molecules of
the supramembranous coat, or by stimulating the cells to excrete or 
release some molecules. In either case it is conceivable that only
comparatively few types of molecules would be recovered in the
supernatant. This has obvious advantages for the identification and
purification of active compounds. Furthermore, since the extracting
procedure does not rely on enzymatic digestion or denaturing but simply
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on changes in ternary and quaternary molecular structure and changes in 
affinity of reciprocal binding sites (all usually reversible upon reinstating 
of a physiological environment) it would be less likely that, if the 
molecules responsible for the adhesion were present in the extract, the 
adhesive activity would not be detected because of inactivation. Early 
experiments showed that such an approach was promising since the 
extracted material adsorbed on plastic would support tumour cell adhesion
in a way comparable to that obtained with the intact monolayer.
Exclusion chromatography indicated that the active material had a 
molecular weight of several hundred kD or more (see figures 52 and 53). 
Molecular weight determination of very large molecules by gel filtration is 
not very precise and can sometimes be unreliable since the molecules in
solution may interact with some reactive groups present in the gel. 
Molecules like thrombospondin, laminin, fibronectin and von Willebrand 
factor as well as GAGs had to be taken into consideration as possible
candidates for the unidentified factor, because of their molecular weight. 
All these molecules are produced by the endothelial cells and immuno dot- 
blot analysis of the extract revealed, albeit with a certain degree of
variability, the presence of both fibronectin and laminin. Anti-fibronectin 
antibodies did not block the adhesion or spreading activity of the extract,
but this alone did not rule out the presence of fibronectin. In fact, if
the activity was due to the presence of many different adhesive molecules, 
blocking one would still leave all the others to elicit adhesion. To exclude 
this, it was decided to remove any such adhesive molecules, if present, by
affinity chromatography. Fibronectin binds to gelatin and heparin; laminin
has a heparin binding site and so has thrombospondin; heparan sulfate
and other GAG’s bind to poiy-L-lysine; vitronectin (which can self 
associate to form higher molecular weight aggregates) binds to heparin.
Additionally each one of these molecules has a strong affinity for most of
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the others when these are immobilized.
All the affinity chromatography ligands used failed to remove the 
adhesion activity from the extract, and this gives strong, although not 
conclusive, indications that the high molecular weight adhesive factor 
extracted from the endothelium is not one of the above mentioned adhesive 
molecules. Alternatively if such adhesive molecules were engaged in 
interactions with each other to form large molecular weight complexes, 
they could have reduced affinity for the immobilized ligands used in these 
experiments- The existence of soluble complexes of proteins and 
glycosaminoglycans (adhérons) has been confirmed by the work of 
Schubert and his group (Schubert et a l., 1986 and references within; Tsui 
et a l., 1988 and references within).
Attempts to filter sterilize the extract resulted in rapid clogging of the 
filter and the loss of some activity. The type of filter used was a low 
protein binding membrane with a mean pore size of 0.2 um. If a solution 
of laminin is passed through such a filter, a very marked loss of activity 
of the preparation will result, while a solution of fibronectin can be 
filtered with no detectable loss of activity. This indicates that, in the 
case of the extract and of laminin, these large size molecules are retained 
by the filter because of physical trapping.
Adhesion to a plastic substratum coated with purified endothelial cell 
extract was almost totally inhibited by the peptide GRGDS (which failed to 
inhibit the adhesion to fibronectin). It has been shown that many 
interactions between adhesive ligands and their receptors at or near the 
cell surface involve the binding of RGD or closely related sequences to 
specific RGD receptors. Implying that these are specialized sequences for 
adhesive phenomena. In the course of this work adhesion to fibronectin 
was not modulated by the peptide, nor was the adiiesion to laminin. This 
would restrict the search among known adhesive molecules to
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thrombospondin and von Willebrand factor. Other RGD containing 
molecules like fibrin and fibrinogen did not support adhesion of tumour 
cells when tested in the adhesion assay. Thrombospondin, which was 
present in the crude extract albeit at very low concentration (results 
courtesy of Dr. Nick Hunter, MRC Blood Components Assay Group, 
Edinburgh), should have been removed during purification against 
heparin-agarose.
Of the known RGD containing adhesive proteins, von Willebrand factor 
fit many of the observations characterizing the extract. Stored by the 
endothelium, it is released upon stimulation and forms the bases of platelet 
adhesion to the vessel wall (Weiss et a l., 1986). Injurious stimuli can 
cause the release of stored von Willebrand factor by the endothelium. The 
released factor will be immobilized on the surface of the endothelium and 
this is thought to happen via the binding to the complex GPIIb/IIIa, a 
receptor for RGD (Parker et a l., 1986). If exposure to chelating agents is 
an injurious stimulus for the endothelium it is conceivable that its cells 
would react by degranulating. The released von Willebrand factor would 
not be able to bind to the endothelial membrane because of the absence of 
divalent cations in the medium and would therefore be recovered in the 
supernatant.
Alternatively, during extraction, some components of the subendothelial 
matrix could be solubilized. Chelating agents are used for instance to 
extract laminin from the basement membrane of EHS tumours (this is in 
fact part of the standard protocol for the purification of commercially 
available laminin) and could have similar effects in the case of the 
subendothelial matrix. Regardless of the localization of the extracted 
adhesive factor, whether it is associated to the cell membrane, released 
from an intracellular pool or incorporated in the subendothelial matrix, 
there are indications that it is an endothelial cell product. Although no
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metabolic labelling has been done, the adhesive factor doesn't seem to be 
derived from the FCS of the culturing medium since there is no trace of it 
in extracts of glass adsorbed medium. There is of course the possibility 
that such a factor is indeed present in the fresh medium but is not 
incorporated to the glass-adsorbed molecular layer in the absence of 
endothelial cells, at least not in an extractable/active form. Preliminary 
experiments have shown that endothelial cells cultured in defined medium 
with an FCS substitute yield a similar extractable factor.
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Sum m ary
In sum m ary., th e  e n d o th e liu m  is  a v e r y  a d h e s iv e  su b str a tu m  for  BIG  
m a lig n a n t  m e la n o m a  c e l l s .  R e s u lt s  in d ic a te  th a t th is  is  a s  a d h e s iv e  as th e  
s u b e n d o th e lia l m a tr ix  or as i s o la t e d  a d h e s iv e  p r o te in s  s u c h  as la m in in  an d  
f ib r o n e c t in . T h e a d h e s iv e n e s s  o f  th e  e n d o th e liu m  for  t lie  tu m ou r c e l l s  c a n  
b e  m o d u la te d  an d  rap id ly  in c r e a s e d  (by try p sin , fo r  in s ta n c e ) .  T h e  r o le
o f  th e  e n d o th e liu m  during th e  a r r e s t  o f  m e ta s ta s iz in g  tu m o u r  c e l l s  sh o u ld  
b e  r e v ie w e d  in th e  lig h t  o f  t h e s e  f in d in g s .
R ap id  a d iie s io n  is d e p e n d e n t  on  th e  c o n c e n tr a t io n  o f  a d h e s iv e  fa c to r s
on  th e  su b str a tu m  and is inhibite<.î at. lo v / te m p e r a tu r e s  and in a c a t io n -
fr e e  m ed iu m . S p rea d in g  is  a s lo w e r  p h en o m en o n  and r e iiu ir e s  a s m a lle r  
c o n c e n tr a t io n  o f  a d lie s iv e  fa c to r s  on th e  su b str a tu m . C o lla g e n  a id  g e la t in  
do n o t e l i c i t  e i th e r  a d h esio n  o r  .spread ing  o f  B 16 F 1 0  tu m ou r c e l ls .
C a rb o h y d ra te  m o ie t ie s  on  th e  tu m ou r c e l l  s u r fa c e  ;.lo n o t s e e m  t:: b e  
In v o lv ed  in a d h esio n  o f t h e s e  c e l l s  to  th e  (m d o tlie liu m . T ryp sin , on th e  
o th e r  h an d  can  d ig e s t  m o le c u le s  on th e  tu m ou r c e l l  s u r fa c e  w h ich  a r e  
im p o r ta n t in a d h es io n  to  th e  e n d o th e liu m .
An a t te m p t  to  e x t r a c t  from  th e  e n d o th e liu m  th e  m o ie l )  r e sp o n s ib le  '’or  
th e  rap id  a d iie s io n  o f  th e  B IS  c e l l s  w a s s u c c e s s f u l ,  and p a r t ia l  
c h a r a c te r iz a t io n  o f  th is fa c t o r  s u g g e s t s  th a t  i t  is  a h ig h  m o le c u la r  m a ss , 
R G D -c o n ta in in g  or R G D -b in d in g  m o le c u le .
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